Soluble bone morphogenetic protein (BMP) receptor type-1b proteins and uses for the treatment of retinopathies

Abstract

This application relates generally to the field of Bone Morphogenetic Protein (BMP) antagonists (soluble ALK6 fusion proteins), compositions thereof, and methods for use in treating retinopathy diseases and / or ocular neo-vascular diseases including age related macular degeneration.

Description

1902004-0002-005-W01SOLUBLE BONE MORPHOGENETIC PROTEIN (BMP) RECEPTOR TYPE-1B PROTEINS AND USES FOR THE TREATMENT OF RETINOPATHIES|0001] RELATED APPLICATIONS

[0002] This application claims priority to U.S. Provisional Application Ser. No. 63 / 753,279 filed on 03 February 2025 and U.S. Provisional Application Ser. No. 63 / 757,653 filed on 12 February 2025, each of which is incorporated by reference into this application in its entirely.

[0003] SEQUENCE LISTING

[0004] The instant application contains a sequence listing which has been submitted electronically in ASCII format via the USPTO Patent Center and hereby incorporated by reference in its entirety. Said ASCII copy, created on 30 January 2026, is named 1902004-0002-005-WO1_S.xml and is 655,554 bytes in size.

[0005] FIELD OF THE DISCLOSURE

[0006] This application relates generally to the field of Bone Morphogenetic Protein (BMP) antagonists, compositions thereof, and methods for use in treating diseases related to BMPs.

[0007] BACKGROUND OF THE DISCLOSURE

[0008] Blinding eye disease remains a major global health challenge in the 21st century. An estimated 43 million people worldwide were blind in 2020, and another 295 million people had moderate to severe vision impairment!. The economic burden of vision loss in the United States was estimated to be over US$134 billion in 2021. The leading causes of irreversible blindness are neurodegenerative, including diseases caused by death of photoreceptors and associated retinal pigment epithelium (RPE) — such as age-related macular degeneration (AMD) and retinitis pigmentosa (RP), the most common form of inherited retinal disorder — and death of retinal ganglion cells (RGCs), the neurons of the optic nerve, in a condition known as glaucoma. Reversal of vision loss remains an elusive goal,

[0009] Diabetic retinopathy (DR), diabetic macular edema (DME), and age related macular degeneration (AMD), such as age-related macular degeneration (AMD) are eye conditions that impact vision and involve neo-vascularization. The most severe form of diabetic retinopathy is proliferative retinopathy which can also lead to vision loss. Both DR and AMD are caused in part by blood vessel damage and / or undesirable proliferation.1902004-0002-005-W01

[0010] Macular degeneration is caused in part by blood vessels that grow under the retina. Retinopathy is caused by damage to the blood vessels of the light-sensitive tissue at the back of the eye (retina). Early diabetic retinopathy, also referred to as non-proliferative diabetic retinopathy (NPDR) is the most common form of diabetic retinopathy. In non-proliferative diabetic retinopathy (NPDR), the walls of the blood vessels in the retina weaken. Tiny bulges protrude from the walls of the smaller vessels, sometimes leaking fluid and blood into the retina. Larger retinal vessels can begin to dilate and become irregular in diameter as well. NPDR can progress from mild to severe as more blood vessels become blocked.

[0011] Diabetic retinopathy can progress to proliferative diabetic retinopathy. In this type, damaged blood vessels close off, causing the growth of new, abnormal blood vessels in the retina. These new blood vessels are fragile and can leak into the clear, jellylike substance that fills the center of your eye (vitreous). Eventually, scar tissue from the growth of new blood vessels can cause the retina to detach from the back of your eye. If the new- blood vessels interfere with the normal flow' of fluid out of the eye, pressure can build in tire eye. This buildup can damage the nerve that carries images from your eye to your brain (optic nerve), resulting in glaucoma.

[0012] Current standard of care for retinopathies today are intravitreal injections of anti-VEGF drugs to control neovascularization and reduce the area of fluid below' the retinal pigment epithelium. These drugs are commonly known as AVASTIN® (Bevacizumab) (mostly used off label), LUCENTIS® (Ranibizumab), MACUGEN® (Pegaptanib) and EYLEA® (aflibercept) and although their effectiveness has been shown to significantly improve visual prognosis with choroidal neovascularization (CNV), the recurrence rate for these neovascular areas remains high. LUCENTIS® is a Fab, AVASTIN® is a monoclonal antibody, MACUGEN® is a pegylated RNA aptamer directed against the VEGF-A 165 isoform and EYLEA® is a VEGF Trap fused to an Fc domain of human IgG 1. All bind vascular endothelial growth factor (VEGF) and may be used to treat neo-vascularization; however, only a minority of treated patients experiences a significant improvement in prolonged visual acuity.

[0013] The transforming growth factor-beta (TGF-beta) superfamily contains a variety of growth factors that share common sequence elements and structural motifs. These proteins are known to exert biological effects on a large variety of cell types in both vertebrates and invertebrates. Members of the superfamily perform important functions during embryonic development in pattern formation and tissue specification and can influence a variety of differentiation processes, including adipogenesis, myogenesis, osteogenesis, chondrogenesis,1902004-0002-005-W01cardiogenesis, hematopoiesis, neurogenesis, and epithelial cell differentiation. The family is divided into two general phylogenetic clades: the more recently evolved members of the superfamily, which includes TGF-betas, Activins, and nodal and the clade of more distantly- related proteins of the superfamily, which includes a number of BMPs and GDFs. Hinck (2012) FEBS Letters 586:1860-1870. TGF-beta family members have diverse, often complementary' biological effects. By manipulating the activity of a member of the TGF-beta family, it is often possible to cause significant physiological changes in an organism. For example, the Piedmontese and Belgian Blue cattle breeds carry a loss-of-function mutation in the GDF8 (also called myostatin) gene that causes a marked increase in muscle mass. Grobet et al. (1997) Nat Genet., 17(1 ):71-4. Furthermore, in humans, inactive alleles of GDF8 are associated with increased muscle mass and, reportedly, exceptional strength. Schuelke et al. (2004) N Engl J Med, 350:2682-8. Changes in muscle, bone, fat, red blood cells, and other tissues may be achieved by enhancing or inhibiting signaling (e.g., SMAD 1, 2, 3, 5, and / or 8) that is mediated by ligands of the TGF-beta family. Thus, there is a need for agents that regulate the activity of various ligands of the TGF-beta superfamily, including the bone morphogenetic proteins (BMPs) related to this disclosure.|0014] SUMMARY OF THE DISCLOSURE

[0015] Described herein are polypeptides, compositions, other reagents related to Bone Morphogenetic Protein (BMP) antagonists, and methods for use in treating retinopathy and / or ocular neo-vascular disorders related to BMP ligand and endogenous signaling. In particular, this disclosure relates to soluble bone morphogenetic protein (BMP) receptor type IB polypeptides comprising an extracellular domain of ALK6 (activin receptor-like kinase 6) and soluble variants thereof (“ALK6 polypeptides”), which bind BMP ligands and sequester the ligands from binding to their receptors (“BMP antagonists"’). The ALK-6 polypeptides of this disclosure bind BMP ligands, including, but not limited to BMP 4, 6, 7 and / or 10, In certain embodiments, ALK-6 polypeptides of this disclosure bind BMP 10. In certain other embodiments, the ALK-6 polypeptides of this disclosure do not bind BMP10. In certain embodiments, the ALK6 ECD sequence may comprise one or more point mutations, addition or deletion of c -terminal residues, wherein position 60 is glycine (G) as provided in SEQ ID NO:1

[0016] In embodiments, proved herein are methods for treatment of retinopathy in a human subject in need thereof comprising administering an effective amount of a pharmaceutical1902004-0002-005-W01composition to a subject in need thereof, wherein the composition comprises a soluble recombinant bone morphogenetic protein receptor type-lB fusion protein comprising an ALK6 ECD polypeptide and a Fc sequence, wherein the ALK6 ECD polypeptide comprises an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to an ALK6 ECD sequence of SEQ ID NO: 3; SEQ ID NO: 5; SEQ ID NO: 79, SEQ ID NO: 81, SEQ ID NO: 82, SEQ ID NO: 83, SEQ ID NO: 108; SEQ ID NO: 109; SEQ ID NO: 130, SEQ ID NO: 157, SEQ ID NO: 190 and SEQ ID NO: 437

[0017] In certain embodiments provided herein are methods for treatment of retinopathy in a human subject in need thereof, comprising administering an effective amount of a pharmaceutical composition to a subject in need thereof, wherein the composition comprises a soluble recombinant bone morphogenetic protein receptor type-1 B fusion protein comprising an ALK6 ECD polypeptide, a linker and a Fc sequence, wherein the ALK6 ECD polypeptide comprises an amino acid sequence having at least 70%, 75%. 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to an ALK6 ECD sequence selected from SEQ ID NO: 1, 4, 11-45, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 80, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 110, 113, 132-156, 158-189, 191-194, 202, 213, 218, 223, 228, 233, 242, 247, 252, 257, 262, 272, 277, 283, 286, 292, 298, 304, 310, 316, 322, 328, 334 340, 346, 352, 358, 364, 370, 376, 382, 388, 394, 400, 406, 412, 418, 425, or 431.

[0018] In certain embodiments provided herein are methods for treatment of retinopathy in a human subject in need thereof, comprising administering an effective amount of a pharmaceutical composition to a subject in need thereof, wherein the composition comprises a soluble recombinant bone morphogenetic protein receptor type-lB fusion protein comprising an ALK6 ECD polypeptide, a linker and a Fc sequence, wherein the ALK6 ECD polypeptide comprises an amino acid sequence having at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity' to an ALK6 ECD sequence selected from SEQ ID NO: 3, 5, 79, 81, 82, 83, 108, 109, 112, 130, 157 190, 202, 213, 218, 223, 228, 233, 242, 247, 252, 257, 262, 272, 277 and 283.

[0019] In certain embodiments provided herein are method for treatment of retinopathy in a human subject in need thereof, comprising: administering an effective amount of a pharmaceutical composition to the subject, wherein the composition comprises a soluble1902004-0002-005-W01recombinant bone morphogenetic protein receptor type-lB fusion protein comprising an ALK6 ECD polypeptide, a linker and a heterologous sequence, wherein the ALK6 Fc fusion protein comprises an amino acid sequence having at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to an ammo acid sequence selected from SEQ ID NO: 291, 297, 303, 309, 315, 321, 327, 333, 339, 345, 351, 357, 363, 369, 375, 381, 387, 393, 399, 405, 411, 417, 423, 424, 430, and 436,

[0020] In certain embodiments, the fusion protein polypeptide comprises an amino acid sequence having at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to an ALK6 fusion protein sequence selected from SEQ ID NO: 291,

[0021] In embodiments, the ALK6 ECD comprises an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 69; or the ALK6 ECD comprises an amino acid sequence that is at least 70%. 75%, 80%, 85%, 86%, 87%, 88%, 89%. 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 90, or the ALK6 ECD comprises an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 286.

[0022] In embodiments, the retinopathy is selected from any one of diabetic retinopathy, age- related macular degeneration (AMD), choroidal neovascularization (CNV), vision loss, night blindness, photopsia, proliferative retinopathy, non-proliferative retinopathy, and hypertensive retinopathy.

[0023] In certain embodiments provided herein are soluble recombinant bone morphogenetic protein receptor type-lB fusion proteins comprising: an ALK6 extra cellular domain (ECD), a linker sequence and an Fc domain sequence wherein the ALK6 ECD sequence comprises an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%. 99%, or 100% identical to an ALK6 ECD sequence selected from SEQ ID NO: 46-50, 52-56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 110 and 113, wherein amino acid position 60 is a glycine residue. In embodiments, the polypeptide binds BMP 10. In embodiments, the ALK6 ECD sequence selected from SEQ ID NO: 86, 90, 92, 94, 96, 98, 100, and 102. In certain embodiments, the ALK6 ECD comprises one or more point mutations selected from K20Y, K20F, K20V, H22S,1902004-0002-005-W01H22G, H23S, and H23G. In further embodiments, the ALK6 ECD comprises an amino acid insertion between position 22 and position 23 of an alanine (A) residue.|0024] Provided herein are soluble recombinant bone morphogenetic protein receptor type- IB fusion proteins comprising: an ALK6 extra cellular domain (ECD), a linker sequence and an Fc domain sequence wherein the ALK6 ECD sequence comprises an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to an ALK6 ECD sequence selected from SEQ ID NO: 86 or 90, wherein amino acid position 60 is a glycine (G) residue. In embodiments, the ALK6 ECD sequence comprises at least one point mutation as compared to SEQ ID NO: 1. in embodiments, the point mutation is selected from K20Y, K20F, K20V, H22S, H22G, H23S, and H23G. In embodiments, the polypeptide binds BMP10.

[0025] Provided herein are pharmaceutical composition comprising an ALK6 fusion protein of this disclosure; and, at least one pharmaceutical acceptable carrier or buffer.

[0026] In certain embodiments provided herein are methods for treating retinopathy disorders, comprising administering an effective amount of a pharmaceutical composition comprising an ALK6 fusion protein of this disclosure to a subject in need thereof.

[0027] In embodiments provided herein, are methods for treatment of retinopathy in a human subject in need thereof,

[0028] In certain embodiments, the disclosure provides a method for treatment of retinopathy¬ in a human subject in need thereof comprising: administering an effective amount of a pharmaceutical composition to the subject, wherein the composition comprises a soluble recombinant bone morphogenetic protein receptor type-lB fusion protein comprising an ALK6 ECD polypeptide and a heterologous sequence, wherein the ALK6 ECD polypeptide comprises an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to an ALK6 ECD sequence of SEQ ID NO: 3; SEQ ID NO: 5; SEQ ID NO: 79, SEQ ID NO: 81, SEQ ID NO: 82, SEQ ID NO: 83, SEQ ID NO: 108; SEQ ID NO: 109; SEQ ID NO: 130, SEQ ID NO: 157, SEQ ID NO: 190 and SEQ ID NO: 437.

[0029] In certain embodiments, the disclosure provides method for treatment of retinopathy in a human subject in need thereof, comprising: administering an effective amount of a pharmaceutical composition to the subject, wherein the composition comprises a soluble1902004-0002-005-W01recombinant bone morphogenetic protein receptor type-lB fusion protein comprising an ALK6 ECD polypeptide, a linker and a heterologous sequence, wherein the ALK6 ECD polypeptide comprises an amino acid sequence having at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to an ALK6 ECD sequence selected from SEQ ID NO: 1, 4, 11-45, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 80, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 110, 113, 132-156, 158-189, 191-194, 202, 213, 218, 223, 228, 233, 242, 247, 252, 257, 262, 272, 277, 283, 286, 292, 298, 304, 310, 316, 322, 328, 334 340, 346, 352, 358, 364, 370, 376, 382, 388, 394, 400, 406, 412, 418, 425, or 431.

[0030] In certain embodiments, the disclosure provides method for treatment of retinopathy in a human subject in need thereof, comprising: administering an effective amount of a pharmaceutical composition to the subject, wherein the composition comprises a soluble recombinant bone morphogenetic protein receptor type- IB fusion protein comprising an ALK6 ECD polypeptide, a linker and a heterologous sequence, wherein the ALK6 Fc fusion protein comprises an amino acid sequence having at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to an amino acid sequence selected from SEQ ID NO: 291, 297, 303, 309, 315, 321, 327, 333, 339, 345, 351, 357, 363, 369, 375, 381, 387, 393, 399, 405, 411, 417, 423, 424, 430, and 436.

[0031] In some embodiments, the fusion protein polypeptide comprises an amino acid sequence having at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to an ALK6 fusion protein sequence selected from SEQ ID NO: 291. In some embodiments, the ALK6 ECD sequence comprises at least one point mutation as compared to SEQ ID NO: 1. In some embodiments, the soluble recombinant bone morphogenetic protein receptor type-IB fusion protein comprises an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 86, SEQ ID NO: 88, SEQ ID NO: 90 or SEQ ID NO: 286. In some embodiments, the ALK6 ECD comprises an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 69. In some embodiments, the ALK6 ECD comprises an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 90. In some embodiments, the ALK6 ECD comprises an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%,1902004-0002-005-W0192%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 286. In some embodiments, the ALK6 ECD comprises an amino acid sequence that is at least 70%, 75%, 80%. 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%. 96%, 97%. 98%, 99%, or 100% identical to SEQ ID NO: 233 or SEQ ID NO:242.

[0032] In some embodiments, the point mutation is selected from one or more of VI 61; K20Y, K20F, H22S, _22’A, H23G, V30I, I33T, I33S, S35I, S49Q and L51M. In some embodiments, the polypeptide binds one or more of BMP6, BMP7 and / or BMP10. In some embodiments, the ALK6 ECD sequence is selected from SEQ ID NO: 190 and the sequence comprises point mutations K20Y and H22S. In some embodiments, the ALK6 ECD sequence is selected from SEQ ID NO: 190 and the sequence comprises point mutations K20Y, H22S and I33T. In some embodiments, the ALK6 ECD sequence is selected from SEQ ID NO: 190 and the sequence comprises point mutations H22S and 133T.

[0033] In some embodiments, the heterologous region is an Fc region. In some embodiments, the heterologous region is a hinge region. In some embodiments, the heterologous sequence is an Fc sequence according to SEQ ID NO: 285.

[0034] In some embodiments, the retinopathy is selected from diabetic retinopathy, age-related macular degeneration (AMD), choroidal neovascularization (CNV), vision loss, night blindness, photopsia, proliferative retinopathy, non-proliferative retinopathy, retinitis pigmentosa and hypertensive retinopathy.

[0035] In certain embodiments, the disclosure provides a method for treatment of age-related macular degeneration (AMD) in a human subject in need thereof comprising: administering an effective amount of a pharmaceutical composition to the subject, wherein the composition comprises a soluble recombinant bone morphogenetic protein receptor type-lB fusion protein comprising an ALK6 ECD polypeptide and a heterologous sequence, wherein the ALK6 ECD polypeptide comprises an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to an ALK6 ECD sequence of SEQ ID NO: 3; SEQ ID NO: 5; SEQ ID NO: 79, SEQ ID NO: 81, SEQ ID NO: 82, SEQ ID NO: 83, SEQ ID NO: 108; SEQ ID NO: 109; SEQ ID NO: 130, SEQ ID NO: 157, SEQ ID NO: 190 and SEQ ID NO: 437.

[0036] In certain embodiments, the disclosure provides, a method for treatment of age-related macular degeneration (AMD) in a human subject in need thereof, comprising: administering an effective amount of a pharmaceutical composition to the subject, wherein the composition comprises a soluble recombinant bone morphogenetic protein receptor type-lB fusion protein1902004-0002-005-W01comprising an ALK6 ECD polypeptide, a linker and a heterologous sequence, wherein the ALK6 ECD polypeptide comprises an amino acid sequence having at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to an ALK6 ECD sequence selected from SEQ ID NO: 1, 4, 11-45, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 80, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 110, 113, 132-156, 158-189, 191-194, 202, 213, 218, 223, 228, 233, 242, 247, 252, 257, 262, 272, 277, 283, 286, 292, 298, 304, 310, 316, 322, 328, 334 340, 346, 352, 358, 364, 370, 376, 382, 388, 394, 400, 406, 412, 418, 425, or 431.

[0037] In certain embodiments, the disclosure provides a method for treatment of age-related macular degeneration (AMD) in a human subject in need thereof, comprising: administering an effective amount of a pharmaceutical composition to the subject, wherein tire composition comprises a soluble recombinant bone morphogenetic protein receptor type-lB fusion protein comprising an ALK6 ECD polypeptide, a linker and a heterologous sequence, wherein the ALK6 Fc fusion protein comprises an amino acid sequence having at least 70%, 75%. 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to an amino acid sequence selected from SEQ ID NO: 291, 297, 303, 309, 315, 321, 327, 333, 339, 345, 351, 357, 363, 369, 375, 381, 387, 393, 399, 405, 411, 417, 423, 424, 430, and 436.

[0038] In some embodiments, the fusion protein polypeptide comprises an amino acid sequence having at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to an ALK6 fusion protein sequence selected from SEQ ID NO: 291. In some embodiments, the ALK6 ECD sequence comprises at least one point mutation as compared to SEQ ID NO: 1. In some embodiments, the soluble recombinant bone morphogenetic protein receptor type- IB fusion protein comprises an amino acid sequence that is at least 70%, 75%. 80%, 85%, 86%, 87%, 88%, 89%, 90%. 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to an amino acid sequence of SEQ ID NO: 86, SEQ ID NO: 88, SEQ ID NO: 90 or SEQ ID NO: 286. In some embodiments, the ALK6 ECD comprises an amino acid sequence that is at least 70%, 75%. 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 69. In some embodiments, the ALK6 ECD comprises an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%. 97%, 98%, 99%, or 100% identical to SEQ ID NO: 90. In some embodiments, the ALK6 ECD comprises an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%,1902004-0002-005-W0189%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 286.

[0039] In embodiments, provided herein are uses of a soluble recombinant bone morphogenetic protein receptor type- 1 B fusion protein for treatment of retinopathy in a human subject in need thereof.

[0040] In certain embodiments, the disclosure provides use of a soluble recombinant bone morphogenetic protein receptor type- IB fusion protein for treatment of retinopathy in a human subject in need thereof, comprising administering an effective amount of the fusion protein, comprising: an ALK6 extra cellular domain (ECD); a linker sequence; and, an Fc domain sequence; wherein the ALK6 ECD sequence comprises or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to an ALK6 ECD sequence of SEQ ID NO: 286, wherein the position corresponding to position 60 of SEQ ID NO: 69 is a glycine (G) residue, and wherein the ALK6 fusion protein demonstrates retained BMP 10 binding.

[0041] In certain embodiments, the disclosure provides use of a soluble recombinant bone morphogenetic protein receptor type- IB fusion protein for treatment of retinopathy in a human subject in need thereof, composing administering an effective amount of the fusion protein, comprising: an ALK6 extra cellular domain (ECD); a linker sequence; and an Fc domain sequence; wherein the ALK6 Fc fusion protein sequence comprises or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to an ALK6 Fc fusion sequence of SEQ ID NO: 291, wherein the position corresponding to position 60 of SEQ ID NO: 69 is a glycine (G) residue, and wherein the ALK6 fusion protein demonstrates retained BMP 10 binding.

[0042] In certain embodiments, the disclosure provides use of a soluble recombinant bone morphogenetic protein receptor type- 1 B fusion protein for treatment of retinopathy in a human subject in need thereof, comprising administering an effective amount of the fusion protein, comprising: an ALK6 extra cellular domain (ECD); a linker sequence; and an Fc domain sequence; wherein the ALK6 ECD sequence comprises or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to an ALK6 ECD sequence of SEQ ID NO: 437, wherein the position corresponding to position 60 of SEQ ID NO: 69 is a glycine (G) residue, and wherein the ALK6 fusion protein demonstrates complete BMP 10 binding.1902004-0002-005-W01

[0043] In some embodiments, the ALK6 fusion protein demonstrates BMP 10 binding comparable to SEQ ID NO: 49. In some embodiments, the ALK6 fusion protein demonstrates BMP 10 binding comparable to binding of an ALK6 wildtype (wt) Fc fusion protein. In some embodiments, the ALK6 fusion protein demonstrates an nM IC50value of about 7.2 for BMP10 binding. In some embodiments, the ALK6 fusion protein demonstrates an nM IC50value of about 4.8 for BMP7 binding. In some embodiments, the retinopathy is age related macular degeneration (AMD).

[0044] In embodiments, provided herein are soluble recombinant bone morphogenetic protein receptor type- IB fusion proteins comprising an ALK6 ECD polypeptide and a Fc sequence.

[0045] In certain embodiments, the disclosure provides a soluble recombinant bone morphogenetic protein receptor type- 1 B fusion protein comprising an ALK6 ECD polypeptide and a Fc sequence, wherein the ALK6 ECD polypeptide comprises an amino acid sequence selected from a sequence of SEQ ID NO: 130: Lysi - Lyss - Glus - Aspr - Glys - Glue - Ser? - Thrs - Ala9 - Proio - Thru - Pro - Argis ~Proi4 - Lysis - Xaaie - Leui? - Argis - Cysi9 - Xaa?.o - Cyszi - Xaa??-- Xaa’?.?- Xaa”?.?-Xaa?3 - Xaa’2.3 - Xaa?_4 - Cyszs - Proze - Xaa?_7 - Aspzs - Xaa29 - Xaaso - Asnsi - Asn32 - Xa 33 - Cys34 - Xaass - Ilirse - Xa 37 - Glyss - Xaa39 - Cys4o - Phe i - Xaa42 - Xaa43 - 11644 - Ghus - Ghi46 - Asp47 - Asp s - Xaa49 - Glyso - Xaasi - Xaass -Xaas3 - Xaas4 - Xaass - Serse - Glys? - Cysss - Xaas9 - Xaaeo - Xaaei - Glue? - Gives - Sere4 - Aspes - Pheee - Gln67 - Cyses - Xaa, 9 - Asp?o - Xaa?i - Pro?2 - Xaa?3 - Xaa?4 - Xaa?5 - Xa?6 - Arg77 - Arg78 - Xaa?9 - Ileso - Glusi - Cyssz - Cysss - Xaag4 - Xaass - Xaase - Xaas? - Xaass -Cys89 - Asn9o - Xaa9i - Xaa92 - Leu93 - Xaa94 - Pro s - Thr96 - Leu97 - Progs - Pro99 - Leuioo - Lysioi - Asnio?. - Argios - Aspio - Pheios - Valioe - Xaaio? - Xaaios - Xaaio9 - Xaano - Xaam -Xaam - Xaam; wherein Xaais is V or I; Xaazo is V, F, K, Y, T, or A; Xaazz is G, E, H or S; Xaa’ 22 is absent, G, S, or A; Xaa”22 is absent or S; Xaazi is S, H, G, or L; Xaass’ is absent, L or H; Xaa24 is H or S; Xaa?? is E or D; Xaa29 is S or A; Xaa3o is V or I; Xaa33is I or T; Xaa35is S or I; Xaas? is D or N; Xaa39 is Y or H; Xa 42 is T or A; Xaars is M or I; Xaa49 is S or Q; Xaa51is L or E; Xaa52 is P or T; Xaass is V or T: Xaas4 is V or L; Xaass is T or A; Xaa59is L or M; Xaaeo is G or K; Xaa61is L or Y; Xaaeo is R or K; Xaa?i is T or S; Xaa?3 is I or K; Xaa?4 is P or A' Xaars is H or Q. Xaa76is Q or L; Xaa?9 is S or T; Xaas is T or R; Xaass is absent, T or E; Xaase is R or N; Xaa87is N or L; Xaass is absent, E or L; Xaa9i is K or Q; Xaa92 is D or L; Xaa94 is H or Q; Xaaio? is absent; Xaa108is absent; Xa io9 is absent; Xaa110is absent; Xaa111is absent; Xaa111is absent; and, Xaam is absent.1902004-0002-005-W01

[0046] In some embodiments Xaa60 is a glycine (G) residue. In some embodiments, the polypeptide binds BMP 10. In some embodiments, the fusion protein further comprises a linker sequence. In some embodiments, the fusion protein further comprises a linker sequence selected from SEQ ID NO: 6, SEQ ID NO: 7 or SEQ ID NO: 8. In some embodiments, the Fc sequence comprises an amino acid sequence according to SEQ ID NO: 285.

[0047] In certain embodiments, the disclosure provides a soluble recombinant bone morphogenetic protein receptor type- IB fusion protein comprising an ALK6 ECD polypeptide and a Fc sequence, wherein the ALK6 ECD polypeptide comprises an amino acid sequence selected from a sequence of SEQ ID NO: 157: Xaai - Xaa2 - Xaas - Xaa4 - Xaas - Xaas - Xaa? - Xaas - Xaas - Xaaio - Xaau - Xaa12 - Xaai3 - Xaai4 - Xaais - Xaais - Leun - Argis -Cysts - Xaa?o - Cys2i - Xaa22 - Xaa’ 22 - Xaa” 22 - Xaa23 - Xaa’23 - Xaa?4 - Cys25 - Pro26 - Xaa?7 - Asp28 - Xaa29 - Xaa?,o - Asnsi - Asn?? - Xaa33 - Cys34 - Xaau - Tims - Xaa37 - Gly - Xaa39 - Cys4o - Phe4i - Xaa42 - Xaa.43 - Ile44 - Glu45 - Glu46 - Asp47 - Asp48 - Xaa49- Glyso - Xaasi - Xaa52 - Xaass - Xaas4 - Xaass - Serss - Glys? - Cysss - Xaass - Xaaeo - Xaasi - Glu62 - Gly63 - Sers -- Aspss - Phess -- Ghi67 - Cysss - Xaas9 - Asp?o - Xaa7i - Pro72 - Xaa?3 - Xaa74 - Xaa? 5 - Xaa?s — Arg?? — Ar 78 - a?9 - Ileso — Glusi — Cyss? — Cys83 - Xaa84 - Xaa85 - aa86 - Xaas? - Xaass - Cys89 - Asii o - X a9i - Xa 92 - Leii93 - Xaa94 - Progs - Thr96 - Leu97 - Pro98 - Pro99 -Xaaioo - Xaaioi - Xaaioz - Xaaio3 - Xaaio4 - Xaaios - Xaaios - Xaaio? - Xaaios - Xaaioo - Xaauo - Xaain - Xaai 12 - Xaau?; wherein: Xaai is K or absent; Xaa? is K or absent; Xaa; is E or absent; Xaa4 is D or absent; Xaas is G or absent; Xaas is E or absent; Xaa? is S or absent; Xaas is T or absent; Xaa9 is A or absent; Xaaio is P or absent; Xaau is T or absent; Xaan is P or absent; Xaai3 is R or absent; Xaai is P or absent; Xaais is K, P or absent; Xaaio is V or absence; Xaa?.o is V, F, K, A, R, N, D, C, E, Q, G, H, I, L, M, P, S, T, W, or Y; Xaa22is G, H, V, F, K, A, R, N, D, C, E, Q, I, L, M, P, T, W, Y or S; Xaa’22 is absent, G, S. or A; Xaa’ 22 is absent or S: Xaa23 is S, II, V, F, K, A, R, N, D, C, E, Q, I, L, M, P, T, W, Y or G; Xaa’23 is absent, L or II; Xaa; 1 is V, F, K, A, R, N, D, C, E, Q, G, H, I, L, M, P, S, T, W, or Y; Xaa27 is E or D; Xa 29 is S, G or A; Xaaso is V, A, G or I; Xa 33 is I, S or T; Xaass is S, T, G, A or I; Xaa37 is D, A, G or N; Xaa39 is Y, A, G or II; Xaai? is T or A; Xaa: is M or I; Xaa49 is S, A, G or Q; Xaasi is L, A, G or E; Xaas?. is P or T; Xaa.53 is V, A, G or T; Xa s4 is V, A, G or L; Xaass is T, G or A; Xaas9 is L, M, V, F, K, A, R, N, D, C, E, Q, G, H, I, P, S, T, W, or Y; Xaaso is G, K, V, F, A, R, N, D, C, E, Q, H, I, L, M, P, S. T, W, or Y; Xaasi is L, Y, V, F, K, A, R, N, D, (. E, Q, G, II, I, M, P, S, T, or W; Xaaso is R or K; Xaa?i is T or S; Xaa?3 is I or K; Xaa-: is P or A; Xaa?s is H or Q; Xaa76is Q or L; Xaa?9 is S or T; Xaasr is T, R or absent; Xaass is absent, T or E;1902004-0002-005-W01Xaa86is R, N or absent; Xaa87is N, L or absent; Xaa88is absent, E or L; Xaa91is K, Q or absent; Xaa92is D, L, Y or absent; Xaa94is H, Q or absent; Xaa100is absent, V or L; Xaa101is absent, V or K; Xaa102is absent, I or N; Xaa103is absent, G or R; Xaa104is absent, P, D or A; Xaa105is absent or F; Xaa106is absent, F, W, Y, N, Q, K, H, D, G, E or V; Xaa107is absent, L, M, V, F, K, A, R, N, C, E, Q, G, H, I, P, S, T, W, or Y or D; Xaa108is absent, R, T, Q, L, K, W or G; Xaa109is absent, S or P; Xaa110is absent or I; Xaa111is absent, R or H; Xaa112is absent or H; and Xaa113is absent or R.

[0048] In some embodiments, Xaa60 is a glycine (G) residue. In some embodiments, the polypeptide binds BMP 10. In some embodiments, the fusion protein further comprises a linker sequence. In some embodiments, the fusion protein further composes a linker sequence selected from SEQ ID NO: 6, SEQ ID NO: 7 or SEQ ID NO: 8. In some embodiments, the Fc sequence comprises an amino acid sequence according to SEQ ID NO: 285. In some embodiments, the ALK6 ECD sequence an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%. 97%, 98%. 99%, or 100% identical to a sequence selected from any one of SEQ ID NO: 132 to 155.

[0049] In certain embodiments, the disclosure provides a soluble recombinant bone morphogenetic protein receptor type- IB fusion protein composing an ALK6 ECD polypeptide and a Fc sequence, wherein the ALK6 ECD polypeptide comprises an amino acid sequence selected from a sequence of SEQ ID NO: 190: Lysi - Lys2 - Glus - Asp4- Glys - Glus - Sen - Tlirs - Ala9 - Proio - Thru - Proi2 - Argi3 -Prow - Xaais - Xaais - Leun - Argis - Cysi9 -Xaa2o - Cys2i - Xaa22 - Xaa’22 - Xaa’22 - Xaa23 - Xaa’23 - Xaa24 - Cys25 - Pro26 - Xa 2? - Asp28 - Xaa29 - Xaaso - As i - Asmz - Xaa33 - Cys34 - Xaass - Thr,s - Xaa.37 - Glyss - Xaa39 - Cys4o - Phe4i - Xaa42 - Xaa 3 - 11644 - Ghus - Ghus - Asp47 - Asp48 - Xaai9 - Glyso - Xaasi - Xaas 2 - Xaas3 - Xaas4 - Xaass - Serse - Glys7 - Cysss - Xaas9 - Xaaso - Xaasi - Glu62 - Gives - Set64 -Aspes - Phese - Gins? - Cyses - Xaaeo - Asp?o - Xaa?i - Pro?2 - Xaa?3 - Xaa?4- Xaa7s - Xaa76 - Arg77 - Arg78 - Xaa79 - Ileso - Glusi -- Cyss2 - Cyss3 - Xaas4 - Xaass - Xaass - Xaas7 - Xaass - Cys89 - Asii9o - Xaa9i - Xaa92 - Leu93 - Xaa94 - Proos - Thr e - Leu97 - Progs - Pro99 - Leuioo -Lysioi - Asmo2 - Argios - Xaaior - Pheios - Valioe - Xaaio? - Xaaios - Xaaioo - Xaano - Xaam - Xaam. - Xaai 13; wherein Xaais is K or P; Xaaie is V or I; Xaa20 is V, F, K, A, R, N, D, C, E, Q, G, H, I, L, M, P, S, T, W, or Y; Xaa22is G, H, V, F, K, A, R, N, D, C, E, Q, I, L, M, P, T, W, Y or S; Xaa’22 is absent, G, S, or A; Xaa”22 is absent or S; Xaa23 is S, H, V, F, K, A, R, N, D, C, E, Q, I, L, M, P, T, W, Y or G; Xaa’23 is absent, L or FI; Xaa24is V, F, K, A, R, N, D, C, E, Q, G, H, I, L, M, P, S, T, W, or Y; Xaam is E or D; Xaa?,9 is S, G or A; Xaaso is V, A, G or I;1902004-0002-005-W01Xaa33is I, S or T; Xaa35is S, T, G, A or I; Xaa37is D, A, G or N; Xaa39is Y, A, G or H; Xaa42is T or A; Xaa43is M or I; Xaa49is S, A, G or Q; Xaa51is L, A, G or E; Xaa52is P or T; Xaa53is V, A, G or T; Xaa54is V, A, G or L; Xaa55is T, G or A; Xaa59is L, M, V, F, K, A, R, N, D, C, E, Q, G, H, I, P, S, T, W, or Y; Xaa60is G, K, V, F, A, R, N, D, C, E, Q, H, I, L, M, P, S, T, W, or Y; Xaa61is L, Y, V, F, K, A, R, N, D, C, E, Q, G, H, I, M, P, S, T, or W; Xaa69is R or K; Xaa71is T or S; Xaa73is I or K; Xaa74is P or A; Xaa75is H or Q; Xaa76is Q or L; Xaa79is S or T; Xaa84is absent, T or R; Xaa85is absent, T or E; Xaa86is absent, R or N; Xaa87is N or L; Xaa88is absent, E or L; Xaa91is absent, K or Q; Xaa92is absent, D, Y or L; Xaa94is absent, H or Q; Xaa104is D or A; Xaa107is absent; Xaa108is absent; Xaa109is absent; Xaa110is absent; Xaa111is absent; Xaa112is absent; and, Xaa113is absent,

[0050] In some embodiments, Xaa60 is a glycine (G) residue. In some embodiments, the polypeptide binds BMP 10. In some embodiments, the fusion protein further comprises a linker sequence. In some embodiments, the fusion protein further comprises a linker sequence selected from SEQ ID NO: 6, SEQ ID NO: 7 or SEQ ID NO: 8. In some embodiments, the Fc sequence comprises an amino acid sequence according to SEQ ID NO: 285. In some embodiments, the ALK6 ECD sequence an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a sequence selected from any one of SEQ ID NO: 158 to 189.

[0051] In certain embodiments, the disclosure provides a soluble recombinant bone morphogenetic protein receptor type- IB fusion protein comprising an ALK6 ECD polypeptide and a heterologous sequence, wherein the ALK6 ECD polypeptide comprises an amino acid sequence selected from a sequence of SEQ ID NO: 437: Lys1– Lys2– Glu3– Asp4– Gly5– Glu6– Ser7– Thr8– Ala9– Pro10– Thr11– Pro12– Arg13–Pro14– Xaa15– Xaa16– Leu17– Arg18– Cys19– Xaa20– Cys21– Xaa22– Xaa23– His24– Cys25– Pro26– Xaa27– Asp28– Xaa29– Xaa30– Asn31– Asn32– Xaa33– Cys34– Xaa35– Thr36– Xaa37– Gly38– Xaa39– Cys40– Phe41– Xaa42– Xaa43– Ile44– Glu45– Glu46– Asp47– Asp48– Xaa49– Gly50– Xaa51– Xaa52– Xaa53– Xaa54– Xaa55– Ser56– Gly57– Cys58– Xaa59– Xaa60– Xaa61– Glu62– Gly63– Ser64– Asp65– Phe66– Gln67– Cys68– Xaa69– Asp70– Xaa71– Pro72– Xaa73– Xaa74– Xaa75– Xaa76– Arg77– Arg78– Xaa79– Ile80– Glu81– Cys82– Cys83– Xaa84– Xaa85– Xaa86– Xaa87– Xaa88– Xaa89– Xaa90– Xaa91– Xaa92– Xaa93– Xaa94– Xaa95– Xaa96– Xaa97– Xaa98– Xaa99– Xaa100– Xaa101– Xaa102– Xaa103– Xaa104– Xaa105– Xaa106– Xaa107– Xaa108– Xaa109– Xaa110– Xaa111– Xaa112– Xaa113; wherein: Xaais is K or P; Xaais is V or I; Xaaso is V, F, K or Y; Xaa22 is G, II or S; Xaa’ 22 is absent, G, S or A; Xaa?,3 is S, H or G; Xaa?.? is E or D; Xaa29 is S or A; Xaa30is V or I; Xaass1902004-0002-005-W01is I or T; Xaa35is S or I; Xaa37is D or N; Xaa39is Y or H; Xaa42is T or A; Xaa43is M or I; Xaa49is S or Q; Xaa51is L or E; Xaa52is P or T; Xaa53is V or T; Xaa54is V or L; Xaa55is T or A; Xaa59is L or M; Xaa60is G or K; Xaa61is L or Y; Xaa69is R or K; Xaa71is T or S; Xaa73is I or K; Xaa74is P or A; Xaa75is H or Q; Xaa76is Q or L; Xaa79is S or T; Xaa84is T or R; Xaa85is absent, T or E; Xaa86is R or N; Xaa87is absent, N or L; Xaa88is absent, E or L; Xaa89is absent or C; Xaa90is absent or N; Xaa91is absent, K or Q; Xaa92is absent, D or L; Xaa93is absent or L; Xaa94is absent, H or Q; Xaa95is absent or P; Xaa96is absent or T; Xaa97is absent or L; Xaa98is absent or P; Xaa99is absent or P; Xaa100is absent, V or L; Xaa101is absent, V or K; Xaa102is absent, I or N; Xaa103is absent, G or R; Xaa104is absent, P, D or A; Xaa105is absent or F; Xaa106is absent, F or V; Xaa107is absent or D; Xaa108is absent or G; Xaa109is absent, S or P; Xaa110is absent or I; Xaa111is absent, R or H; Xaa112is absent or H; and, Xaa113is absent or R.

[0052] The fusion protein of claim 57, wherein Xaa60 is a glycine (G) residue. In some embodiments, the polypeptide binds one or more of BMP6, BMP7 and / or BMP10. In some embodiments, the fusion protein further comprises a linker sequence, in some embodiments, the fusion protein further comprises a linker sequence selected from SEQ ID NO: 6, SEQ ID NO: 7 or SEQ ID NO: 8. In some embodiments, the Fc sequence comprises an amino acid sequence according to SEQ ID NO: 285. In some embodiments, the ALK6 ECD sequence an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a sequence selected from any one of SEQ ID NO: 90, 286, 292, 298, 304, 310, 316, 322, 328, 334 340, 346, 352, 358, 364, 370, 376, 382, 388, 394, 400, 406, 412, 418, 425 and 431.

[0053] In certain embodiments, the disclosure provides a soluble recombinant bone morphogenetic protein receptor type-IB fusion protein composing an ALK6 extra cellular domain (ECD) polypeptide and a heterologous sequence, wherein the ALK6 ECD polypeptide comprises an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to an ALK6 ECD sequence selected from SEQ ID NO: 132-156, 158-189, 191-194, 202, 213, 218, 223, 228, 233, 242, 247, 252, 257, 262, 272, 277 and 283. In certain embodiments, the disclosure provides a soluble recombinant bone morphogenetic protein receptor type-IB fusion protein comprising: an ALK6 extra cellular domain (ECD) and a heterologous sequence wherein the ALK6 ECD sequence comprises an amino acid sequence that is at least 70%, 75%, 80%. 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to an1902004-0002-005-W01ALK6 ECD sequence selected from SEQ ID NO: 202, 213, 218, 223, 228, 233, 242, 247, 252, 257, 262, 272, 277 and 283. In certain embodiments, tire disclosure provides a soluble recombinant bone morphogenetic protein receptor type- IB fusion protein comprising: an ALK6 extra cellular domain (ECD) and a heterologous sequence wherein the ALK6 ECD sequence comprises an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to an ALK6 ECD sequence selected from SEQ ID NO: 90, 286, 292, 298, 304, 310, 316, 322, 328, 334, 340, 346, 352, 358, 364, 370, 376, 382, 388, 394, 400, 406, 412, 418, 425 and 431. In some embodiments, the disclosure provides a soluble recombinant bone morphogenetic protein receptor type-lB fusion protein comprising: an ALK6 extra cellular domain (ECD) and a heterologous sequence wherein the ALK6 ECD sequence comprises an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to an ALK6 ECD sequence according to SEQ ID NO: 286.

[0054] In some embodiments, the polypeptide binds BMP6, BMP7 and / or BMP 10. In some embodiments, the fusion protein further comprises a linker sequence. In some embodiments, the fusion protein further comprises a linker sequence selected from SEQ ID NO: 6, SEQ ID NO: 7 or SEQ ID NO: 8. In some embodiments, the Fc sequence comprises an amino acid sequence according to SEQ ID NO: 285.

[0055] In certain embodiments, the disclosure provides a soluble recombinant bone morphogenetic protein receptor type-lB fusion protein comprising: an ALK6 extra cellular domain (ECD), a linker sequence and a heterologous sequence wherein the fusion protein sequence comprises an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical SEQ ID NO: 291, 297, 303, 309, 315, 321, 327, 333, 339, 345, 351, 357, 363, 369, 375, 381, 387, 393, 399, 405, 411, 417, 423, 424, 430, and 436.

[0056] In certain embodiments, the disclosure provides a soluble recombinant bone morphogenetic protein receptor type-lB fusion protein comprising: an ALK6 extra cellular domain (ECD), a linker sequence and a heterologous sequence wherein the fusion protein sequence comprises an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 291.1902004-0002-005-W01

[0057] In some embodiments, the linker sequence is according to SEQ ID NO: 6. In some embodiments, the heterologous sequence is an Fc sequence comprising an amino acid sequence according to SEQ ID NO: 285. In some embodiments, the ALK6 ECD polypeptide is present as a homodimer.

[0058] In certain embodiments, the disclosure provides a soluble recombinant bone morphogenetic protein receptor type- IB fusion protein comprising: (i) an ALK6 extra cellular domain (ECD); (ii) a linker sequence; and (iii) an Fc domain sequence; wherein the ALK6 ECD sequence comprises or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to an ALK6 ECD sequence of SEQ ID NO: 286, wherein the position corresponding to position 60 of SEQ ID NO: 69 is a glycine (G) residue, and wherein the ALK6 fusion protein demonstrates retained binding to BMP 10.

[0059] In some embodiments, the ALK6 fusion protein demonstrates BMP10 binding comparable to SEQ ID NO: 49. In some embodiments, the ALK6 fusion protein demonstrates BMP 10 binding comparable to binding of an ALK6 wildtype (wt) Fc fusion protein. In some embodiments, the ALK6 fusion protein demonstrates an nM IC50value of about 7.2 for BMP10 binding. In some embodiments, the ALK6 fusion protein demonstrates an nM IC50value of about 4.8 for BMP7 binding.

[0060] In certain embodiments, the disclosure provides a soluble recombinant bone morphogenetic protein receptor type- IB fusion protein comprising: (i) an ALK6 extra cellular domain (ECD); (ii) a linker sequence; and, (iii) an Fc domain sequence; wherein the fusion protein sequence comprises or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to an ALK6 fusion protein sequence of SEQ ID NO: 291, wherein the position corresponding to position 60 of SEQ ID NO: 69 is a glycine (G) residue, and wherein the ALK6 fusion protein demonstrates retained BMP 10 binding.

[0061] In some embodiments, the ALK6 fusion protein demonstrates BMP10 binding comparable to SEQ ID NO: 49. In some embodiments, the ALK6 fusion protein demonstrates BMP 10 binding comparable to binding of an ALK6 wildtype (wt) Fc fusion protein. In some embodiments, the ALK6 fusion protein demonstrates an nM IC50value of about 7.2 for BMP10 binding. In some embodiments, the ALK6 fusion protein demonstrates an nM IC50value of about 4.8 for BMP7 binding. In some embodiments, the position corresponding to position 60 of SEQ ID NO: 69 is a glycine (G) residue, and wherein the ALK6 fusion protein demonstrates1902004-0002-005-W01retained BMP 10 binding. In some embodiments, the ALK6 fusion protein demonstrates BMP 10 binding comparable to SEQ ID NO: 49. In some embodiments, the ALK6 fusion protein demonstrates BMP 10 binding comparable to binding of an ALK6 wildtype (wt) Fc fusion protein. In some embodiments, the ALK6 fusion protein demonstrates an nM IC50value of about In some embodiments, the ALK6 fusion protein demonstrates an nM IC50value of about 4.8 for BMP7 binding. In some embodiments, the linker sequence comprises an amino acid sequence selected from SEQ ID NO: 6, SEQ ID NO: 7 or SEQ ID NO: 8. In some embodiments, the Fc sequence comprises an amino acid sequence selected from SEQ ID NO: 10, SEQ ID NO: 106 or SEQ ID NO: 107.

[0062] In embodiments, provided herein are pharmaceutical composition comprising a fusion protein disclosed herein; and at least one pharmaceutical acceptable carrier or buffer. In some embodiments, the pharmaceutical composition comprises an ALK6 ECD polypeptide. In some embodiments, the ALK6 ECD polypeptide is present as a homodimer,

[0063] BRIEF DESCRIPTION OF THE DRAWINGS

[0064] Figure 1 A and Figure 1 B show SDS-PAGE gels for a number soluble ALK6 Fc fusion proteins purified using protein A chromatography (SEQ ID NO: 46-50, 70, 72, 74, 76, 84 and 85) and the cleavage fragment indicating a protease cleavage site present in SEQ ID NO: 49, 47 and 76. See Example 1.

[0065] Figure 2A and Figure 2B show SDS-PAGE gels for a number of soluble ALK6 Fc fusion protein variants using purified using protein A chromatography and demonstrating no cleavage fragments and indicating removal of the protease cleavage site and reduced aggregation for some variants in the non-reduced lanes of the gel. Figure 2A shows the quantity of soluble ALK6 Fc fusion protein generated in 200 ml of cell culture demonstrating significantly improved expression for some of the variant (e.g. SEQ ID NO: 60 and 62). Those variants have point mutations replacing two histidine residues (aa22 and aa23) with serine and glycine, (SEQ ID NO: 60 also has the lysine at position 20 replaced with a tyrosine) and when compared to the expression of SEQ ID NO: 46, indicates doing so provides dramatic improvement in the expression level of those fusion proteins. See Example 2.

[0066] Figure 2C shows SDS-PAGE gels for a number of soluble ALK6 Fc fusion protein variants using purified using protein A chromatography and demonstrating no cleavage fragm ents and indicating removal of the protease cleavage site and reduced aggregation in the non-reduced lanes of the gel. The gel also shows the quantity of soluble ALK6 Fc fusion1902004-0002-005-W01protein generated in 10ml of cell culture demonstrating significantly improved expression for some of the variants (e.g., SEQ ID NO: 234 and SEQ ID NO: 243. Those variants have point mutations replacing isoleucine (I) at aa33 and serine (S) at aa35 with threonine (T) and isoleucine (I), respectively. Those point mutations on either side of the cystine residue (at position 34) introduce a glycosylation site dramatically improving folding and expression of the fusion protein. See Example 2.

[0067] Figure 3 A shows BMP4 and BMP 10 binding for soluble ALK6 Fc fusion proteins of this disclosure. The binding data demonstrates two of the variants (SEQ ID NO: 46 and 52) retain BMP4 and BMP 10 ligand binding (as compared to the ALK6 wt sequence, which binds BMP2, BMP4, BMP6, BMP7, BMP 10 and GDF5, GDF6 and GDF7), but that SEQ ID NO: 55 no longer binds BMP 10 indicating the LGL to MKY change at positions 59, 60 and 61, respectively, is responsible for the loss of binding. See Example 3.

[0068] Figure 3B shows ligand binding for soluble ALK6 Fc fusion proteins of this disclosure, wherein NB indicates no binding and a blank box in the table means the ligand binding was not tested. SEQ ID NO: 89 demonstrated a loss of BMP10 binding (as compared to ALK6 wt sequence) and which contains the same G60K point mutation as SEQ ID NO: 55 (which also has a loss of BMP 10 binding and a reduction in BMP7 binding) indicating that point mutation is responsible for the change in ligand binding for BMP 10. SEQ ID NO: 89 (and SEQ IDNO:91 and 93) also demonstrates a retention of BMP7 binding (as compared to ALK6 wt sequence), while SEQ ID NO: 55 only demonstrates weak binding to BMP7. See Example 3.

[0069] Figure 4 shows an IC50 test of SEQ ID NO: 87 in a BMP Responsive Luciferase Assay for the BMP2, BMP4, BMP6 and BMP10 ligands. See Example 4.

[0070] Figure 5 shows an IC50 test of SEQ ID NO: 70 in a BMP Responsive Luciferase Assay for the BMP2, BMP4, BMP6 and BMP10 ligands. See Example 4.|0071] Figure 6 shows representative fundus fluorescein angiography (FFA) images before treatment, wherein no significant differences were observed in either the number of leakage lesions or the total leakage area of the treatment groups (G2: ALK6-Fc fusion comprising SEQ ID NO: 286 and G3: ALK6-Fc fusion comprising SEQ ID NO: 87) as compared to tire control group (Gl). See Example 9.1902004-0002-005-W01

[0072] Figure 7 shows representative fundus fluorescein angiography (FFA) images on Day 14 of systemic dosing, wherein the number of leakage lesions and leakage area were significantly decreased in G2 and G3 compared to G1 (PBS). See Example 9.

[0073] Figure 8 shows representative fundus fluorescein angiography (FFA) images on Day 21 of systemic dosing, wherein the number of leakage lesions and leakage area 'ere significantly decreased in G2 and G3 compared to Gl (PBS). See Example 9.

[0074] Figure 9 show's a graph of the number of counted leakage lesions pre-dosing, Day 14 and Day 21 in each of Gl, G2 and G3. Gl - PBS; G2 - ALK6 ECD Fc fusion protein comprising SEQ ID NO: 286; G3 - ALK6 ECD Fc fusion protein comprising SEQ ID NO: 87. See Example 9.

[0075] Figure 10 show s a graph of the measured area of the leakage lesions pre-dosing, Day 14 and Day 21 in each of Gl, G2 and G3. Gl - PBS; G2 - ALK6 ECD Fc fusion protein comprising SEQ ID NO: 286; G3 - ALK6 ECD Fc fusion protein comprising SEQ ID NO: 87. See Example 9.

[0076] Figure 11 show s a graph of the measured area of the leakage lesions pre-dosing, and on Day 7 and Day 14 of intravitreal dosing of an ALK6 Fc fusion protein comprising SEQ ID NO: 286 as compared to EYLEA. Gl - PBS; G2 - ALK6 ECD Fc fusion protein comprising SEQ ID NO: 286; G3 - EYLEA. See Example 10.

[0077] Figure 12 show s a decrease in leakage area in DL-AAA rabbit model; left graph show s aggregate of all animals treated with an ALK6 ECD Fc fusion protein comprising SEQ ID NO: 286 and the graph on right show s individual animals with same treatment and the bottom image is an FA image of rabbit no. 104 showing decreased leakage area on Day 0, Day 7 and Day 14 of intravitreal dosing of an ALK6 Fc fusion protein comprising SEQ ID NO: 286. See Example 11.

[0078] Figure 13 shows pictures from three SDS-PAGE gels with reduced and not reduced lanes with the ALK6wt-Fc fusion protein (SEQ ID NO:49), left gel, variant construct SEQ ID NO: 70 (middle gel) and variant construct SEQ ID NO: 287 (right gel), wherein SEQ ID NO: 49 is aggregated and has a protease cleavage site in the c -terminus (indicated on gel); SEQ ID NO: 70 remains aggregated (multiple bands above the * band of the fusion protein) but is no longer cleaved; and SEQ ID NO: 287 is no longer aggregated or cleaved. See Example 1.1902004-0002-005-W01

[0079] Figure 14 shows the reduced and non-reduced SDS-PAGE gels with a number of ALK6 variant constructs demonstrating those constructs are not aggregated or cleaved. See Example lb.

[0080] Figure 15 shows the ligand binding (BMP2, BMP7, BMP 10, BMP4 and BMP6) for SEQ ID NO: 287 wherein SEQ ID NO: 287 is a weak and partial inhibitor of BMP2 signaling. See Example 4.

[0081] DETAILED DESCRIPTION OF THE DISCLOSURE

[0082] Overview

[0083] This disclosure relates to soluble bone morphogenetic protein (BMP) receptor type IB polypeptides comprising an extracellular domain of ALK6 (activin receptor-like kinase 6) and variants thereof (“ALK6 polypeptides”), soluble polypeptides, dimeric complexes, methods of making and uses thereof. Endogenous ALK6 is a member of the TGF-beta superfamily wherein signaling in vivo is mediated by heteromeric complexes of type I and type II serine / threonine kinase receptors, which phosphorylate and activate downstream SMAD proteins (e.g., SMAD proteins 1, 2, 3, 5, and 8) upon ligand stimulation. See, e.g., Massague (2000) Nat. Rev. Mol. Cell Biol. 1:169-178. These type I and type II receptors are transmembrane proteins, composed of a ligand-binding extracellular domain (ECD) with cysteine-rich region, a transmembrane domain, and a cytoplasmic domain with predicted serine / threonine kinase specificity. In general, type I receptors mediate intracellular signaling while the type II receptors are required for binding TGF-beta superfamily ligands. Type I and II receptors form a stable complex after ligand binding, resulting in phosphorylation of type I receptors by type II receptors.

[0084] Ligands for ALK6 are BMPs which are members of the TGF-beta superfamily, and exhibit broad spectra of biological activities in various tissues, including bone, cartilage, blood vessels, endothelia, heart, kidney, neurons, liver and lung. The BMPs and GDFs together form a family of cysteine-knot cytokines sharing the characteristic fold of the TGF-beta superfamily. See, e.g., Rider et al. (2010) Biochem J., 429(1): 1-12. This family includes, for example, BMP2, BMP4, BMP5, BMP6, BMP7, BMP2a, BMP3, BMP3b (also known as GDF10), BMP8, BMP8a, BMP8b, BMP9 (also known as GDF2), BMP 10, BMP 11 (also known as GDF11), BMP12 (also known as GDF7), BMP13 (also known as GDF6), BMP14 (also known as GDF5), BMP 15, GDFI, GDF3 (also known as VGR2), GDF8 (also known as myostatin),1902004-0002-005-W01GDF9, and GDF15. Besides the ability to induce bone formation, which gave the BMPs their name, the BMP / GDFs display morphogenetic activities in the development of a wide range of tissues. BMP / GDF homo- and hetero-dimers interact with combinations of type I and type II receptor dimers to produce multiple possible signaling complexes, leading to the activation of one of two competing sets of SMAD transcription factors. BMP / GDFs have highly specific and localized functions. These are regulated in a number of ways, including the developmental restriction of BMP / GDF expression and through the secretion of several specific BMP antagonist proteins that bind with high affinity to the cytokines.

[0085] BMP signaling has also been shown to contribute to the degeneration of various cell types in the eye including retinal pigment epithelial cells and inhibition of BMP signaling in various models of eye disease has been shown to improve retinal structure. For example in a murine model of retinitis pigmentosa mice homozygous for the PDE6B mutation, inhibition of BMP signaling decreased glial fibrillary acidic protein (GFAP), a marker of Muller cell stress, and a significant reduction in cell death and significantly increased retinal thickness and electrophysiologic performance (ERG) by the retinas from treated mice.

[0086] Many eye diseases lead to loss of retinal structure and function. BMP inhibition has also been shown to promote activation of retinal stem cells providing the potential for restoration of mature retinal cells and improved vision in diseases associated with retinal degeneration.

[0087] In addition, BMP signaling has also been shown to promote vascular inflammation which is an important contributor to several diseases including atherosclerosis, Alzheimer’s disease multiple sclerosis, and several retinopathies. The endothelium is defined as the thin internal cell layer of blood and lymphatic vessels that are derived from mesodermal lineage. BMP signaling has been shown to lead to endothelial mesenchymal transformation or EMT leading to dysfunctional vasculature and pathological sequela. Healthy endothelium plays an essential role mainly in providing nutrients and oxygen to organs, regulating antioxidant factors, modulating the response to infection, controlling the vascular tone, and the formation of new blood vessels. This last process, named angiogenesis consists of the formation of new blood vessels from the pre-existing ones as a result of angiogenic growth factor induction. In adulthood, the endothelium is quiescent, meaning that the balance between pro- and anti-angiogenic modulators ensures the stability of blood vessel. However, angiogenesis can be reactivated under either physiological (wound healing, placentation, menstruation) or1902004-0002-005-W01pathological conditions (tumorigenesis, stroke, inflammation, rheumatoid arthritis, etc.). Among the factors contributing to vascular development and homeostasis, vascular endothelial growth factor (VEGF) is a key endothelial cell activator. VEGF triggers proliferation toward VEGF gradient, survival, and permeability of endothelial cell. To ensure the stability of the new formed-vessel, a step of vessel maturation is required through quiescent factors control.

[0088] Angiogenesis plays a crucial role in numerous pathological conditions such as inflammation and tumorigenesis. In addition, regenerative medicine for vascular systems has attracted much attention as a potential means of eliminating the vascular-system defects accompanying diabetes and other diseases. Provided herein are molecules that bind selectively to BMP for the treatment of inflammation and vascular dysfunction.

[0089] Provided herein in embodiments are BMP trap molecules (“BMP antagonists”) comprising the soluble ALK6 polypeptides of this disclosure, which bind BMP ligands and prevent their binding to endogenous transmembrane receptors thus down regulating the BMP signaling pathway. Inhibiting selective BMPs (those that naturally bind to ALK-6, provided above, or those through point mutation have been engineered to bind by ALK6 variants of this disclosure), are provided herein as treatment for inflammation and vascular dysfunction. ALK6 ligands including BMP 2, 4, 5, 6, and 7 are associated with vascular inflammation, inhibiting any those while not inhibiting / binding to BMP-9 and / or BMP-10 may participate in quiescence of endothelia cells. This down regulation of selected BMP signaling pathways inhibits, for example, the Smad 1 / 5 / 8 cascade alleviating certain vascular inflammation disorders such as retinopathy. In embodiments, selective inhibition of BMP molecules may shift or restore a balance so that the BMP molecules not bound by the ALK-6 polypeptide of this disclosure (e.g. BMP 9) are now free to bind their target receptor without competition from other BMP ligands (e.g. BMP 2, 4, 5, 6, and 7). In certain embodiments, BMP9 endothelia quiescent activity is increased by inhibiting competing ligands. As used herein, a “trap molecule” sequesters the respective ligand (e.g. BMPs) before it can interact with the endogenous receptor and thus inhibiting the signal transduction pathway. The soluble ALK6 polypeptides, when fused to a heterologous domain (e.g., Fc domain or IgG hinge region) (“fusion polypeptide”) form homodimers. In embodiments, any sequence that will form one or more disulfide bonds can be used to form the homodimers.

[0090] Provided in certain embodiments are methods for the treatment of retinopathy, comprising administering the soluble ALK6 polypeptides of this disclosure to a subject in need1902004-0002-005-W01thereof. In certain embodiments the method for the treatment of retinopathy comprises administering a pharmaceutical composition to a subject in need thereof, wherein the composition comprises a soluble recombinant bone morphogenetic protein receptor type- IB fusion protein comprising an ALK6 ECD polypeptide and a Fc sequence of this disclosure. In embodiments, the Fc sequence is not full length but just long enough to for the fused ALK6 ECD polypeptides to form homodimers.

[0091] Applicants surprisingly found that maintaining a glycine (G) residue at position 60, according to SEQ ID NO: 1, provides an ALK6 ECD variant that binds BMP10 (even with one or more point mutations or a deletion of C- or N-terminal residues). ALK6 ECD variants, such as SEQ ID NO: 55 and SEQ ID NO: 89, that had a point mutation at that position (e.g., G60K) lost BMP 10 binding as compared to the ALK6 wt ECD sequence (SEQ ID NO: 46).See Figure 3B. In certain embodiments, the ALK6 fusion proteins of this disclosure bind BMP10 (variants with glycine at amino acid position 60). In certain other embodiments, the ALK6 fusion proteins of this disclosure do not bind BMP 10 (e.g. contain a point mutation at amino acid position such as G60K). In certain embodiments provided herein are soluble recombinant bone morphogenetic protein receptor type-lB fusion proteins comprising an ALK6 extra cellular domain (ECD) polypeptide according to this disclosure, a linker sequence and a Fc sequence, which partially inhibit BMP2 signaling.

[0092] Provided in certain embodiments are methods for treating a retinopathy disease, comprising administering the soluble ALK6 Fc fusion proteins of this disclosure to a subject in need thereof. In certain embodiments the method for treating the retinopathy disease comprises administering a pharmaceutical composition to a subject in need thereof, wherein the composition comprises a soluble recombinant bone morphogenetic protein receptor type-1B fusion protein comprising an ALK6 ECD polypeptide, a linker and a Fc sequence of this disclosure. In certain embodiments the soluble ALK6 ECD-Fc fusion protein is SEQ ID NO: 291, or a sequence having at least 90% identity to SEQ ID NO: 291.

[0093] Definitions

[0094] The terms used in this specification generally have their ordinary meanings in the art, within the context of this disclosure and in the specific context where each term is used. Certain terms are discussed below or elsewhere in the specification to provide additional guidance to the practitioner in describing the compositions and methods of the disclosure and how to make1902004-0002-005-W01and use them. The scope or meaning of any use of a term will be apparent from the specific context in which it is used.

[0095] Tire term “sequence similarity,” in all its grammatical forms, refers to the degree of identity or correspondence between nucleic acid or amino acid sequences that may or may not share a common evolutionary origin.

[0096] " Percent (%) sequence identity" with respect to a reference polypeptide (or nucleotide) sequence is defined as the percentage of amino acid residues (or nucleic acids) in a candidate sequence that are identical to the amino acid residues (or nucleic acids) in the reference polypeptide (nucleotide) sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared. For purposes herein, however, % amino acid (nucleic acid) sequence identity values are generated using the sequence comparison computer program ALIGN-2. The ALIGN-2 sequence comparison computer program was authored by Genentech, Inc., and the source code has been filed with user documentation in the U. S. Copyright Office, Washington D C, 20559, where it is registered under U. S. Copyright Registration No. TXU510087. The ALIGN-2 program is publicly available from Genentech, Inc., South San Francisco, Calif., or may be compiled from the source code. The ALIGN-2 program should be compiled for use on a UNIX operating system, including digital UNIX V4.0D, All sequence comparison parameters are set by the ALIGN-2 program and do not vary.

[0097] “Antagonize”, in all its grammatical forms, refers to the process of inhibiting a protein and / or gene (e.g., by inhibiting or decreasing that protein’s gene expression or by inducing an active protein to enter an inactive state) or decreasing a protein’s and / or gene’s activity. As used herein the ALK6 polypeptides are referred to as antagonists for the endogenous ALK6 transmembrane receptor signaling pathway wherein the ALK6 polypeptides bind and sequester their endogenous BMP ligand.

[0098] Tire terms "about" and "approximately" as used in connection with a numerical value throughout the specification and the claims denotes an interval of accuracy, familiar and1902004-0002-005-W01acceptable to a person skilled in the art. In general, such interval of accuracy is ± 10%. Alternatively, and particularly in biological systems, the terms "about" and "approximately" may mean values that are within an order of magnitude, preferably < 5 -fold and more preferably < 2-fold of a given value.

[0099] Numeric ranges are inclusive of the numbers defining tire range. Measured and measurable values are understood to be approximate, taking into account significant digits and the error associated with the measurement. Accordingly, unless indicated to the contrary, the numerical parameters set forth in the following description and appended claims are approximations that may vary depending upon the desired properties sought to be obtained. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should at least be construed in light of the number of reported significant digits and by applying ordinary rounding techniques.

[0100] The terms "a" and "an" include plural referents unless the context in which the term is used clearly dictates otherwise. The terms "a" (or "an"), as well as the terms "one or more," and "at least one" can be used interchangeably herein. Furthermore, "and / or" where used herein is to be taken as specific disclosure of each of the two or more specified features or components with or without the other. Thus, the term “and / or" as used in a phrase such as " A and / or B" herein is intended to include " A and B," " A or B," " A" (alone), and " B" (alone). Likewise, the term "and / or" as used in a phrase such as " A, B, and / or C" is intended to encompass each of the following aspects: A, B, and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone).

[0101] The term “or” is used herein in the inclusive sense, i.e., equivalent to “and / or” unless the context clearly requires otherwise.

[0102] The use of “comprise”, “comprises”, “comprising”, “contain”, “contains”, “containing”, “include”, “includes”, and “including” is not intended to be limiting, and means that at least the named compound, element, particle, or method step is present in the composition or article or method, but does not exclude the presence of other compounds, materials, particles, method steps, even if the other such compounds, material, particles, method steps have the same function as what is named.

[0103] The terms "treatment", "treating", “alleviating” and the like are used herein to generally mean obtaining a desired pharmacologic and / or physiologic effect, and may also be used to refer to improving, alleviating, and / or decreasing the severity of one or more clinical1902004-0002-005-W01complication of a condition being treated. The effect may be prophylactic in terms of completely or partially delaying the onset or recurrence of a disease, condition, or complications thereof, and / or may be therapeutic in terms of a partial or complete cure for a disease or condition and / or adverse effect attributable to the disease or condition. " Treatment" as used herein covers any treatment of a disease or condition of a mammal, particularly a human. As used herein, a therapeutic that “prevents” a disorder or condition refers to a compound that, in a statistical sample, reduces the occurrence of the disorder or condition in a treated sample relative to an untreated control sample, or delays the onset of the disease or condition, relative to an untreated control sample.

[0104] In general, treatment or prevention of a disease or condition as described in the present disclosure is achieved by administering one or more soluble ALK6 polypeptides of the present disclosure in an "effective amount". An effective amount of an agent refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic or prophylactic result. A "therapeutically effective amount" of an agent of the present disclosure may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the agent to elicit a desired response in the individual. A "prophylactically effective amount" refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired prophylactic result.

[0105] The term "eye disorder" is used herein interchangeable with “retinopathy” and as used herein refers to any eye disorder associated with pathological angiogenesis (also referred to herein interchangeably as "eye condition"), include. Eye disorders can be characterized by alteration or uncontrolled proliferation of new blood vessels and / or invasion of ocular tissue structures such as the retina or cornea. Non-limiting eye disorders include, for example, AMD (e.g., exudative AMD, dry AMD, intermediate AMD, progressive AMD, and map-like atrophy (GA)), macular degeneration, macular edema, DME. Local non-central DME and diffuse central involvement-related DME), retinopathy, diabetic retinopathy (DR) (e.g., proliferative DR (PDR), non-proliferative DR (NPDR), and high altitude DR), and others. Ischemic-related retinopathy, ROP, retinal vein occlusion (RVO) (e.g., central retinal vein occlusion (CRVO) and retinal branch vein occlusion (BRVO) morphology), CNV (e.g., myopic CNV), macular blood vessels Newborn, diseases associated with corneal angiogenesis, retinal angiogenesis, diseases associated with retinal / choroidal angiogenesis, pathological myopia, von Hippel Lindow's disease, eye macular degeneration, FEVR, Coates' disease, Norie's disease, OPPG, subconjunctival bleeding, cutaneous erythema, ocular angiogenesis, angiogenic glaucoma,1902004-0002-005-W01retinal pigment degeneration (RP), hypertensive retinopathy, macular degeneration, macular degeneration, macular degeneration, eye Internal angiogenesis, retinal degeneration, cyst-like macular edema (CME), vasculitis, optic nerve papilla edema, retinitis, conjunctivitis (e.g., infectious conjunctivitis and non-infectious (e.g., allergic) conjunctivitis), Labor congenital black internal disorder (also known as Labor congenital macular degeneration or LCA), macular degeneration (including infectious and non-infectious macular degeneration), choroiditis (e.g., polyfocal macular degeneration), ocular macular degeneration, eyelid inflammation Includes, dry eyes, traumatic eye damage, Sjogren's disease, and other eye disorders in which the disease or disorder is associated with ocular neovascularization, vascular leakage, and / or retinal edema. Additional exemplary eye disorders include all forms of proliferative vitreoretinopathy, diseases associated with cutaneous neovascularization of the angle, and fibrovascular or fibers. Includes diseases caused by overgrowth of tissue,

[0106] The term ‘“retina” refers to a region of the central nervous system with approximately 150 million neurons. It is located at the back of the eye where it rests upon a specialized epithelial tissue called retinal pigment epithelium or RPE. The retina initiates the first stage of visual processing by transducing visual stimuli in specialized neurons called “photoreceptors”. Their synaptic outputs are processed by elaborate neural networks in the retina and then transmitted to the brain. The retina has evolved two specialized classes of photoreceptors to operate under a wide range of light conditions. “Rod” photoreceptors transduce visual images under low light conditions and mediate achromatic vision. “Cone” photoreceptors transduce visual images in dim to bright light conditions and mediate both color vision and high acuity vision.

[0107] Every’ photoreceptor is compartmentalized into two regions called the “outer” and “inner” segment. The inner segment is the neuronal cell body containing the cell nucleus. The inner segment survives for a lifetime in the absence of retinal disease. The outer segment is the region where the light sensitive visual pigment molecules are concentrated in a dense array of stacked membrane structures. Part of the outer segment is routinely shed and regrown in a diurnal process called outer segment renewal. Shed outer segments are ingested and metabolized by RPE cells.

[0108] The term “macula” refers to the central region of the retina, which contains the fovea where visual images are processed by long slender cones in high spatial detail (“visual acuity”). “Macular degeneration” is a form of retinal neurodegeneration, which attacks the1902004-0002-005-W01macula and destroys high acuity vision in the center of the visual field. AMD can be in a “dry form” characterized by residual lysosomal granules called lipofuscin in RPE cells, and by extracellular deposits called “drusen”. Drusen contain cellular waste products excreted by RPE cells. “Lipofuscin” and drusen can be detected clinically by ophthalmologists and quantified using fluorescence techniques. They can be the first clinical signs of macular degeneration.

[0109] Lipfuscin contains aggregations of A2E. Lipofuscin accumulates in RPE cells and poisons them by multiple known mechanisms. As RPE cells become poisoned, their biochemical activities decline and photoreceptors begin to degenerate. Extracellular drusen may further compromise RPE cells by interfering with their supply of vascular nutrients. Drusen also trigger inflammatory processes, which leads to choroidal neovascular invasions of the macula in one patient in ten who progresses to wet form AMD. Both the dry form and wet form progress to blindness.

[0110] The term “ERG” is an acronym for electroretinogram, which is the measurement of the electric field potential emitted by retinal neurons during their response to an experimentally defined light stimulus. ERG is a non-invasive measurement, which can be performed on either living subjects (human or animal) or a hemisected eye in solution that has been removed surgically from a living animal.

[0111] The term “RAL” means retinaldehyde. “Free RAL” is defined as RAL that is not bound to a visual cycle protein. The terms “trans-RAL” and “all-trans-RAL” are used interchangeably and mean all-trans-retinaldehyde.

[0112] Also, in describing the embodiments, terminology will be resorted to for the sake of clarity. It is intended that each term contemplates its broadest meaning as understood by those skilled in the art and includes all technical equivalents which operate in a similar manner to accomplish a similar purpose.

[0113] Bone Morphogenetic Protein (BMP) Receptor Type IB Polypeptides

[0114] The present disclosure generally relates to soluble ALK6 polypeptides, variants thereof, compositions, and uses thereof (e.g., treating, preventing or reducing the progression rate and / or severity) of retinopathy disorders (e.g., diabetic retinopathy, age-related macular degeneration (AMD), choroidal neovascularization (CNV), vision loss, night blindness, photopsia, proliferative retinopathy, non-proliferative retinopathy, retinitis pigmentosa and hypertensive retinopathy)). As used herein the term “ALK6 polypeptide” refers to the1902004-0002-005-W01extracellular domain of human ALK6 provided for example in SEQ ID NO: 1, as well as any variants thereof (including mutants, fragments, fusions, and peptidomimetic forms) that retain a useful activity.

[0115] Numbering of amino acids for all ALK6-related polypeptides described herein is based on the numbering of the human ALK6 processed (mature) extracellular domain (ECD) human protein sequence provided below (SEQ ID NO: 1), unless specifically designated otherwise.KKEDGESTAPTPRPKVLRCKCHHHCPEDSVNNICSTDGYCFTMIEEDDSGLPVVTSG CLGLEGSDFQCRDTPI PHQRRS IECCTERNECNKDLHPTLPPLKNRDFVDGPIHHR(SEQ ID NO: 1)

[0116] The C -terminal “tail” of the extracellular domain is indicated by single underline in SEQ ID NO:1 (above). In certain embodiments the ALK6 ECD sequence with the “tail” deleted (a A14 sequence or A13 sequence) (“SEQ ID NO: 4 variant”) is as follows:KKEDGESTAPTPRPKVLRCKCHHHCPEDSVNNICSTDGYCFTMIEEDDSGLPVVTSG CLGLEGSDFQCRDTPI PHQRRS I ECCTERNECNKDLHPTLPP (L) (SEQ ID NO: 4 )

[0117] In certain embodiments the 14 amino acid deleted C terminal tail sequence is replaced with WIGPFFDGSIR (SEQ ID NO: 2) providing a variant AEK6 ECD polypeptide (“SEQ ID NO: 11 variant”) as follows:KKEDGESTAPTPRPKVLRCKCHHHCPEDSVNNICSTDGYCFTMIEEDDSGLPVVTSG CLGLEGSDFQCRDTPI PHQRRSIECCTERNECNKDLHPTLPPWIGPFFDGSIR(SEQ ID NO: 11)

[0118] In certain embodiments the C -terminus tail is further deleted for a total of 30 amino acids (SEQ ID NO: 439) and the amino acid deleted C terminal tail sequence is replaced with RTNLCNQYLQPTLPPWIG (SEQ ID NO: 195) providing a variant ALK6 ECD polypeptide (“SEQ ID NO: 156 variant”) as follows:KKEDGESTAPTPRPKVLRCKCHHHCPEDSVNNICSTDGYCFTMIEEDDSGLPVVTSG CLGLEGSDFQCRDTPI PHQRRS I ECCRTNLCNQYLQPTLPPWIG

[0119] In certain embodiments the C-terminus tail is further deleted for a total of 30 amino acids (SEQ ID NO: 439) and the amino acid deleted C terminal tail sequence is replaced with TNLCNQYLQPTLPPWIGPFFDGSIR (SEQ ID NO: 438) providing a variant AEK6 ECD polypeptide (“SEQ ID NO: 425 variant”) as follows:1902004-0002-005-W01KKEDGESTAPTPRPKVLRCKCHHHCPEDSVNNICSTDGYCFTMIEEDDSGLPVVTSG CLGLEGSDFQCRDTPI PHQRRS I ECCTNLCNQYLQPTLPPWIGPFFDGSIR

[0120] In certain other embodiments, a seven amino acid portion of tire “tail” sequence is deleted (a A7 sequence) from SEQ ID NO: 1 (“SEQ ID NO: 69 variant”), providing the following sequence:KKEDGESTAPTPRPKVLRCKCHHHCPEDSVNNICSTDGYCFTMIEEDDSGLPVVTSG CLGLEGSDFQCRDTPI PHQRRS IECCTERNECNKDLHPTLPPLKNRDFV (SEQ ID NO: 69)

[0121] In certain other embodiments provided herein the last two histidine amino acids of the “tail” sequence from SEQ ID NO: 1 (“SEQ ID NO: 80 variant”) are deleted providing an ALK6 ECD polypeptide having the sequence:KKEDGESTAPTPRPKVLRCKCHHHCPEDSVNNICSTDGYCFTMIEEDDSGLPVVTSG CLGLEGSDFQCRDTPI PHQRRSIECCTERNECNKDLHPTLPPLKNRDFVDGPI R(SEQ ID NO: 80)

[0122] In certain other embodiments provided herein the mutations K20Y; H22S; _22’A (inserted between aa22 and aa23) H23G are inserted into SEQ ID NO: 69 (“SEQ ID NO: 90 variant”) providing the following sequence:KKEDGESTAPTPRPKVLRCYCSAGHCPEDSVNNICSTDGYCFTMIEEDDSGLPWTS GCLGLEGSDFQCRDTPI PHQRRS IECCTERNECNKDLHPTLPPLKNRDFV

[0123] In certain other embodiments, a seven amino acid portion of the “tail” sequence is deleted (a A7 sequence) from SEQ ID NO: 1 (“SEQ ID NO: 113 variant”), and an arginine amino acid added between aa22 and aa23, providing the following sequence:KKEDGESTAPTPRPKVLRCKCHAHHCPEDSVNNICSTDGYCFTMIEEDDSGLPWTS GCLGLEGSDFQCRDTPI PHQRRS IECCTERNECNKDLHPTLPPLKNRDFV(SEQ ID NO: 113)

[0124] In certain embodiments the ALK6 ECD sequence within the N-terminus is deleted (a A10 sequence, a A13 sequence or a A16 sequence) (“SEQ ID NO: 153 variant”, “SEQ ID NO: 154 variant” or “SEQ ID NO: 155 variant”,) is as follows:

[0125] TPRPKVLRCKCHHHCPEDSVNNICSTDGYCFTMIEEDDSGLPWTSGCLGLEGSDFQ CRDTPI PHQRRS I ECCTERNECNKDLHPTLPPLKNRDFVDGPIHHR (SEQ ID NO:1902004-0002-005-W01

[0126] PKVLRCKCHHHCPEDSVNNICSTDGYCFTMIEEDDSGLPWTSGCLGLEGSDFQCRD TPIPHQRRSIECCTERNECNKDLHPTLPPLKNRDFVDGPIHHR (SEQ ID NO: 154)

[0127] LRCKCHHHCPEDSVNNICSTDGYCFTMIEEDDSGLPWTSGCLGLEGSDFQCRDTPI PHQRRSIECCTERNECNKDLHPTLPPLKNRDFVDGPIHHR (SEQ ID NO: 155)

[0128] In certain embodiments, the ALK6 polypeptide comprises a combination of a modified version of SEQ ID NO: 1 (i.e., the extracellular domain of “wild-type” or naturally occurring BMP antagonist). In embodiments, the wild-type ALK-6 does not include the C -terminal sequence of SEQ ID NO: 1, such as that shown in SEQ ID NO: 4. In embodiments, the ALK6 polypeptide comprises a modified version of SEQ ID NO: 1 wherein a seven amino acid portion of the “tail” sequence is deleted (SEQ ID NO: 69) or wherein two histidine amino acids at positions 111 and 112 of the ALK6 polypeptide ECD sequence are deleted (SEQ ID NO: 80). In certain embodiments, the ALK6 polypeptide comprises SEQ ID NO: 11 wherein the fourteen (14) amino acid “tail” deleted sequence is replaced with SEQ ID NO: 2. In certain embodiments, the ALK6 polypeptide comprises SEQ ID NO: 156 wherein a thirty (30) ammo acid “tail” deleted sequence is replaced with SEQ ID NO: 2. In certain embodiments, the ALK6 polypeptide comprises SEQ ID NO: 425 wherein a thirty (30) amino acid “tail” sequence is replaced with SEQ ID NO: 438. In certain embodiments, the ALK6 polypeptide has the N terminus deleted or truncated, by 10 (SEQ ID NO: 153), 13 (SEQ ID NO: 154) or 16 (SEQ ID NO: 155) amino acid positions. As described in more detail below, any of these sequences (e.g., SEQ ID NO: 1, 4, 11, 69, 80, 113, 153, 154, 155, 156 or 425) can be modified to alter and / or optimize ligand binding and / or to remove undesirable properties (e.g., protease cleave site(s) or aggregation).

[0129] Accordingly, a general formula for an active portion (e.g., ligand binding) of ALK6 is a polypeptide that comprises, consists essentially of, or consists of SEQ ID NO: 1. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%. 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 ECD of SEQ ID NO: 1.

[0130] In embodiments, an active portion (e.g., ligand binding) of ALK6 is a polypeptide that comprises, consists essentially of, or consists of SEQ ID NO: 4. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 41902004-0002-005-W01

[0131] In embodiments, an active portion (e.g., ligand binding) of ALK6 is a polypeptide that comprises, consists essentially of, or consists of SEQ ID NO: 11. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 11.

[0132] In embodiments, an active portion (e.g., ligand binding) of ALK6 is a polypeptide that comprises, consists essentially of, or consists of SEQ ID NO: 69. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 69.

[0133] In embodiments, an active portion (e.g., ligand binding) of ALK6 is a polypeptide that comprises, consists essentially of, or consists of SEQ ID NO: 80. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 76%. 75%, 80%, 85%, 86%, 87%, 88%, 89%. 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 80.

[0134] In embodiments, an active portion (e.g., ligand binding) of ALK6 is a polypeptide that comprises, consists essentially of, or consists of SEQ ID NO: 90. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 90.

[0135] In embodiments, an active portion (e.g., ligand binding) of ALK6 is a polypeptide that comprises, consists essentially of, or consists of SEQ ID NO: 113. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 113.

[0136] In embodiments, an active portion (e.g., ligand binding) of ALK6 is a polypeptide that comprises, consists essentially of, or consists of SEQ ID NO: 153, Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 153.

[0137] In embodiments, an active portion (e.g., ligand binding) of ALK6 is a polypeptide that comprises, consists essentially of, or consists of SEQ ID NO: 154. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid1902004-0002-005-W01sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 154.

[0138] In embodiments, an active portion (e.g., ligand binding) of ALK6 is a polypeptide that comprises, consists essentially of, or consists of SEQ ID NO: 155. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 155.

[0139] In embodiments, an active portion (e.g., ligand binding) of ALK6 is a polypeptide that comprises, consists essentially of, or consists of SEQ ID NO: 156. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 156.

[0140] Provided herein are specific point mutations, additions or point deletions within any of the above disclosed SEQ ID NO: 1, 4, 11, 69, 80, 90, 113, 153, 154, 155 or 156. Those exemplified mutations and / or deletions and / or additions are represented in SEQ ID NO: 3, 5, 79, 81, 82, 83, 108, 109, 130, 157, 190 or 437. Provided herein are ALK6 ECD sequences selected from any sequence according to SEQ ID NO: 3, 5, 79, 81, 82, 83, 108, 109, 130, 157, 190 or 437.

[0141] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 3. In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 5. In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 79. In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 81. In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 82. In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 83, In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 108. In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 109. In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 153. In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 154. In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 155. In1902004-0002-005-W01certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 156. In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 157. In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 190. In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 437.

[0142] In certain embodiments, tire soluble ALK-6 polypeptide comprises an active portion (e.g., ligand binding) of ALK6 according to SEQ ID NO: 3 as shown below using standard three-letter amino acid abbreviations:Lysi - Lys? - Glus - Aspr - Gly 5 - Glus - Ser? - Thrs - Alas - Proio - Thru - Proi 2 - Argis -Prou - Xaare - Valis - Leun - Argis - Cysis - Xaa2o - Cy S21 - Xaa22 - Xaa23 - His24 - Cys25 - Pro26 - Xaa27 - Asp28 - Xaa29 - Xaa30- Asnsi - ASH32 - Xaa33 - Cysai - Xaass - Three - Xaas? - Glyss - Xaa39 - Cys4o - Phe4i - Xaa 2 - Xa 43 -- Ue44 -- Glu45 - Ghus - Asp47 - Asp48 - Xaa 9 - Gly 50 - Xaasi - Xaas2 - Xaass - Xa s4 - Xaass - Seres - Glys? - Cysss - Xaas9 - Xaaso - Xa si - G1U62 - GIys3 - Sers - Aspss - Phess - Gins? - Cysss - Xa s9 - Asp?o - Xaan - Pro?2 - Xaa?3 - Xaa?4 - Xaa?s - Xaars - Arg?? - Arg?s - Xaa?s - Ileso - Glusi - Cys»2 - Cysss - Xaas4 - Xaass - Xaass - Xaas? - Xaass - Cyss9 - Asnso - Xaasi - Xaa92 - Leu93 - Xaa94- Pross - Three- Leu97 - Pro98 - Pro99 - Xaaioo - Xaaioi - Xaaio2 - Xaaio3 - Xaaio - Xaaios - Xaaios - Xaaio? - Xaaios - Xaaio9 - Xaaiio - Xaam - Xaanz - Xaai 13;wherein Xaais is K or P;Xaazo is V, F, K or Y;Xaa22 is G, II or S;Xaass is S. H or G;Xaa?,7 is E or D;Xaa29 is S or A;Xaa30is V or I;Xaa33 is I or T;Xaa35is S or I;1902004-0002-005-W01 Xaa37is D or N;Xaa?9 is Y or H;Xaa42 is T or A;Xaars is M or 1;Xaa49is S or Q;Xaa51is L or E;Xaa52is P or T;Xaass is V or T;Xaa54 is V or L;Xaa55is T or A;Xaa59is L or M;Xaa60is G or K;Xaa61is L or Y;Xaa69is R or K;Xaa?i is T or S;Xaa73 is I or K;Xaa74 is P or A;Xaars is H or Q;Xaa76 is Q or L;Xaa79 is S or T;Xa 84 is T or R;Xaass is absent, T or E;Xaase is R or N;Xa 87 is N or L;1902004-0002-005-W01Xaass is absent, E or L;Xaa9i is K or Q;Xaa92 is D or L;Xa 94 is H or Q;Xaaioo is absent, V or L;Xaaioi is absent, V or K;Xaaioz is absent, I or N;Xaaic>3 is absent, G or R;Xaaior is absent, P, D or A;Xaaios is absent or F;Xaaios is absent, F or V;Xaaio? is absent or D;Xaaios is absent or G;Xaaio9 is absent, S or P;Xaauo is absent or I;Xaam is absent, R or H;Xaam is absent or H; and,Xaai 13 is absent or R (SEQ ID NO: 3).

[0143] In embodiments, the ALK6 ECD polypeptide of the fusion protein comprises a substitution selected from K15P, K20Y, K20V, K20F, H22S, H22G, H23G, H23S, E27D, S29A, V30I, I33T, S35I, D37N, Y39H, T42A, M43I, S49Q, L5 IE, P52T, V53T, T55A, L59M, G60K, L61Y, R69K, T71S, I73K, P74A, H75Q, Q76L, S79T, T84R, E85T, E85_, R86N, N87L, E88, K91Q, D92L, H94Q, D104A, D107, or a combination thereof, wherein is a deletion at that position. In certain embodiments, the ALK6 ECD polypeptide of the fusion protein comprises one or more substitutions selected from L59M, G60K, and L61Y. In certain embodiments, the ALK6 ECD polypeptide of the fusion protein comprises one or more1902004-0002-005-W01substitutions selected from K20Y, H22S and H23G. In certain embodiments, Xaaioo-Xaaii3 of the ALK6 ECD polypeptide according to SEQ ID NO: 3 are absent. In certain other embodiments, the ALK6 ECD polypeptide of the fusion protein comprises one or more substitutions selected from K20Y, H22S, H23G and G60K.

[0144] In certain embodiments, the ALK6 ECD polypeptide of tire fusion protein according to SEQ ID NO: 3 comprises an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%. 89%, 90%, 91%, 92%, 93%. 94%, 95%, 96%, 97%, 98%. 99%, or 100% identical to an ALK6 ECD sequence selected from SEQ ID NO: 1, 4, 11-45, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 80, 86, 88, 92, 94, 96, 98, and 100.

[0145] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 5 as shown below using standard three-letter amino acid abbreviations:Lysi - Lys2 - Glus - Asp4 - Glys - Ghis - Ser? - Thrs - Alas - Proio - Thru - Pro - Argis -Prou - Xaais - Valis - Lem? - Argis - Cysi9 - Xaa?o - Cys2i - Xaa?.2 - Xaa?_3 - His24 - Cys?s - Pro?.6 - Xaa?.? - Aspzs - Xaa?.9 - Xaaso - Asnsi - Asii32 - Xaass - Cys34 - Xaass - Thns - Xaa37 - Gly 38 - Xaass - Cys4o - Phe4i - Xaa42 - Xaa43 - Ue44 - Ghus - Glu46 - Asp47 - Asp48 - Xaa49- Glyso - Xaasi - Xaasz - Xaa.53 - Xaas4 - Xaass - Sei 'se - Glys? - Cysss - Xaas9 - Xaaco - Xaasi - G1U62 - Gives - Ser64 - Aspes - Phe66 - Gins? - Cysss - Xaa, 9 - Asp?o - Xaa?i - Pro72 - Xaa?3 - X a?4 - Xaa75 - Xaa?6 - Arg77 - Arg?s - Xaa?9 - Ileso - Ghisi - Cyss2 - Cys83 - Xaas - Xaass - Xaass - Xaas? - Xaass - Cyss9 - As o - Xaasi - Xaag?. - Leu93 - Xaa?4 - Pross - Thr% -- Leug? - Progs -- Pro99-Leui 00;wherein Xaais is K or P;Xaa?.o is V, F, K orT;Xaa22 is G, H or S;Xaa23 is S. H or G;Xaa?.7 is E or D;Xaa29 is S or A;Xaa30is V or I;Xaa33 is I or T;1902004-0002-005-W01 Xaa35is S or I;Xaa?7 is D orN;Xaass is Y or H;Xaa42 is T or A;Xaa43is M or I;Xaa49 is S or Q;Xaa51is L or E;Xaa52is P or T;Xaa53is V or T;Xaa54is V or L;Xaass is T or A;Xaa59is L or M;Xaa60is G or K;Xaa61is L or Y;Xa s9 is R or K;Xaa?i is T or S;Xaa?3 is I or K;Xaa74 is P or A;Xaa75 is H or Q;Xaa76is Q or L;Xa 79 is S or I';Xaas4 is T or R;Xaass is absent, T or E;Xaass is R or N;1902004-0002-005-W01Xaass is N or L;Xaass is absent, E or L;Xaa91is K or Q;Xaa92 is D or L; and,Xaa94 is II or Q (SEQ ID NO: 5).

[0146] In embodiments, the ALK6 ECD polypeptide of the fusion protein according to SEQ ID NO: 5 comprises a substitution selected from K15P, K20Y, K20V, K20F, H22S, H22G, H23G, H23S, E27D, S29A, V30I, I33T, S351, D37N, Y39H, T42A, M43I, S49Q, L51E, P52, T, V53T, T55A, L59M, G60K, L61Y, R69K, 17 IS, I73K, P74A, H75Q, Q76L, S79T, T84R, E85T, E85_, R86N, N87L, E88_, K91Q, D92L, H94Q, or a combination thereof, wherein > is a deletion at that position. In certain embodiments, the ALK6 ECD polypeptide of the fusion protein according to SEQ ID NO: 5 comprises one or more substitutions selected from L59M, G60K, and L61 Y. In certain embodiments, the ALK6 ECD polypeptide of the fusion protein according to SEQ ID NO: 5 comprises one or more substitutions selected from K20Y, H22S and H23G. In certain other embodiments, the ALK6 ECD polypeptide of the fusion protein comprises one or more substitutions selected from K20Y, H22S, H23G and G60K.

[0147] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 79 as shown below using standard three-letter amino acid abbreviations:Lysi - LyS2 - Glus - Aspr - Glys - Glus - Sen - Ilirs - Ala9 - Proio - Thru - Pro:; - Argis -Proi4 - Xaais - Valis - Leun - Argis - Cysis - Xaaso - Cyssi - Xaa22 - Xaa23 - IIis24 - Cys?s - Pro2.s - Xaass - Asps.8 - Xaass - Xaaso- Asnsi - Asii32 - Xaass - Cy ss 4 - Xaass - Thrss - Xaa37 - Glyss - Xaass - Cys o - Phe4i - Xaa42 - Xa is - Ile44 - Ghus - Glu4s - Asp47 - Asp48 - Xaan- Glyso - Xaasi - Xaass - Xaass - Xaasi - Xaass - Sens - Glyss - Cysss - Xaas9 - Xaaso - Xaasi - G1US2 - Glyss - Sers - Aspss - Phess - Gins? - Cysss - Xaas -- Aspso - Xaa?i - Pro72 - Xaass - Xaa?4 - Xaass - Xaass - Arg77 - Argss - Xaass - Ileso - Glusi - Cyss2—Cysss - Xaas - Xaass - Xaass - Xaa87 - Xaass—Cys89—Asnso - aa9i - Xaa92 - Leu93 - Xaa94- Pross - Thm,- Leu97 - Pro s - Pross-Vahoo-Valioi-Ileio2- Glyio3-Proio4-Pheio5-Pheio6-Aspio7-Glyio8-Serio9-Ileiio-Argin;1902004-0002-005-W01 wherein Xaai 5 is K or P;Xaa2o is V, F, K or Y;Xaa22 is G, H or S;Xaa23is S, H or G;Xaa27 is E or D;Xaa29is S or A;Xaa30is V or I;Xaa33 is I or T;Xaa35is S or I;Xaa37is D or N;Xaa39is Y or H;Xaa42is T or A;Xaa43is M or I;Xaa49is S or Q;Xaa51is L or E;Xaa52is P or T;Xaa53is V or T;Xaa54is V or L;Xaa55is T or A;Xaa59is L or M;Xaa60is G or K;Xaa61is L or Y;Xaa69is R or K;Xaa71is T or S;1902004-0002-005-W01Xaa73 is I or K;Xaa74is P or A;Xaa75is H or Q;Xaa76is Q or L;Xaa79 is S or T;Xaa84is T or R;Xaas5 is absent, T or E;Xaa86 is R or N;Xaa87is N or L;Xaass is absent, E or L;Xaa9i is K or Q;Xaa92 is D or L; and,Xaa94is H or Q (SEQ ID NO: 79).

[0148] In embodiments, the ALK6 ECD polypeptide of the fusion protein according to SEQ ID NO: 79 comprises a substitution selected from K15P, K20Y, K20V, K20F, H22S, H22G, H23G, H23S, E27D, S29A, V30I, I33T, S35I, D37N, Y39H, T42A, M43I, S49Q, L51E, P52, T, V53T, T55A, L59M, G60K, L61Y, R69K, T71S, I73K, P74A, H75Q, Q76L, S79T, T84R, E85T, E85_, R86N, N87L, E88_, K91Q, D92L, H94Q, D104A, D107, or a combination thereof, wherein is a deletion at that position. In certain embodiments, the ALK6 ECD polypeptide of the fusion protein according to SEQ ID NO: 79 comprises one or more substitutions selected from L59M, G60K, and L61Y. In certain embodiments, the ALK6 ECD polypeptide of the fusion protein according to SEQ ID NO: 79 comprises one or more substitutions selected from K20Y, H22S and H23G. In certain other embodiments, the ALK6 ECD polypeptide of the fusion protein comprises one or more substitutions selected from K20Y, H22S, H23G and G60K.

[0149] In certain embodiments, the ALK6 ECD polypeptide of the fusion protein according to SEQ ID NO: 79 comprises an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%,1902004-0002-005-W0187%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to an ALK6 ECD sequence selected from SEQ ID NO: 15-45, 57, 59, 61, 63, 65, and 88. |0150] In certain embodiments, the soluble ALK-6 polypeptide comprises an active portion (e.g,, ligand binding) of ALK6 according to SEQ ID NO: 81 as shown below using standard three-letter amino acid abbreviations:Lys1– Lys2– Glu3– Asp4– Gly5– Glu6– Ser7– Thr8– Ala9– Pro10– Thr11– Pro12– Arg13–Pro14- Xaa15– Val16– Leu17– Arg18– Cys19- Xaa20– Cys21- Xaa22- Xaa23– His24– Cys25– Pro26- Xaa27– Asp28– Xaa29– Xaa30– Asn31– Asn32- Xaa33– Cys34- Xaa35– Thr36- Xaa37– Gly38– Xaa39– Cys40– Phe41- Xaa42– Xaa43– Ile44– Glu45– Glu46– Asp47– Asp48- Xaa49– Gly50- Xaa51- Xaa52- Xaa53- Xaa54- Xaa55– Ser56– Gly57– Cys58- Xaa59- Xaa60- Xaa61– Glu62– Gly63– Ser64– Asp65– Phe66– Gln67– Cys68- Xaa69– Asp70– Xaa71– Pro72- Xaa73- Xaa74- Xaa75- Xaa76– Arg77– Arg78- Xaa79- Ile80– Glu81– Cys82– Cys83- Xaa84- Xaa85- Xaa86- Xaa87- Xaa88– Cys89– Asn90- Xaa91- Xaa92– Leu93- Xaa94– Pro95– Thr96– Leu97– Pro98– Pro99– Leu100– Lys101- Asn102- Arg103- Asp104- Phe105- Val106- Xaa107- Xaa108- Xaa109- Xaa110- Xaa111- Xaa112- Xaa113;wherein Xaais is K or P;Xaa2o is V, F, K or Y;Xaa22is G, H or S;Xaa23is S, H or G;Xaa27 is E or D;Xaa29is S or A;Xaa30is V or I;Xaa33 is I or T;Xaa35is S or I;Xaa37is D or N;Xaa39 is Y or H;1902004-0002-005-W01 Xaa42 is T or A;Xaa43is M or I;Xaa49 is S or Q;Xaa51is L or E;Xaa52is P or T;Xaa53is V or T;Xaa54is V or L;Xaass is T or A;Xaa59is L or M;Xaa60is G or K;Xaa61is L or Y;Xaa69is R or K;Xaa?i is T or S;Xaa?3 is I or K;Xaa74 is P or A;Xaa75 is H or Q;Xaa76 is Q or L;Xaa79is S or T;Xaas4 is T or R;Xaass is absent, T or E;Xaa86 is R or N;Xaa87is N or L;Xaass is absent, E or L;Xaa9i is K or Q;1902004-0002-005-W01Xaa92 is D or L;Xaa94is H or Q;Xaa107 is absent;Xaa108is absent;Xaa109is absent;Xaa110is absent;Xaa111is absent;Xaa111is absent; and,Xaa113is absent (SEQ ID NO: 81).

[0151] In embodiments, the ALK6 ECD polypeptide of the fusion protein according to SEQ ID NO: 81 comprises a substitution selected from K15P, K20Y, K20V, K20F, H22S, H22G, H23G, H23S, E27D, S29A, V30I, I33T, S35I, D37N, Y39H, T42A, M43I, S49Q, L51E, P52, T, V53T, T55A, L59M, G60K, L61Y, R69K, T71S, I73K, P74A, H75Q, Q76L, S79T, T84R, E85T, E85 ___, R86N, N87L, E88 ___, K91Q, D92L, H94Q, D104A, or a combination thereof, wherein > is a deletion at that position. In certain embodiments, the ALK6 ECD polypeptide of the fusion protein according to SEQ ID NO: 81 comprises one or more substitutions selected from L59M, G60K, and L61Y. In certain embodiments, the ALK6 ECD polypeptide of the fusion protein according to SEQ ID NO: 81 comprises one or more substitutions selected from K20Y, H22S and H23G. In certain other embodiments, the ALK6 ECD polypeptide of the fusion protein comprises one or more substitutions selected from K20Y, H22S, H23G and G60K.

[0152] In certain embodiments, the ALK6 ECD polypeptide of the fusion protein according to SEQ ID NO: 81 comprises an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to an ALK6 ECD sequence selected from SEQ ID NO: 13, 86, 92, 94, 96, 98, 100, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 147, or 149,

[0153] In certain embodiments, the ALK6 ECD polypeptide of the fusion protein is selected from a sequence according to SEQ ID NO: 81 comprises an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%. 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%. 96%,1902004-0002-005-W0197%, 98%, 99%, or 100% identical to an ALK6 ECD sequence of SEQ ID NO: 86 wherein amino acid position 60 is a glycine (G) residue.|0154] In certain embodiments, the ALK6 ECD polypeptide of the fusion protein is selected from a sequence according to SEQ ID NO: 81 comprises an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%. 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%. 96%, 97%, 98%, 99%, or 100% identical to an ALK6 ECD sequence of SEQ ID NO: 86 wherein amino acid position 60 is other than a glycine (G) residue, suck lysine (K). The point mutation G60K removes BMP 10 binding,|0155] In embodiments, the soluble ALK-6 polypeptide comprises an active portion (e.g., ligand binding) of ALK6 according to SEQ ID NO: 82 as shown below using standard three-letter amino acid abbreviations:Lys1– Lys2– Glu3– Asp4– Gly5– Glu6– Ser7– Thr8– Ala9– Pro10– Thr11– Pro12– Arg13–Pro14- Xaa15– Val16– Leu17– Arg18– Cys19- Xaa20– Cys21- Xaa22- Xaa23– His24– Cys25– Pro26- Xaa27– Asp28– Xaa29– Xaa30– Asn31– Asn32- Xaa33– Cys34- Xaa35– Thr36- Xaa37– Gly38– Xaa39– Cys40– Phe41- Xaa42– Xaa43– Ile44– Glu45– Glu46– Asp47– Asp48- Xaa49– Gly50- Xaa51- Xaa52- Xaa53- Xaa54- Xaa55– Ser56– Gly57– Cys58- Xaa59- Xaa60- Xaa61– Glu62– Gly63– Ser64– Asp65– Phe66– Glu67– Cys68- Xaa69– Asp70– Xaa71– Pro72- Xaa73- Xaa74- Xaa75- Xaa76– Arg77– Arg78- Xaa79- Ile80– Glu81– Cys82– Cys83- Xaa84- Xaa85- Xaa86- Xaa87- Xaa88– Cys89– Asn90- Xaa91- Xaa92– Leu93- Xaa94– Pro95– Thr96– Leu97– Pro98– Pro99– Leu100– Lys101- Asn102- Arg103- Asp104- Phe105- Val106- Xaa107- Gly108- Xaa109- Ile110- Xaa111- Xaa112- Arg113;wherein Xaais is K or P;Xaa2o is V, F, K or Y;Xaa22is G, H or S;Xaa23is S, H or G;Xaa27 is E or D;Xaa29is S or A;Xaa30is V or I;1902004-0002-005-W01 Xaa33 is I or T;Xaa35is S or I;Xaa37 is D or N;Xaa39 is Y or H;Xaa42 is T or A;Xaa43is M or I;Xaa49 is S or Q.Xaa51is L or E;Xaa52 is P or T;Xaa.53 is V or T;Xaa54is V or L;Xaass is T or A;Xaa59is L or M;Xaa60is G or K;Xaa61is L or Y;Xaa69is R or K;Xaa?i is T or S;Xaa73is I or K;Xaa74is P or A;Xaa75is H or Q;Xaa76is Q or L;Xaa?9 is S or T;Xaas4 is T or R;Xaass is absent, T or E;1902004-0002-005-W01Xaa86is R or N;Xaa87is N or L;Xaa88is absent, E or L;Xaa91is K or Q;Xaa92 is D or L;Xaa94 is H or Q;Xaaio7 is D or A;Xaaio9 is P or S;Xaa111is absent; and,Xaa112is absent (SEQ ID NO: 82).

[0156] In embodiments, the ALK6 ECD polypeptide of the fusion protein according to SEQ ID NO: 82 comprises a substitution selected from K15P, K20Y, K20V, K20F, H22S, H22G, H23G, H23S, E27D, S29A, V30I, I33T, S35I, D37N, Y39H, T42A, M43I, S49Q, L51E, P52, T, V53T, T55A, L59M, G60K, L61Y, R69K, T71S, I73K, P74A, H75Q, Q76L, S79T, T84R, E85T, E85_, R86N, N87L, E88_, K91Q, D92L, H94Q, D104A, D107, or a combination thereof, wherein is a deletion at that position. In certain embodiments, the ALK6 ECD polypeptide of the fusion protein according to SEQ ID NO: 82 comprises one or more substitutions selected from L59M, G60K, and L61Y. In certain embodiments, the ALK6 ECD polypeptide of the fusion protein according to SEQ ID NO: 82 comprises one or more substitutions selected from K20Y, H22S and H23G. In certain other embodiments, the ALK6 ECD polypeptide of the fusion protein comprises one or more substitutions selected from K20Y, H22S, H23G and G60K.

[0157] In certain embodiments, the ALK6 ECD polypeptide of the fusion protein according to SEQ ID NO: 82 comprises an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to an ALK6 ECD sequence selected from SEQ ID NO: 67, 73, 75, and 77.

[0158] In embodiments, the soluble ALK-6 polypeptide comprises an active portion (e.g., ligand binding) of ALK6 according to SEQ ID NO: 83 as shown below using standard three- letter amino acid abbreviations:1902004-0002-005-W01Lys1– Lys2– Glu3– Asp4– Gly5– Glu6– Ser7– Thr8– Ala9– Pro10– Thr11– Pro12– Arg13–Pro14- Xaa15– Val16– Leu17– Arg18– Cys19- Xaa20– Cys21- Xaa22- Xaa23– His24– Cys25– Pro26- Xaa27– Asp28– Xaa29– Xaa30– Asn31– Asn32- Xaa33– Cys34- Xaa35– Thr36- Xaa37– Gly38– Xaa39– Cys40– Phe41- Xaa42– Xaa43– Ile44– Glu45– Glu46– Asp47– Asp48- Xaa49– Gly50- Xaa51- Xaa52- Xaa53- Xaa54- Xaa55– Ser56– Gly57– Cys58- Xaa59- Xaa60- Xaa61– Glu62– Gly63– Ser64– Asp65– Phe66– Gln67– Cys68- Xaa69– Asp70– Xaa71– Pro72- Xaa73- Xaa74- Xaa75- Xaa76– Arg77– Arg78- Xaa79- Ile80– Glu81– Cys82– Cys83- Xaa84- Xaa85- Xaa86- Xaa87- Xaa88– Cys89– Asn90- Xaa91- Xaa92– Leu93- Xaa94– Pro95– Thr96– Leu97– Pro98– Pro99– Leu100– Lys101- Asn102- Arg103- Xaa104- Phe105- Val106- Xaa107- Gly108- Xaa109- Ile110- His111- His112- Arg113;wherein Xaa 15 is K or P;Xaa20is V, F, K or Y;Xaa22is G, H or S;Xaa23is S, H or G;Xaa27 is E or D;Xaa29 is S or A;Xaa30is V or I;Xaa33is I or T;Xaa35is S or I;Xaa37is D or N;Xaa39is Y or H;Xaa42 is T or A;Xaa43is M or I;Xaa49 is S or Q;Xaa51is L or E;1902004-0002-005-W01 Xaa52is P or T;Xaa53is V or T;Xaa54 is V or L;Xaa55is T or A;Xaa59is L or M;Xaa6o is G or K;Xaa61is L or Y;Xaa69is R or K;Xaa?i is T or S;Xaa?3 is I or K;Xaa74is P or A;Xaa75is H or Q;Xaa76is Q or L;Xaa?9 is S or T;Xaa84 is T or R;Xaas5 is absent, T or E;Xaase is R or N;Xaa87 is N or L;Xaass is absent, E or L;Xaa91is K or Q;Xaa92 is D or L;Xaa94 is H or Q;Xaaio4 is D or A;Xaaio7 is absent or D; and,1902004-0002-005-W01Xaaios is P or S. (SEQ ID NO: 83).

[0159] In embodiments, the ALK6 ECD polypeptide of the fusion protein according to SEQ ID NO: 83 comprises a substitution selected from K15P, K20Y, K20F, K20V, H22S, H22G, H23G, H23S, E27D, S29A, V30I, 133 T, S35L D37N, Y39H, T42A, M43I, S49Q, L51E, P52, T, V53T, T55A, L59M, G60K, L61Y, R69K, T71S, I73K, P74A, H75Q, Q76L, S79T, T84R, E85T, 1:85. R86N, N87L, E88, K91Q, D92L, H94Q, D104A, D107, or a combination thereof, wherein is a deletion at that position. In certain embodiments, the ALK6 ECD polypeptide of the fusion protein according to SEQ ID NO: 83 comprises one or more substitutions selected from L59M, G60K, and L61 Y. In certain embodiments, the ALK6 ECD polypeptide of the fusion protein according to SEQ ID NO: 83 comprises one or more substitutions selected from K20Y, H22S and H23G. In certain other embodiments, the ALK6 ECD polypeptide of the fusion protein comprises one or more substitutions selected from K20Y, H22S, H23G and G60K.

[0160] In certain embodiments, the ALK6 ECD polypeptide of the fusion protein according to SEQ ID NO: 83 comprises an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to an ALK6 ECD sequence selected from SEQ ID NO: 12, 14 and 71.

[0161] In embodiments, the soluble ALK-6 polypeptide comprises an active portion (e.g., ligand binding) of ALK6 according to SEQ ID NO: 108 as shown below using standard three-letter amino acid abbreviations:Lysi - Lys2 - Giro -,\sp; - Glys - Glue - Ser? - Thrs - Alas - Proio - Thru - Proi2 - Argu -Proi4 - Xaais - Xaaie - Leun - Argis - Cysi9 - Xaaao - Cys2i - Xaa22- Xaa’22-Xaa23 - His24 - Cys25 - Pro26 - Xaa27 - Asp28 - Xaa29 - Xaaso - Asroi - As - Xaass -Cys34 - Xaass - Thn? - Xaas? - Glyss - Xaaso - Cys o - Phe4i - Xaa42 - Xaa43 - Ile44 - Glros - Gif: e - Asp4? - Asp4s - Xa 49 Glyso - Xaasi - Xaas?. - Xaass - Xaass - Xaass - Serss - Glys? - Cysss - Xaas - Xaaso - Xaaei - Ghi62 - Gly63 - Sere4 - Aspss - Phess - Gins? - Cyses - Xaae9 - Asp?o - Xaa?i - Pro?2 - Xaa73 - Xaa74 - Xaa?s - Xaa?6 - Arg?7 -Arg78 - Xaa?9 - Ileso - Glusi - Cyss2 - Cysss - Xaasi - Xaass - Xaass - Xaas? - Xaass - Cyss9 - Asn9o - Xaa9i - Xa 92 - Leu93 - Xaa94 - P1095 - Thr96 -- Leu97 - Progs - Pro99 - Leuioo - Lysioi - Asmo2 - Argios - Aspio4 - Pheios - Valios - Xaaio? - Xaaios - Xaaio9 - Xaano - Xaain - Xaans - Xaans;wherein:1902004-0002-005-W01Xaai 5 is K or P;Xaai6 is V or I;Xaa2o is V, F, K or Y;Xaa?,?, is G, H or S;Xaa’22 is absent or A;Xaa23is S, H or G;Xaa2? is E or D;Xaa?_9 is S or A;Xaa30is V or I;Xaa? 3 is I or T;Xaaas is S or I;Xa 37 is D or N;Xaa39 is Y or H;Xaa42 is T or A;Xaa43is M or I;Xaa49 is S or Q;Xaa51is L or E;Xa 52 is P or T;Xa s3 is V or T;Xaa54 is V or L;Xaass is T or A;Xaaso is L or M;Xaa60is G or K;Xaa61is L or Y;Xaas is R or K;Xaa7i is T or S;Xaa73 is I or K;Xaa74is P or A;Xa 75 is H or Q;Xaa76is Q or L;Xa 79 is S or T;Xaa84 is T or R;Xaa«5 is absent, T or E;1902004-0002-005-W01Xaass is R or N;Xaa«7 is N or L;Xaass is absent, E or L;Xaas>i is K or Q;Xaa92 is D or L;Xaa94 is H or Q;Xaaio? is absent;Xaa108is absent;Xaaio9 is absent;Xaa110is absent;Xaai 11 is absent;Xaaii2 is absent; and,Xaa113 is absent (SEQ ID NO: 108)

[0162] In embodiments, the ALK6 ECD polypeptide of the fusion protein according to SEQ ID NO: 108 comprises a substitution selected from K15P, V16I, K20Y, K20V, K20F, H22S, I-I22G, __22’A, H23G, II23S, E27D, S29A, V30I, I33T, S35I, D37N, Y39H, T42A, M43I, S49Q, L51E, P52, T, V53T, T55A, L59M, G60K, L61Y, R69K, T71S, I73K, P74A, H75Q, Q76L, S79T, T84R, E85T, E85_ R86N, N87L, E88__, K91Q, D92L, H94Q, D104A, or a combination thereof, wherein > is a deletion at that position. In certain embodiments, the ALK6 ECD polypeptide of the fusion protein according to SEQ ID NO: 108 comprises one or more substitutions selected from L59M, G60K, and L61Y. In certain embodiments, the ALK6 ECD polypeptide of the fusion protein according to SEQ ID NO: 108 comprises one or more substitutions selected from K20Y, H22S and H23G. In certain other embodiments, the ALK6 ECD polypeptide of the fusion protein comprises one or more substitutions selected from K20Y, H22S, H23G and G60K. In certain embodiments, the ALK6 ECD polypeptide of the fusion protein according to SEQ ID NO: 108 comprises one or more substitutions selected from K20Y, H22S, _22’A and H23G. In certain embodiments, the ALK6 ECD polypeptide of the fusion protein according to SEQ ID NO: 108 comprises one or more substitutions selected from K20Y, H22G, _ 2T A and H23S.

[0163] In certain embodiments, the ALK6 ECD polypeptide of the fusion protein according to SEQ ID NO: 108 comprises an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%1902004-0002-005-W01identical to an ALK6 ECD sequence selected from SEQ ID NO: 13, 86, 90, 92, 94, 96, 98, 100, 102, 104, and 110.|0164] In embodiments, the soluble ALK-6 polypeptide comprises an active portion (e.g., ligand binding) of ALK6 according to SEQ ID NO: 109 as shown below using standard three- letter amino acid abbreviations:Lysi - Lys2 - Glus - Asp4 - Glys - Glus - Ser? - This - Alas - Prow - Thru - Prow - Argis -Proi4 - Xaais - Xaais - Leui? - Argis - Cysi9 - Xaa2o - Cys2i - Xaazz - Xaa’22 - Xaa23 - His24 - Cys25 - Pro26 - Xaa?,7 - Aspzs - Xaazs - Xaaso- Asii3i - Asii32 - Xaa33 - Cys34 - Xaa 5 -- Thns - Xaa37 - Gly38 - Xaa39 - Cys4o - Phe i - Xaa42 - Xaa 3 - Ile44 - Gluis - Glu46 - Asp47 - Aspis - Xaa49 - Glyso - Xaasi - Xaa52 - Xaass - Xaasi - Xaass - Ser.-. - Glys? - Cysss - Xa s9 - Xaaso - Xaa i - G1U62 - Gly«3 - Sers4 - Aspss - Phess - Gins? - Cysss - Xaas -- Asp?o - Xaa?i - Pro72 - Xaa?3 - Xaa?4 - Xaa?s - Xaa?6 - Arg77 - Arg78 - Xaa?9 - Ileso - Glu8i - Cys82 - Cys83 - Xaas4 - Xaass - Xaass - Xaas? - Xaass - Cyss - Asn o - Xaasi - Xaa92 - Leu93 - Xaa94 - Pro9s - Thrss - Leu? - Pro s - Pro99-Valioo- Val w 1 -He 102-Gly 103-Pro 104-Phe 1 os -Phe 1 os- Asp 107-Gly 1 os -Ser 109-Ile 110- Arg 111; wherein Xaais is K or P;Xaais is V or I;Xa 2.o is V, F, K or Y;Xaa22 is G, H or S;Xaa’22 is absent or A;Xaa2 is S, II or G;Xaa?,7 is E or D;Xaa29 is S or A;Xaa30is V or I;Xa 33 is I or T;Xaaas is S or I;Xaa 7 is D or N;Xaa39is Y or H;Xaa z is T or A;Xaa43is M or I;Xaa 9 is S or Q;1902004-0002-005-W01Xaa51is L or E;Xaa52 is P or T;Xaa53is V or T;Xaa54is V or L;Xaass is T or A;Xaass is L or M;Xaaeo is G or K;Xaa61is L or Y;Xaass is R or K;Xaa?i is T or S;Xaa?3 is I or K;Xaa74is P or A;Xaa75is H or Q;Xaa76is Q or L;Xaa?9 is S or T;Xaas is T or R;Xaass is absent, T or E;Xaass is R or N;Xaa«7 is N or L;Xaass is absent, E or L;Xaa9i is K or Q;Xa 92 is D or L; and,Xaa9 is H or Q. (SEQ ID NO: 109)

[0165] In embodiments, the ALK6 ECD polypeptide of the fusion protein according to SEQ ID NO: 109 comprises a substitution selected from K15P, V16I, K20Y, K20V, K20F, H22S, H22G, _22’A, H23G, H23S, E27D, S29A, V30I, I33T, S35I, D37N, Y39H, T42A, M43I, S49Q, L51E, P52, T, V53T, T55A, L59M, G60K, L61Y, R69K, T71S, I73K, P74A, H75Q, Q76L, S79T, T84R, E85T, E85 ___, R86N, N87L, E88, K91Q, D92L, H94Q, D104A, D107, or a combination thereof, wherein >_ is a deletion at that position. In certain embodiments, the ALK6 ECD polypeptide of the fusion protein according to SEQ ID NO: 109 comprises one or more substitutions selected from L59M, G60K, and L61Y. In certain embodiments, the ALK6 ECD polypeptide of the fusion protein according to SEQ ID NO: 109 comprises one or more substitutions selected from K20Y, H22S and H23G. In certain other embodiments, the ALK61902004-0002-005-W01ECD polypeptide of the fusion protein comprises one or more substitutions selected from K20Y, H22S, H23G and G60K. In certain embodiments, the ALK6 ECD polypeptide of the fusion protein according to SEQ ID NO: 109 comprises one or more substitutions selected from K20Y, H22S, __22’A and H23G. In certain embodiments, the ALK6 ECD polypeptide of the fusion protein according to SEQ ID NO: 109 comprises one or more substitutions selected from K20Y, H22G, _22’A and H23S.

[0166] In certain embodiments, the ALK6 ECD polypeptide of the fusion protein according to SEQ ID NO: 109 comprises an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to an ALK6 ECD sequence selected from SEQ ID NO: 15-45, 57, 59, 61, 63, 65, and 88.

[0167] In embodiments, the soluble ALK-6 polypeptide comprises an active portion (e.g., ligand binding) of ALK6 according to SEQ ID NO: 130 as shown below using standard three- letter amino acid abbreviations:

[0168] Lysi - Lys2 - Glus - Aspr - Glys - Glus - Ser? - Thrs - Ala9 - Proio - Thru - Pron - Argis -Prou - Lysis - Xaai6 - Leun - Argis - Cysts - Xaa2o - Cys?,i - Xaa22- Xaa’22- Xaa’22-Xaa23 - Xaa’23 - Xaa24 - Cys25 - Pro26 - Xaa2? - Asp2s - Xaaz9 - Xaaso - Asnsi - Asun - Xaa33 - Cyss - Xaaas- Th ns - Xaaa?- Gly n - Xaa39- Cys4o - Phe4i - Xaa42 - Xaa-43 - Ile44 - Gluts -GIu46 - Asp47 - Asp48 - Xaa49- Glyso - Xaasi - Xaasz - Xaas3 - Xaas4 - Xaass - Serss - Glys? - Cyssg - Xaas9 - Xaass - Xaasi - Glus2 - Glyss - Sers4 - Aspss - Phess - Gins? - Cysss - Xaas9 - Asp?o - Xaa?i - Pro?2 - Xaa?3 - Xaa?4 - Xaa75 - Xaa?s - Arg?? - Argis - Xaa?9 - Ileso - Glusi -Cys82 - CyS83 - Xaas4 - Xaass - Xaass - Xaas? - Xaass - Cyss9 - Asngo - Xaa9i - Xaa92 - Leu93 - Xaa94 - Press - Thr9s - Leu97 - Pro98 -- Pro99 - Leuioo - Lysioi - Asms?. - Argios - Aspio4 - Pheios - Valias - Xaaio? - Xaaios - Xaaio9 - Xaano - Xaam - Xaam - Xaans;

[0019] wherein Xaa16is V or I;

[0170] Xaaio is V, F, K, Y, T, or A;

[0171] Xaa22 is G, E, H or S;

[0172] Xaa’22 is absent, G, S, or A;

[0173] Xaa”22 is absent or S;

[0174] Xa 23 is S, H, G, or L;

[0175] Xaa235is absent, L orH;

[0176] Xaa?,4 is H or S;1902004-0002-005-WO1

[0177] Xaa27 is EorD;

[0178] Xaa29 is S or A;

[0179] Xaa3o is V or I;

[0180] Xaa33 is I or T;

[0181] Xaa35 is S or I;

[0182] Xaaa? is D orN;

[0183] Xaas9 is Y or H;

[0184] Xaa42 is T or A;

[0185] Xaa43 is M or I;

[0186] Xaai9 is S or Q;

[0187] Xaa51is L or E;

[0188] Xaa52 is P or T;

[0189] Xaa53is VorT;

[0190] Xaas4 is V or L;

[0191] Xaa55is T or A;

[0192] Xaa59 is L or M;

[0193] Xaaeo is G or K;

[0194] Xaa6i is L or Y;

[0195] Xaaw is R or K;

[0196] Xaa71 is T or S;

[0197] Xaa.73 is I or K;

[0198] Xaa74is P or A;

[0199] Xaa75is H or Q;

[0200] Xaa76is Q or L;

[0201] Xaa?9 is S or T;

[0202] Xaa84is T or R;

[0203] Xaass is absent, T or E;

[0204] Xaa.86 is R or N;

[0205] Xaa87is N or L;

[0206] Xaass is absent, E or L;

[0207] Xaa9iis K or Q;

[0208] Xaa92 is D or L;

[0209] Xaa94 is H or Q;1902004-0002-005-W01

[0210] Xaaio7 is absent;

[0211] Xaa108is absent;

[0212] Xaaio9 is absent;

[0213] Xaauo is absent;

[0214] Xaai 11 is absent;

[0215] Xaa111is absent; and,

[0216] Xaans is absent. (SEQ ID NO: 130)

[0217] In embodiments, the ALK6 ECD polypeptide of the fusion protein according to SEQ ID NO: 130 comprises a substitution selected from K15P, V16I, K20Y, K20V, K20F, K20A, K20A, H22S, H22G, H22E, H22S, _22’A, _22’_, _22’G, _22’S, _22”_, _22”S, H23G, H23S, 11248, E27D, S29A, V30I, I33T, I33S, S35I, D37N, Y39H, T42A, M43I, S49Q, L51E, P52T, V53T, T55A, L59M, G60K, L61Y, R69K, T71S, I73K, P74A, H75Q, Q76L, S79T, T84R, E85T, E85_, R86N, N87L, E88_, K91Q, D92L, H94Q, D104A, or a combination thereof, wherein > is a deletion at that position. In certain embodiments, the ALK6 ECD polypeptide of the fusion protein according to SEQ ID NO: 130 comprises one or more substitutions selected from L59M, G60K, and L61Y. In certain embodiments, the ALK6 ECD polypeptide of the fusion protein according to SEQ ID NO: 130 comprises one or more substitutions selected from K20Y, H22S and H23G. In certain other embodiments, the ALK6 ECD polypeptide of the fusion protein comprises one or more substitutions selected from K20Y, H22S, H23G and G60K. In certain embodiments, the ALK6 ECD polypeptide of the fusion protein according to SEQ ID NO: 130 comprises one or more substitutions selected from K20Y, K20V, K20F, K20A, K20A, H22S, _22’A, __22’__, _22’G, _22’S, _22”_, _22”S and H23G. In certain embodiments, the ALK6 ECD polypeptide of the fusion protein according to SEQ ID NO: 130 comprises one or more substitutions selected from K20Y, H22G, _22’A and II23S.

[0218] In certain embodiments, the ALK6 ECD polypeptide of the fusion protein according to SEQ ID NO: 130 comprises an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to an ALK6 ECD sequence selected from SEQ ID NO: 150, 151 or 152.

[0219] In embodiments, the soluble ALK-6 polypeptide comprises an active portion (e.g., ligand binding) of ALK6 according to SEQ ID NO: 157 as shown below using standard three- letter amino acid abbreviations:1902004-0002-005-W01

[0220] Xaai - Xaa2 - Xa? - Xaai - Xaas - Xaas - Xaa? - Xaas - Xaas - Xaaio - Xaai i - Xaan - Xaai3 - Xaai4 - Xaais - Xaaie - Leui7 - Argis - Cysi9 - Xaa2o - Cys2i - Xaa22 - Xaa’ 22 - Xaa’ ’22 - Xaa23 - Xaa’ 23 - Xaa24 - Cys25 - Proas - Xaa27 - Asp28 - Xaa29 - Xaaso - Asnsi - Asri <? - Xaass - Cys34 - Xaass - Thrss - Xaa37 Glyss - Xaa39 - Cys o Phe4i - Xaa42 - Xaats Ile44 - GI1145 - Glu 6 - Asp47 - Asp48 - Xaai9 - Glyso - Xaasi - Xaas2 - Xaass - Xaas4 - Xaass - Serss -G1V57 - Cysss - Xaas9 - Xaaeo - Xaaei - Glu62 - Glyss - Sei64 - Aspss - Phess - Gins? - Cyses -Xa 69 - Asp7o - Xaa7i - Pro72 - Xaa?s - Xaa?4 - Xa 75 - Xaa76 - Arg?7 - Argrs - Xaa?9 - Ileso -Glusi - Cys82 - Cysss - Xaas4 - Xaass - Xaase - Xaas? - Xaass- Cyss9 - Asireo - Xaa9i - Xaa92 - Leu93 - Xaa94~ Pro9s - Three- Leu97 - Pro98 - Pro99 - Xaaioo - Xaaioi - Xaai 02 - Xaaios - Xaaio4 - Xaaios - Xaaioe - Xaai 07 - Xaaios - Xaaio9 - Xaai 10 - Xaai 11 - Xaai 12 - Xaai 13

[0221] wherein: Xaai is K or absent;

[0222] Xaa?. is K or absent;

[0223] Xaas is E or absent;

[0224] Xaai is D or absent;

[0225] Xaas is G or absent,

[0226] Xaae is E or absent;

[0227] Xaa? is S or absent;

[0228] Xaas is T or absent;

[0229] Xaa9 is A or absent;

[0230] Xaai 0 is P or absent;

[0231] Xaan is T or absent;

[0232] Xaa is P or absent;

[0233] Xaai 3 is R or absent;

[0234] Xaan is P or absent,

[0235] Xaai 5 is K, P or absent;

[0236] Xaai 6 is V or absence;1902004-0002-005-W01

[0237] Xaa2o is V, F, K, A, R, N, D, C, E, Q. G, H, I, L, M, P, S, T, W, or Y;

[0238] Xaa22is G, H, V, F, K, A, R, N, D, C, E, Q, I, L, M, P, T, W, Y or S;

[0239] Xaa’22 is absent, G, S, or A;

[0240] Xaa”?,2 is absent or S;

[0241] Xaa23is S, H, V, F, K, A, R, N, D, C, E, Q, I, L, M, P, T, W, Y or G;

[0242] Xaa’23 is absent, L or H;

[0243] Xaa24 is V, F, K, A, R, N, D, C, E, Q, G, H, I, L, M, P, S, T, W, or Y;

[0244] Xaa27 is E or D;

[0245] Xa29 is S, GorA;

[0246] Xaaso is V, A, G or 1;

[0247] Xaa.33 is I, S or T;

[0248] Xaaas is S, T, G, A orI;

[0249] Xaa37 is D, A, G or N;

[0250] Xaa39 isY, A, GorH;

[0251] Xaa42 is TorA;

[0252] Xaa43is M or I;

[0253] Xaa49 is S, A, G or Q;

[0254] Xaasi is L, A, G or E;

[0255] Xaa52is P or T;

[0256] Xaas3 is V, A, G or T;

[0257] Xa54 is V, A, G or L;

[0258] Xaa.55 is T, G or A;

[0259] Xaa59 is L, M, V, F, K, A, R, N, D, C, E, Q, G, H, I, P, S, T, W, or Y;

[0260] Xaa6o is G, K, V, F, A, R, N, D, C, E, Q, H, I, L, M, P, S, T, W, or Y;1902004-0002-005-W01

[0261] Xaasi is L, Y, V, F, K, A, R, N, D, C, E, Q, G, H, I, M, P, S, T, or W;

[0262] Xaa69is R or K;

[0263] Xaa71 is T or S;

[0264] Xaa?3 is I or K;

[0265] Xaa74 is P or A;

[0266] Xaa75 is H or Q;

[0267] Xaa76is Q or L;

[0268] Xaa79 is S or T;

[0269] Xaas4 is T, R or absent;

[0270] Xaass is absent, T or E;

[0271] Xaass is R, N or absent;

[0272] Xaas? is N, L or absent;

[0273] Xaass is absent, E or L;

[0274] Xaa9i is K, Q or absent;

[0275] Xaa92is D, L, Y or absent;

[0276] Xaa94 is H, Q or absent;

[0277] Xaaioo is absent, V or L;

[0278] Xaai oi is absent, V or K;

[0279] Xaaioz is absent, I or N;

[0280] Xaaios is absent, G or R;

[0281] Xaai 04 is absent, P, D or A;

[0282] Xaaios is absent or F;

[0283] Xaaioo is absent, F, W, Y’, N, Q, K, H, D, G, E or V;

[0284] Xaai 07 is absent, L, M, V, F, K, A, R, N, C, E, Q, G, H, I, P, S, T, W, or Y or D;1902004-0002-005-W01

[0285] Xaaios is absent, R, T, Q, L, K, W or G;

[0286] Xaaio9 is absent, S or P;

[0287] Xaaiio is absent or I;

[0288] Xaam is absent, R or H;

[0289] Xaam is absent or II; and

[0290] Xaam is absent or R.

[0291] In embodiments, the ALK6 ECD polypeptide of the fusion protein according to SEQ ID NO: 157 comprises a substitution selected from Kl__, K2__, E3. D4. G5 E6_ S7__, T8_,A9_, P10_, TJ P12_, R13_, P14_, K15P, K15_, V16_, K20Y, K20V, K20F, K20A, K20R, K20N, K20D, K20C, K20E, K20Q, K20G, K20H, K20I, K20L, K20M, K20P, K20S, K20T, K20W, H22S, H22G, H22E, H22V, H22F, H22K, H22A, H22R, H22N, H22D, H22C, H22Q, H22I, H22L, H22M, H22P, H22T, H22W, H22Y, _22’A, _22’_, _22’G, _22’S, _22”_, _22”S, H23G, H23S, II23V, II23F, II23K, II23A, H23R, H23N, II23D, II23C, II23E, H23Q, H23I, H23L, H23M, H23P, H23T, H23W, H23Y, H23G, 23'. __23’L, 23 ’H, H24S, H24V, H24F, H24K, H24A, H24R, H24N, H24D, H24C, H24E, H24Q, H24G, H24I, H24L, H24M, H24P, H24T, H24W, H24Y, E27D, S29A, S29G, V30I, V30A, V30G, I33T, I33S, S35I, S35A, S35G, S35T, D37N, D37A, D37G, Y39H, Y39A, Y39G, T42A, M43I, S49Q, S49A, S49G, L51E, L51A, L51G, P52T, V53T, V53A, V53G, V54A, V54G, V54L, T55A, T55G, L59M, L59V, L59F, L59K, L59A, L59R, L59N, L59D, L59C, L59E, L59Q, L59G, L59H, L59I, L59P, L59S, L59T, L59W, L59Y, G60K, G60V, G60F, G60A, G60R, G60N, G60D, G60C, G60E, G60Q, G60H, G60I, G60L, G60M, G60P, G60S, G60T, G60W, G60Y, L61Y, L61V, L61F, L61K, L61A, L61R, L61N, L61D, L61C, L61E, L61Q, L61G, L61H, L61I, L61M, L61P, L61S, L61T, L61 W, R69K, T71S, I73K, P74A, H75Q, Q76L, S79T, T84R, T84 E85T, E85_, R86N, R86_, N87L, N87__, E88__, K91Q, K91__, D92L, D92__, D92Y, H94Q, H94_, D104A, V106F, V106W, V106Y, V106N, V106Q, V106K, V106H, V106D, V106G, V106E, D107L, D107M, D107V, D107F, D107K, D107A, D107R, D107N, D107C, D107E, D107Q, D107G, D107H, D107I, D107P, D107S, D107T, D107W, D107Y, G108R, G108T, G108Q, G108L, G108K, G108W, or a combination thereof, wherein is a deletion at that position.. In certain embodiments, the ALK6 ECD polypeptide of the fusion protein according to SEQ ID NO: 157 comprises one or more substitutions selected from L59M, G60K, and L61Y. In certain embodiments, the ALK6 ECD polypeptide of the fusion protein according to SEQ ID NO: 1571902004-0002-005-W01comprises one or more substitutions selected from K20Y, H22S and H23G. In certain other embodiments, the ALK6 ECD polypeptide of the fusion protein comprises one or more substitutions selected from K20Y, H22S, and H23G wherein position 60 (Xaaeo) is glycine. In certain embodiments, the ALK6 ECD polypeptide of the fusion protein according to SEQ ID NO: 157 comprises one or more substitutions selected from K20Y, H22S, _22’A and H23G. In certain embodiments, the ALK6 ECD polypeptide of the fusion protein according to SEQ ID NO: 157 comprises one or more substitutions selected from K20Y, II22G, __22’A and H23S.

[0292] In certain embodiments, the ALK6 ECD polypeptide of the fusion protein according to SEQ ID NO: 157 comprises an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%. 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%. or 100% identical to an ALK6 ECD sequence selected from SEQ ID NO: 132 to 155.

[0293] In embodiments, the soluble ALK-6 polypeptide comprises an active portion (e.g., ligand binding) of ALK6 according to SEQ ID NO: 190 as shown below using standard three- letter amino acid abbreviations:

[0294] Lysi ~ LyS2 - Glus - Aspr - Glys - Glus - Ser? - Thrs - Ala9 - Proio - Thru - Pron - Argis -Prou - Xaais - Xaais - Leun Argis - Cysis - Xaazo - Cys2i - Xaa?.?. - Xaa’?,?, - Xaa’22 - Xaa23 - Xaa’23 - Xaa24 - Cys2s - Pro26 - Xaa27 - Asp28 - Xaa29 - Xaa?? - Asnsi - Asn32 - Xaaas - Cyss-i - Xaaas - Thrss - Xaaa? - Glyss - Xaa39 - Cys4o - Phe4i - Xaa 42 - Xaai3 - Ile44 -GIu4s - Glu 46 - Asp47 - Asprs - Xaa49~ Glyso - Xaasi - Xaas?. - Xaas3 - Xaas 4 - Xaass - Serse - Gly57 - Cys58 - Xaa59 - Xaaeo - Xaasi - Glus2 - Gives - Sers4 - Aspss - Phees - Gins? - Cyses -Xaas9 - Asp?o - Xaa?i - Pro?? - Xaa?3 - Xaa?4 - Xaa?s - Xaa?6 - Arg?? - Arg?s - Xaa?9 - Ileso -Glusi - Cys82 - Cys83 - Xaas4 - Xaass - Xaase - Xaas? - Xaass- Cyss9 - As o - Xaa9i - Xaa92 - Leu93 - Xaa94 - Pro95 - Thr96- Leu97 - Progs - Pro99 - Leuioo - Lysioi - Asnio?. - Argio3 - Xaai«4 - Pheios - Vahos - Xaaio? - Xaaios - Xaaio9 - Xaano - Xaam - Xaaii2 - Xaaiu;

[0295] wherein Xaais is K or P;

[0296] Xaais is V or I;

[0297] Xaa?.o is V, F, K, A, R, N, D, C, E, Q, G, H, I, L, M, P, S, T, W, or Y;

[0298] Xaa.22 is G, H, V, F, K, A, R, N, D, C, E, Q, I, L, M, P, T, W, Y or S:

[0299] Xaa’ 22 is absent, G, S, or A;

[0300] Xaa" -2 is absent or S;1902004-0002-005-W01

[0301] Xaa23 is S, H, V, F, K, A, R, N, D, C, E, Q. 1, L, M, P, T, W, Y or G;

[0302] Xaa’23 is absent, L or II;

[0303] Xaa24 is V, F, K, A, R, N, D, C E, Q, G. H, I, L, M, P, S, T, W, or Y;

[0304] Xa 27 is E or D;

[0305] Xaa29 is S, G or A;

[0306] Xaaso is V, A, G or I;

[0307] Xaa33 is I, S or T;

[0308] Xaass is S, T, G, A or I;

[0309] Xaas? is D, A, G or N;

[0310] Xaa39 is Y, A, G or H;

[0311] Xaat2 is T or A;

[0312] Xaa43 is M or I;

[0313] Xaa49 is S, A, G or Q;

[0314] Xaasi is L, A, G or E;

[0315] Xaa52is P or T;

[0316] Xaa.53 is V, A, G or T;

[0317] Xaas* is V, A, G or L;

[0318] Xaa55is T, G or A;

[0319] Xaa.59 is L, M, V, F, K, A, R, N, D, C, E, Q, G, H, I, P, S, T, W, or Y;

[0320] Xaaeo is G, K, V, F, A, R, N, D, C, E, Q, H, I, L, M, P, S, T, W, or Y; Xaasi is L, Y’, V, F, K, A, R, N, D, (. E, Q, G, II, I, M, P, S, T, or W;

[0321] Xaac9 is R or K;

[0322] Xaari is T or S;

[0323] Xaa73 is I or K;1902004-0002-005-W01

[0324] Xaa74 is P or A;

[0325] Xaa?5 is II or Q;

[0326] Xaa76is Q or L;

[0327] Xaa79 is S or T;

[0328] Xaa«4 is absent, T or R;

[0329] Xaass is absent, T or E;

[0330] Xaass is absent, R or N;

[0331] Xaa«7 is N or L;

[0332] Xaass is absent, E or L;

[0333] Xaaoi is absent, K or Q;

[0334] Xaa92 is absent, D, Y or L;

[0335] Xaa94 is absent, H or Q;

[0336] Xaaio4 is D or A;

[0337] Xaaicn is absent;

[0338] Xaai os is absent;

[0339] Xaaio9 is absent;

[0340] Xaai io is absent;

[0341] Xaai ii is absent;

[0342] Xaai 12 is absent; and,

[0343] Xaai 13 is absent.

[0344] In embodiments, the ALK6 ECD polypeptide of the fusion protein according to SEQ ID NO: 190 comprises a substitution selected from K15P, VI 61, K20Y, K20V, K20F, K20A, K20R, K20N, K20D, K20C, K20E, K20Q, K20G, K20H, K20I, K20L, K20M, K20P, K20S, K20T, K20W, H22S, H22G, H22E, H22V, H22F, H22K, H22A, H22R, H22N, H22D, H22C, H22Q, H22I, H22L, H22M, H22P, H22T, H22W, H22Y, _22’A, __22’_, _22’G, _22’S, __22”__,1902004-0002-005-W01__22”S, H23G, H23S, H23V, H23F, H23K, H23A, H23R, H23N, H23D, H23C, H23E, H23Q, H23I, H23L, H23M, H23P, H23T, H23W, H23Y, __23’_, _23’L, 23 ’H, H24S, H24V, H24F, II24K, II24A, H24R, H24N, H24D, H24C, H24E, H24Q, H24G, H24I, H24L, H24M, H24P, H24T, H24W, H24Y, E27D, S29A, S29G, V301, V30A, V30G, I33T, I33S, S35I, S35A, S35G. S35T, D37N, D37A, D37G, Y39H, Y39Q, Y39A, T42A, M43I, S49Q, S49A, S49G, L51E, L51A, L51G, P52T, V53T, V53, V53G, V54A, V54G, V54L, T55A, T55G, E59M, L59V, L59F, L59K, L59A, L59R, L59N, L59D, L59C, L59E, L59Q, L59G, L59H, L59I, L59P, L59S, L59T, L59W, L59Y, G60K, G60V, G60F, G60A, G60R, G60N, G60D, G60C, G60E, G60Q, G60H, G60L G60L, G60M, G60P, G60S, G60T, G60W, G60Y, L61Y, L61V, L61F, L61K, L61A, L6IR, L61N, L61D, L61C, L61E, L6IQ, L6IG, L61H, L61I, L61M, L6IP, L61S, L61T, L61W, R69K, T71S, I73K, P74A, H75Q, Q76L, S79T, T84R, T84 E85T, E85„, R86N, R86_, N87L, N87__, E88__, K91Q, K91__, D92L, D92_, D92Y, H94Q, H94_, D104A, or a combination thereof, wherein > is a deletion at that position.. In certain embodiments, the ALK6 ECD polypeptide of the fusion protein according to SEQ ID NO: 190 comprises one or more substitutions selected from L59M, G60K, and L61 Y. In certain embodiments, the ALK6 ECD polypeptide of the fusion protein according to SEQ ID NO: 190 comprises one or more substitutions selected from K20Y, H22S and H23G. In certain other embodiments, the ALK6 ECD polypeptide of the fusion protein comprises one or more substitutions selected from K20Y, H22S, and H23G wherein position 60 (Xaaso) is glycine. In certain embodiments, the ALK6 ECD polypeptide of the fusion protein according to SEQ ID NO: 190 comprises one or more substitutions selected from K20Y, H22S, _22’ A and H23G. In certain embodiments, the ALK6 ECD polypeptide of the fusion protein according to SEQ ID NO: 190 comprises one or more substitutions selected from K20Y, H22G, __22‘A and H23S.

[0345] In certain embodiments, the AEK6 ECD polypeptide of the fusion protein according to SEQ ID NO: 190 comprises an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to an ALK6 ECD sequence selected from SEQ ID NO: 158 to 189.

[0346] In embodiments, the soluble ALK-6 polypeptide comprises an active portion (e.g., ligand binding) of ALK6 according to SEQ ID NO: 437 as shown below using standard three- letter amino acid abbreviations:

[0347] Lysi - LyS2 - Glus - Asp4 - Glys - Glus - Ser? - Thrs - Alas - Prow - Thru - Prow - Argi? -Prow - Xaais - Xaais - Leui? - Argis - Cysis - Xa 2o - Cys2i - Xaa22 - Xaa’22 - Xaa231902004-0002-005-W01- H1S24 - Cys25 - Pro26 - Xaa27 - Asp28 - Xaa 29 - Xaaso - ASIBI - Asi - Xaa33 - Cys34 - Xaais - Thrss - Xaa37 - Gly38 - Xaa39 - Cys4o - Pl •>.: 41 - Xaa42 - Xaa 3 - Ile44 - GI1145 - Gli 146 - Asp47 -Asprs - X a49 - Glyso - Xaasi - Xaas 2 - Xaa5 - X a54 - Xaass - Serso - Gly 57 - Cysss - Xaass - Xaaeo - Xaaei - G1U62 - Gly 63 - Sei64 -- Aspes - Pheee - Glne? - CyS 8 - Xaa69 - Asp?o - Xaa7i - Pro72 - Xaa73 - Xaa74 - X a75 - Xaa76 - Arg77 - Arg78 - Xaa?s - lieso - Glusi - Cyss2 - Cyss3 - Xaa84 - Xaass - X s6 - aas7 - aass-X as9—aa9o ~ a9i ■ Xaa92 — aa93 ~ a94—X a95—Xa 96 - Xaa97 - Xaass - Xaa99 - Xaaioo - Xaaioi - Xaaio2 - Xaaios - Xaaio4 - Xaaios - Xaaios - Xaai«7 - Xaaios - Xaaio9 - Xaano - Xaani - Xaai n - Xaam;

[0348] wherein: Xaais is K or P;

[0349] Xaai6 is V or I;

[0350] Xa 2.o is V. F. K or Y;

[0351] Xaa22 is G, II or S;

[0352] Xaa’ 22 is absent, G, S or A;

[0353] Xa 23 is S, H or G;

[0354] Xaa27 is E or D;

[0355] Xaa29 is S or A;

[0356] Xaa30is V or I;

[0357] Xa 33 is I or T;

[0358] Xaa35is S or I;

[0359] Xaa37is D or N;

[0360] Xa 39 is Y or H;

[0361] Xaa42 is T or A;

[0362] Xaa43is M or I;

[0363] Xaa49 is S or Q;

[0364] Xaa51is L or E;

[0365] Xa 52 is P or T;1902004-0002-005-W01

[0366] Xaass is V or T;

[0367] Xaas4 is V or L;

[0368] Xaass is T or A;

[0369] Xaa59is L or M;

[0370] Xaa60is G or K;

[0371] Xaa61is L or Y;

[0372] Xaa69is R or K;

[0373] Xaan is T or S;

[0374] Xaa?3 is I or K;

[0375] Xaa74is P or A;

[0376] Xaa?5 is II or Q;

[0377] Xaa76 is Q orL;

[0378] Xaa?9 is S or T;

[0379] Xaasi is T or R;

[0380] Xaass is absent, T or E;

[0381] Xaass is R or X;

[0382] Xaas? is absent, N or L;

[0383] Xaass is absent, E or L;

[0384] Xaas9 is absent or C;

[0385] Xaa o is absent orN;

[0386] Xaa i is absent, K or Q;

[0387] Xaa92 is absent, D or L;

[0388] Xaa93 is absent or L;

[0389] Xaa94 is absent, H or Q;1902004-0002-005-W01

[0390] Xaass is absent or P;

[0391] Xaa96 is absent or T;

[0392] Xaa97 is absent or L;

[0393] Xaags is absent or P;

[0394] Xaa99 is absent or P;

[0395] Xaaioo is absent, V or L;

[0396] Xaaioi is absent, V or K;

[0397] Xaaice is absent, I orN;

[0398] Xaaios is absent, G or R;

[0399] Xaaio4 is absent, P, D or A;

[0400] Xaaios is absent or F;

[0401] Xaaios is absent, F or V;

[0402] Xaaio7 is absent or D;

[0403] Xaaios is absent or G;

[0404] Xaai 09 is absent, S or P;

[0405] Xaano is absent or I;

[0406] Xaam is absent, R or H;

[0407] Xaai 12 is absent or H; and,

[0408] Xaai 13 is absent or R.

[0409] In embodiments, the ALK6 ECD polypeptide of the fusion protein according to SEQ ID NO: 437 comprises a substitution selected from V16I, K20Y, FI22S, __22’ A, H23G, E27D, V30I, I33T, S35I, D37N, Y39H, T42A, M43I, L51M, T55A, L59M, G60K, L61Y, R68K, T71S, I73K, P74A, H75Q, Q76L, S78T or a combination thereof, wherein > is a deletion at that position,

[0410] 1902004-0002-005-W01

[0411] In certain embodiments, the ALK6 ECD polypeptide of the fusion protein according to SEQ ID NO: 437 comprises one or more substitutions selected from K20Y, H22S, _22’A, and H23G. In certain embodiments, the ALK6 ECD polypeptide of the fusion protein according to SEQ ID NO: 437 comprises one or more substitutions selected from V16I, K20Y, H22S, __22' A, H23G and L51M. In certain other embodiments, the ALK6 ECD polypeptide of the fusion protein comprises one or more substitutions selected from V16I, K20Y, H22S, _22’A, H23G and L5 IM wherein position 60 (Xaaso) is glycine.

[0412] In certain embodiments, tire ALK6 ECD polypeptide of the fusion protein according to SEQ ID NO: 437 comprises an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to an ALK6 ECD sequence selected from SEQ ID NO: 90, 286, 292, 298, 304, 310, 316, 322, 328, 334, 340, 346, 352, 358, 364, 370, 376, 382, 388, 394, 400, 406, 412, 418, 425 and 431,

[0413] In certain embodiments, the soluble ALK-6 polypeptide comprises an active portion (e.g., ligand binding) of SEQ ID NO: 3 (“SEQ ID NO: 1 variants”). In certain embodiments, the soluble ALK-6 polypeptide comprises an active portion (e.g., ligand binding) comprises an ECD sequence of ALK6 selected from exemplified SEQ ID NO: 1, 4, 11-45, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 80, 86, 88, 92, 94, 96, 98, and 100.

[0414] In certain embodiments, the soluble ALK-6 polypeptide comprises an active portion (e.g., ligand binding) of SEQ ID NO: 108 (“SEQ ID NO: 113 variants”). In certain embodiments, the soluble ALK-6 polypeptide comprises an active portion (e.g., ligand binding) comprises an ECD sequence of ALK6 selected from exemplified SEQ ID NO: 90, 102, 104, and 110.

[0415] In certain embodiments, the soluble ALK-6 polypeptide comprises an active portion (e.g., ligand binding) of SEQ ID NO: 83 (“SEQ ID NO:1 variants”). In certain embodiments, the soluble ALK-6 polypeptide composes an active portion (e.g., ligand binding) composes an ECD sequence of ALK6 selected from exemplified SEQ ID NO: 12; SEQ ID NO: 14; and SEQ ID NO: 71

[0416] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 12. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 12.1902004-0002-005-W01

[0417] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 14. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 14.

[0418] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 71. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 71.

[0419] In certain embodiments, the soluble ALK-6 polypeptide comprises an active portion (e.g., ligand binding) of SEQ ID NO: 79 (“SEQ ID NO:11 variants”). In certain embodiments, the soluble ALK-6 polypeptide comprises an active portion (e.g., ligand binding) comprises an ECD sequence of ALK6 selected from exemplified SEQ ID NOs: 15-45, 57, 59, 61, 63, 65 and 88.

[0420] In certain embodiments, tire soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 15. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 15.

[0421] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 16. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 16.

[0422] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 17. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 17.

[0423] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 18. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%,1902004-0002-005-W0175%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 18.

[0424] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 19. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 19.

[0425] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 20. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 20.

[0426] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 21. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 21.

[0427] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 22. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%. 96%, 97%. 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 22.

[0428] In certain embodiments, tire soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 23. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 23.

[0429] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 24. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 24.1902004-0002-005-W01

[0430] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 25. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 25.

[0431] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 26. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 26.

[0432] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 27. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%. 96%, 97%. 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 27.

[0433] In certain embodiments, tire soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 28. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 28.

[0434] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 29. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 29.

[0435] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 30. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 30.

[0436] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 31. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%,1902004-0002-005-W0175%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 31.

[0437] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 32. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 32.

[0438] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 33. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 33.

[0439] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 34. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 34.

[0440] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 35. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%. 96%, 97%. 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 35.

[0441] In certain embodiments, tire soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 36. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 36.

[0442] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 37. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 37.1902004-0002-005-W01

[0443] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 38. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 38.

[0444] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 39. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 39.

[0445] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 40. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%. 96%, 97%. 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 40.

[0446] In certain embodiments, tire soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 41. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 41.

[0447] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 42. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 42.

[0448] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 43. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 43.

[0449] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 44. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%,1902004-0002-005-W0175%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 44.

[0450] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 45. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 45.

[0451] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 57. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 57.

[0452] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 59. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 59.

[0453] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 61. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%. 96%, 97%. 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 61.

[0454] In certain embodiments, tire soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 63. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 63.

[0455] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 65. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 65.1902004-0002-005-W01

[0456] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 88. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 88.

[0457] In certain embodiments, the soluble ALK-6 polypeptide comprises an active portion (e.g., ligand binding) of SEQ ID NO: 82 (“SEQ ID NO:80 variants”). In certain embodiments, the soluble ALK-6 polypeptide comprises an active portion (e.g., ligand binding) comprises an ECD sequence of ALK6 selected from exemplified SEQ ID NO: 67, 73, 75, and 77.

[0458] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 67. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%. 96%, 97%. 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 67.

[0459] In certain embodiments, tire soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 73. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 73.

[0460] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 75. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 75.

[0461] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 77. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 77.

[0462] In certain embodiments, the soluble ALK-6 polypeptide comprises an active portion (e.g., ligand binding) of SEQ ID NO: 81 (“SEQ ID NO:69 variants”). In certain embodiments, the soluble ALK-6 polypeptide comprises an active portion (e.g., ligand1902004-0002-005-W01binding) comprises an ECD sequence of ALK6 selected from exemplified according to SEQ ID NO: 13, 86, 90, 92, 94, 96, 98, 100, 102, 104, 110, 113, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 202, 213, 218, 223, 228, 233, 242, 247, 252, 257, 262, 267, 272, 277 and 283.

[0463] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 13. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%. 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%. 95%, 96%. 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 13.

[0464] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 86. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 86.

[0465] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 90. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 90.

[0466] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 92. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%. 95%, 96%. 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 92.

[0467] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 94. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 94.

[0468] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 96. Therefore ALK6 polypeptides may, for example,1902004-0002-005-W01comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 96.

[0469] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 98. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%. 96%, 97%. 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 98.

[0470] In certain embodiments, tire soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 100. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 100.

[0471] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 102. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 102.

[0472] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 104. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 104.

[0473] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 110. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 110.

[0474] In certain embodiments, tire soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 113. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%. 95%, 96%. 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 113.1902004-0002-005-W01

[0475] In certain embodiments, the soluble ALK-6 polypeptide comprises an active portion (e.g., ligand binding) of SEQ ID NO: 157 (“SEQ ID NO:1 variants”). In certain embodiments, the soluble ALK-6 polypeptide comprises an active portion (e.g., ligand binding) comprises an ECD sequence of ALK6 selected from exemplified according to SEQ ID NO: 132 to 155.

[0476] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 132. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 132.

[0477] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 133. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%. 96%, 97%. 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 133.

[0478] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 134. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 134.

[0479] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 135. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 135.

[0480] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 136. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 136.

[0481] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 137. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%,1902004-0002-005-W0175%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 137.

[0482] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 138. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 138.

[0483] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 139. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 139.

[0484] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 140. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 140.

[0485] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 141. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%. 96%, 97%. 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 141.

[0486] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 142. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 142.

[0487] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 143. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 143.1902004-0002-005-W01

[0488] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 144. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 144.

[0489] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 145 Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 145.

[0490] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 146. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%. 96%, 97%. 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 146.

[0491] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 147. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 147.

[0492] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 148. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 148.

[0493] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 149. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 149.

[0494] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 150. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%,1902004-0002-005-W0175%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 150.

[0495] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 151. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 151.

[0496] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 152. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 152.

[0497] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 153. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 153.

[0498] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 154. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%. 96%, 97%. 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 154.

[0499] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 155. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 155.

[0500] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 156. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 156.1902004-0002-005-W01

[0501] In certain embodiments, the soluble ALK-6 polypeptide comprises an active portion (e.g., ligand binding) of SEQ ID NO: 190 (“SEQ ID NO:69 variants”). In certain embodiments, the soluble ALK-6 polypeptide comprises an active portion (e.g., ligand binding) comprises an ECD sequence of ALK6 selected from exemplified according to SEQ ID NO: 158-189.

[0502] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 158. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 158.

[0503] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 159. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%. 96%, 97%. 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 159.

[0504] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 160. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 160.

[0505] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 161. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 161.

[0506] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 162. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 162.

[0507] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 163. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%,1902004-0002-005-W0175%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 163.

[0508] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 164. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 164.

[0509] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 165. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 165.

[0510] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 166. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 166.

[0511] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 167. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%. 96%, 97%. 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 167.

[0512] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 168. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 168.

[0513] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 169. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 169.1902004-0002-005-W01

[0514] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 170. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 170.

[0515] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 171. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 171.

[0516] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 172. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%. 96%, 97%. 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 172.

[0517] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 173. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 173.

[0518] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 174. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 174.

[0519] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 175. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 175.

[0520] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 176. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%,1902004-0002-005-W0175%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 176.

[0521] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 177. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 177.

[0522] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 178. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 178.

[0523] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 179. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 179.

[0524] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 180. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%. 96%, 97%. 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 180.

[0525] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 181. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 181.

[0526] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 182. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 182.1902004-0002-005-W01

[0527] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 183. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 183.

[0528] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 184. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 184.

[0529] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 185. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%. 96%, 97%. 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 185.

[0530] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 186. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 186.

[0531] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 187. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 187.

[0532] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 188. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 188.

[0533] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 189. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%,1902004-0002-005-W0175%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 189.

[0534] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 191. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 191.

[0535] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 192. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 192.

[0536] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 193. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 193.

[0537] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 202. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%. 96%, 97%. 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 202.

[0538] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 213. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 213.

[0539] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 218. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 218.1902004-0002-005-W01

[0540] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 223. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 223.

[0541] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 228. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 228.

[0542] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 233. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%. 96%, 97%. 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 233.

[0543] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 242. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 242.

[0544] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 247. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 247.

[0545] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 252. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 252.

[0546] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 257. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%,1902004-0002-005-W0175%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 257.

[0547] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 223. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 262.

[0548] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 267. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 267.

[0549] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 272. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 272.

[0550] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 277. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%. 96%, 97%. 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 277.

[0551] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 283. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 283.

[0552] In certain embodiments, the soluble ALK-6 polypeptide comprises an active portion (e.g., ligand binding) of SEQ ID NO: 437 (“SEQ ID NO:90 variants”). In certain embodiments, the soluble ALK-6 polypeptide comprises an active portion (e.g., ligand binding) composing an ECD sequence of ALK6 selected from exemplified sequences according to SEQ ID NO: 286, 292, 298, 304, 310, 316, 322, 328, 334, 340, 346, 352, 358, 364, 370, 376, 382, 388, 394, 400, 406, 412, 418, 425 and 431.1902004-0002-005-W01

[0553] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 286. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 286.

[0554] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 292. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 292.

[0555] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 298. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%. 96%, 97%. 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 298.

[0556] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 304. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 304.

[0557] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 310. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 310.

[0558] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 316. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 316.

[0559] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 322. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%,1902004-0002-005-W0175%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 322.

[0560] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 328. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 328.

[0561] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 334. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 334.

[0562] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 340. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 340.

[0563] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 346. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%. 96%, 97%. 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 346.

[0564] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 352. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 352.

[0565] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 358. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 358.1902004-0002-005-W01

[0566] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 364. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 364.

[0567] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 370. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 370.

[0568] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 376. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%. 96%, 97%. 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 376.

[0569] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 382. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 382.

[0570] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 388. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 388.

[0571] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 394. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 394.

[0572] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 400. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%,1902004-0002-005-W0175%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 400.

[0573] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 406. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 406.

[0574] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 412. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 412.

[0575] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 418. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 418.

[0576] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 425. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%. 96%, 97%. 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 425.

[0577] In certain embodiments, the soluble ALK6 polypeptide comprises an ECD sequence of ALK6 according to SEQ ID NO: 431. Therefore ALK6 polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 431.

[0578] In certain embodiments, the ALK6 ECD polypeptide portion of the soluble ALK6 fusion protein (“BMP antagonist fusion protein”) is selected from the group consisting of: SEQ ID NOs: 1, 3-5, 11-45, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79-83, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 108, 109, 110, 113, 132-194, 202, 213, 218, 223, 228, 233, 242, 247, 252, 257, 262, 272, 277, 283, 286, 292, 298, 304, 310, 316, 322, 328, 334, 340, 346, 352, 358, 364, 370, 376, 382, 388, 394, 400, 406, 412, 418, 425, 431 and 437. For example, the ALK6 ECD1902004-0002-005-W01polypeptide portion of the BMP antagonist fusion protein may comprise an amino acid sequence that is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to an amino acid sequence selected from the group consisting of: SEQ ID NOs: 1, 3-5, 11-45, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79-83, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 108, 109, 110, 113, 132-194, 202, 213, 218, 223, 228, 233, 242, 247, 252, 257, 262, 272, 277, 283, 286, 292, 298, 304, 310, 316, 322, 328, 334, 340, 346, 352, 358, 364, 370, 376, 382, 388, 394, 400, 406, 412, 418, 425, 431 and 437

[0579] In certain embodiments, ALK6 ECD polypeptide portion of the soluble ALK6 fusion protein (“BMP antagonist fusion protein”) is selected from the group consisting of: SEQ ID NO: 33, 86, 8890, 233, 242, 283 and 286. For example, the ALK6 ECD polypeptide portion of the BMP antagonist fusion protein may comprise an amino acid sequence that is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to an amino acid sequence selected from the group consisting of: SEQ ID NOs: 33, 86, 88 90, 233, 242, 283 and 286.

[0580] In embodiments, the ALK6 ECD polypeptide can be adjoined to a heterologous domain sequence which aid formation and stability of homodimer soluble ALK6 polypeptides. In certain embodiments, the heterologous domain can be derived from the constant region of an antibody (i.e., the Fc region or the hinge region between the CHI and CH2 domains). In certain embodiments, the Fc region of the fusion protein is exemplified as:THTCPPCPAPELLGGPSVFEFPPKPKDTEMISRTPEVTCVVVDVSHEDP EVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNG KEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVS LTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 10).

[0581] In certain embodiments, the Fc region of the fusion protein is exemplified as:THTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDP EVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNG KEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVS LTCLVKGFYPSDIAVEWESNGQPENNYKITPPVLDSDGSFFLYSKLTV DKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 106)

[0582] In certain embodiments, the Fc region of the fusion protein is exemplified as:1902004-0002-005-W01THTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDP EVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLWLHQDWLNG KEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVS LTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTV DKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 107)

[0583] In certain embodiments, the Fc region of the fusion protein is exemplified as:THTCPPCPAPEAAGGPSVFLFPPKPKDTLMASRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLAQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 285)

[0584] In certain embodiments, the Fc sequence SEQ ID NO: 285 is combined with any of the ALK6 ECD sequences of this disclosure to provide an ALK6 Fc fusion protein for intra vitreal ("‘IVT”) administration, wherein SEQ ID NO: 285 does not bind complement decreasing the fusion protein’s half-life in circulation. The ALK6 Fc fusion proteins of this disclosure can be administered systemically or intravitreally for the treatment of a retinopathy disease.

[0585] In certain embodiments, the heterologous domain of the fusion protein comprises the cysteine core of the amino acid sequence from the hinge region of IgGl, IgG2, IgG3 or IgG4. For example, EPKSCDKTHTCPPCPAPELLGGP (SEQ ID NO: 196); ERKCCVECPPCPAPPVAGP (SEQ ID NO: 197); and ESKYGPPCPSCPAPEFLGGP (SEQ ID NO: 198); THTCPPCPAPEAAGGP (SEQ ID NO: 199); EHTCPPCKCPEAAGGP (SEQ ID NO: 200); and PTIKPCPPCKCPAP (SEQ ID NO: 201).

[0586] Other heterologous domain sequences may also be suitable to aid in dimerization of the extracellular domains of the ALK6 ECD and the linker regions as would be understood by those of ordinary skill in the art. It is also understood that for certain animal studies murine or the like, homologous Fc sequences are used as needed to test the ALK6 ECD polypeptides of this disclosure.

[0587] In embodiments, the ALK6 ECD polypeptide can be adjoined to a heterologous domain sequence as a fusion protein using a linker peptide. In certain embodiments, the linker peptide can be selected from the group consisting of:TGGGGSGGGGSGGGGSGGGGS (SEQ ID NO: 6);1902004-0002-005-W01TGGG (SEQ ID NO: 7); and,EAAAKEAAAKEAAAKEAAAK (SEQ ID NO: 8).

[0588] Other linker peptides may also be suitable as would be understood by those of ordinary skill in the art. See for example SEQ ID NO: 84 and 85

[0589] In embodiments, the fusion protein can include a leader peptide. In certain embodiments, the leader peptide can be MGWSCIILFLVATATGVHS (SEQ ID NO: 9). Other leader peptides may also be suitable as would be understood by those of ordinary skill in the art. One of skill in the art also understands the leader sequence is cleaved as part of processing resulting in a mature processed polypeptide sequence (e.g. SEQ ID NO: 1).

[0590] Provided herein are a number of exemplified soluble ALK6 fusion polypeptides (proteins) comprising an ALK6 ECD sequence portion, a linker sequence portion and an Fc sequence portion according to any of the portion sequences (e.g., ALK6 ECD, linker and FC) described above and herein. In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence selected from SEQ ID NO: 46-50, 52-56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 84, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 111, 112, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 203, 214, 219, 224, 229, 234, 238, 243, 248, 253, 258, 263, 268, 273, 278, 282, and 284. In certain other embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence selected from SEQ ID NO: 291, 297, 303, 309, 315, 321, 327, 333, 339, 345, 351, 357, 363, 369, 375, 381, 387, 393, 399, 405, 411, 417, 423, 424, 430, and 436.

[0591] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 46, Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 46.

[0592] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 47. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 47.1902004-0002-005-W01

[0593] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 48. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 48.

[0594] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 49. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%. 94%, 95%. 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 49.

[0595] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 50. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 50.

[0596] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 52. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 52.

[0597] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 53, Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 53.

[0598] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 54. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 54.1902004-0002-005-W01

[0599] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 55. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 55.

[0600] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 56. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%. 94%, 95%. 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 56.

[0601] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 60. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 60.

[0602] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 62. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 62.

[0603] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 64, Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 64.

[0604] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 66. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 66.1902004-0002-005-W01

[0605] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 68. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 68.

[0606] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 70. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%. 94%, 95%. 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 70.

[0607] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 72. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 72.

[0608] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 74. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 74.

[0609] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 76, Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 76.

[0610] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 78. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%. 95%, 96%. 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 78.1902004-0002-005-W01

[0611] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 84. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 84.

[0612] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 85. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%. 94%, 95%. 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 85.

[0613] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 87. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 87.

[0614] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 89. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 89.

[0615] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 91, Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 91.

[0616] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 93. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%. 95%, 96%. 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 93.1902004-0002-005-W01

[0617] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 95. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 95.

[0618] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 97. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%. 94%, 95%. 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 97.

[0619] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 99. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 99.

[0620] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 101. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 101.

[0621] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 103. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 103.

[0622] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 105. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%. 95%, 96%. 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 105.1902004-0002-005-W01

[0623] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 111. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 111.

[0624] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 112. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%. 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%. 94%, 95%. 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 112.

[0625] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 114. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 114.

[0626] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 115. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 115.

[0627] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 116. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 116.

[0628] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 117. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%. 95%, 96%. 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 117.1902004-0002-005-W01

[0629] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 118. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 118.

[0630] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 119. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%. 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%. 94%, 95%. 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 119.

[0631] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 120. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 120.

[0632] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 121. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 121.

[0633] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 122. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 122.

[0634] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 123. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%. 95%, 96%. 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 123.1902004-0002-005-W01

[0635] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 124. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 124.

[0636] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 125. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%. 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%. 94%, 95%. 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 125.

[0637] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 126. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 126.

[0638] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 127. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 127.

[0639] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 128. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 128.

[0640] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 129. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%. 95%, 96%. 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 129.1902004-0002-005-W01

[0641] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 203. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 203.

[0642] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 204. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%. 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%. 94%, 95%. 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 204.

[0643] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 205. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 205.

[0644] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 206. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 206.

[0645] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 207. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 207.

[0646] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 208. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%. 95%, 96%. 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 208.1902004-0002-005-W01

[0647] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 209. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 209.

[0648] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 210. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%. 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%. 94%, 95%. 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 210.

[0649] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 211. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 211.

[0650] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 212. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 212.

[0651] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 214. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 214.

[0652] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 215. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%. 95%, 96%. 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 215.1902004-0002-005-W01

[0653] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 216. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 216.

[0654] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 217. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%. 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%. 94%, 95%. 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 217.

[0655] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 219. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 219.

[0656] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 220. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 220.

[0657] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 221. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 221.

[0658] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 222. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%. 95%, 96%. 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 222.1902004-0002-005-W01

[0659] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 224. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 224.

[0660] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 225. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%. 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%. 94%, 95%. 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 225.

[0661] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 226. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 226.

[0662] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 227. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 227.

[0663] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 229. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 229.

[0664] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 230. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%. 95%, 96%. 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 230.1902004-0002-005-W01

[0665] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 231. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 231.

[0666] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 232. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%. 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%. 94%, 95%. 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 232.

[0667] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 234. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 234.

[0668] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 235. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 235.

[0669] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 236. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 236.

[0670] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 237. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an ammo acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%. 95%, 96%. 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 237.1902004-0002-005-W01

[0671] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 238. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 238.

[0672] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 239. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%. 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%. 94%, 95%. 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 239.

[0673] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 240. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 240.

[0674] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 241. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 241.

[0675] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 243. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 243.

[0676] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 244. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an ammo acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%. 95%, 96%. 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 244.1902004-0002-005-W01

[0677] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 245. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 245.

[0678] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 246. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%. 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%. 94%, 95%. 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 246.

[0679] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 248. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 248.

[0680] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 249. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 249.

[0681] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 250. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 250.

[0682] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 251. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an ammo acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%. 95%, 96%. 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 251.1902004-0002-005-W01

[0683] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 253. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 253.

[0684] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 254. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%. 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%. 94%, 95%. 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 254.

[0685] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 255. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 255.

[0686] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 256. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 256.

[0687] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 258. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 258.

[0688] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 259. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an ammo acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%. 95%, 96%. 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 259.1902004-0002-005-W01

[0689] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 260. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 260.

[0690] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 261. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 261.

[0691] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 263. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 263.

[0692] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 264. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 264.

[0693] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 265. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 265.

[0694] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 266. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an ammo acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%. 95%, 96%. 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 266.1902004-0002-005-W01

[0695] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 268. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 268.

[0696] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 269. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%. 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%. 94%, 95%. 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 269.

[0697] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 270. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 270.

[0698] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 271. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 271.

[0699] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 273. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 273.

[0700] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 274. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an ammo acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%. 95%, 96%. 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 274.1902004-0002-005-W01

[0701] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 275. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 275.

[0702] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 276. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%. 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%. 94%, 95%. 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 276.

[0703] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 278. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 278.

[0704] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 279. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 279.

[0705] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 280. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 280.

[0706] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 281. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an ammo acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%. 95%, 96%. 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 281.1902004-0002-005-W01

[0707] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 282. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 282.

[0708] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 283. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%. 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%. 94%, 95%. 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 283.

[0709] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 284. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 284.

[0710] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 291. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 291.

[0711] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 297. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 297.

[0712] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 303. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an ammo acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%. 95%, 96%. 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 303.1902004-0002-005-W01

[0713] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 309. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 309.

[0714] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 315. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%. 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%. 94%, 95%. 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 315.

[0715] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 321. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 321.

[0716] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 327. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 327.

[0717] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 333. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 333.

[0718] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 339. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an ammo acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%. 95%, 96%. 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 339.1902004-0002-005-W01

[0719] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 345. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 345.

[0720] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 351. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%. 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%. 94%, 95%. 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 351.

[0721] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 357. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 357.

[0722] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 363. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 363.

[0723] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 369. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 369.

[0724] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 375. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an ammo acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%. 95%, 96%. 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 375.1902004-0002-005-W01

[0725] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 381. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 381.

[0726] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 387. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%. 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%. 94%, 95%. 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 387.

[0727] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 393. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 393.

[0728] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 375. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 375.

[0729] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 381. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 381.

[0730] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 387. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%. 95%, 96%. 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 387.1902004-0002-005-W01

[0731] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 393. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 393.

[0732] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 399. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%. 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%. 94%, 95%. 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 399.

[0733] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 405. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 405.

[0734] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 411. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 411,

[0735] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 417. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 417.

[0736] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 423. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%. 95%, 96%. 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 423.1902004-0002-005-W01

[0737] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 424. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 424.

[0738] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 430. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%. 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%. 94%, 95%. 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 430.

[0739] In certain embodiments, the soluble ALK6 fusion polypeptide comprises an amino acid sequence according to SEQ ID NO: 436. Therefore ALK6 fusion polypeptides may, for example, comprise, consists essentially of, or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ALK6 of SEQ ID NO: 436.

[0740] In certain embodiments, the soluble ALK6 fusion polypeptides (not including the leader peptide (e.g., SEQ ID NO: 9)) can be selected from the group consisting of: SEQ ID NOs: 46-50, 52-56, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 84, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 111, 112, 114-129, 203, 214, 219, 224, 229, 234, 238, 243, 248, 253, 258, 263, 268, 273, 278, 282, and 284. For example, the ALK6 fusion polypeptides may comprise an amino acid sequence that is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to an amino acid sequence selected from the group consisting of:: SEQ ID NOs: 46- 50, 52-56, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 84, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 111, 112, 114-129, 203, 214, 219, 224, 229, 234, 238, 243, 248, 253, 258, 263, 268, 273, 278, 282, and 284.

[0741] In certain embodiments, the soluble ALK6 fusion polypeptides (not including the leader peptide (e.g., SEQ ID NO: 9)) can be selected from the group consisting of: SEQ ID NOs: 291, 297, 303, 309, 315, 321, 327, 333, 339, 345, 351, 357, 363, 369, 375, 381, 387, 393, 399, 405, 411, 417, 423, 424, 430, and 436. For example, the ALK6 fusion polypeptides may comprise an amino acid sequence that is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to an amino acid sequence selected from the group consisting1902004-0002-005-W01of:: SEQ ID NOs: 291, 297, 303, 309, 315, 321, 327, 333, 339, 345, 351, 357, 363, 369, 375, 381, 387, 393, 399, 405, 411, 417, 423, 424, 430, and 436.

[0742] In certain embodiments, soluble ALK6 fusion polypeptides (not including the leader peptide (e.g., SEQ ID NO: 9)) can be selected from the group consisting of: SEQ ID NOs: 87, 89, 91, 112, 34, 243 and 284. For example, the ALK6 fusion polypeptides may comprise an amino acid sequence that is at least 80%. 85%, 90%, 91%, 92%, 93%. 94%, 95%, 96%, 97%, 98%, or 99% identical to an amino acid sequence selected from the group consisting of::SEQ ID NOs: 87, 89, 91, 112, 234, 243 and 284.

[0743] In certain other embodiments, soluble ALK6 fusion polypeptides (not including the leader peptide (e.g., SEQ ID NO: 9)) can be selected from the group consisting of: SEQ ID NOs: 132-156, 158-189, 191-194, 202, 213, 218, 223, 228, 233, 242, 247, 252, 257, 262, 272, 277 and 283. For example, the ALK6 fusion polypeptides may comprise an amino acid sequence that is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to an amino acid sequence selected from the group consisting of:: SEQ ID NOs: 132- 156, 158-189, 191-194, 202, 213, 218, 223, 228, 233, 242, 247, 252, 257, 262, 272, 277 and 283.

[0744] In certain other embodiments, soluble ALK6 fusion polypeptides (not including the leader peptide (e.g., SEQ ID NO: 9)) can be selected from a sequence according to SEQ ID NOs: 291 or 424. For example, the ALK6 fusion polypeptides may comprise an amino acid sequence that is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to an amino acid sequence of SEQ ID NOs: 291 or 424.

[0745] Other fusion proteins may also be derived from this disclosure as would be understood by those of ordinary skill in the art.

[0746] Compositions and Pharmaceutical Formulations

[0747] The polypeptides described herein may be combined with one or more pharmaceutically acceptable carriers prior to administration to a host. A pharmaceutically acceptable carrier is a material that is not biologically or otherwise undesirable, e.g., the material may be administered to a subject, without causing any undesirable biological effects or interacting in a deleterious manner with any of the other components of tire pharmaceutical composition in which it is contained. The carrier would naturally be selected to minimize any degradation of the active ingredient and to minimize any adverse side effects in the subject, as1902004-0002-005-W01would be well known to one of skill in the art. Suitable pharmaceutical carriers and their formulations are described in, for example, Remington ’s: The Science and Practice of Pharmacy, 21stEdition, David B. Troy, ed., Lippicott Williams & Wilkins (2005). Typically, an appropriate amount of a pharmaceutically-acceptable salt is used in the formulation to render the formulation isotonic. Examples of the pharmaceutically-acceptable carriers include, but are not limited to, sterile water, saline, buffered solutions like Ringer's solution, and dextrose solution. The pH of the solution is generally from about 5 to about 8 or from about 7 to about 7.5. Other carriers include sustained-release preparations such as semipermeable matrices of solid hydrophobic polymers containing polypeptides or fragments thereof. Matrices may be in the form of shaped articles, e.g., films, liposomes or microparticles. It will be apparent to those persons skilled in the art that certain carriers may be more preferable depending upon, for instance, the route of administration and concentration of composition being administered. Carriers are those suitable for administration of polypeptides and / or fragments thereof to humans or other subjects. Pharmaceutical compositions may also include carriers, thickeners, diluents, buffers, preservatives, surface active agents, adjuvants, immunostimulants, in addition to the immunogenic polypeptide. Pharmaceutical compositions may also include one or more active ingredients such as antimicrobial agents, anti-inflammatory agents and anesthetics. The pharmaceutical composition may be administered orally, parentally, by inhalation spray, rectally, intranodally, or topically in dosage unit formulations containing conventional pharmaceutically acceptable carriers, adjuvants, and vehicles. The term “pharmaceutically acceptable carrier” or “physiologically acceptable carrier” as used herein refers to one or more formulation materials suitable for accomplishing or enhancing the delivery of a nucleic acid, polypeptide, or peptide as a pharmaceutical composition. A “pharmaceutical composition” is a composition comprising a therapeutically effective amount of polypeptide and / or fusion protein disclosed herein.

[0748] Methods for treating one or more disease conditions in a mammalian host comprising administering to the mammal at least one or more effective doses of one or more binding agents (and / or derivative(s) thereof) described herein are also provided, as disclosed in more detail below. In some embodiments, one or more polypeptides and / or fusion proteins and / or compositions comprising the same may be administered in a dosage amount of about 1 to about 50 mg (of polypeptide or protein) / kg, about 1 to about 30 mg / kg, or about 5 to about 30 mg / kg (e.g., about any of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, or 40 mg / kg). In certain embodiments, the one or more1902004-0002-005-W01polypeptides and / or fusion proteins and / or compositions comprising the same may be administered to the mammal (e.g., intradermally, intravenously, orally, rectally) at about 10 mg / kg one or more times. When multiple doses are administered, the doses may comprise about the same or different amount of binding agent in each dose. The doses may also be separated in time from one another by the same or different intervals. For instance, the doses may be separated by about any of 6, 12, 24, 36, 48, 60, 72, 84, or 96 hours, one week, two weeks, three weeks, one month, two months, three months, four months, five months, six months, seven months, eight months, nine months, 10 months, 11 months, 12 months, 1.5 years, 2 years, 3 years, 4 years, 5 years, or any time period before, after, and / or between any of these time periods. In some embodiments, the polypeptides and / or fusion proteins and / or compositions comprising the same may be administered in conjunction with other agents (e.g., anti-infective agents and / or chemotherapeutic agent). Such other agents may be administered about simultaneously with the polypeptides and / or fusion proteins and / or compositions comprising tire same, or at a different time and / or frequency. Other embodiments of such methods may also be appropriate as could be readily determined by one of ordinary skill in the art.

[0749] In embodiments the pharmaceutic compositions of this disclosure are administered in any way suitable to effectively achieve a desired therapeutic effect in the eye. Thus, methods of administration include without limitation, topical, intraocular (including intravitreal), transdermal, oral, intravenous, subconjunctival, subretinal, or peritoneal routes of administration. In certain embodiments, the pharmaceutical composition comprising a soluble ALK-6 Fc fusion protein is configured to be administered via an intraocular (including intravitreal) injection.

[0750] Methods of Treatment

[0751] The present disclosure relates to methods for the treatment of a retinopathy disorder. In embodiments, the retinopathy disorder is a neovascular retinopathy disorder. Provided herein is a method for the treatment of diabetic retinopathy in a human subject in need thereof (alleviating one or more symptoms, or stasis of one or more symptoms) by administering to the human subject a therapeutically effective amount of a composition provided herein. The treatment can result in improving the patient's condition and can be assess by determining if one or more of the following factors has occurred: decreased macular edema, or increased1902004-0002-005-W01visual acuity. The compounds described herein can also be used in medicaments for the treatment of diabetic retinopathy.

[0752] As used herein “patient” and “human subject in need thereof" are used interchangeably. As used herein, “patient” or “human subject in need thereof” is a human who exhibits one or more clinical manifestations and / or symptoms of a disease or disorder described herein. In certain situations, the patient may be asymptomatic and yet still have clinical manifestations of the disease or disorder. In one embodiment, a patient to be treated is a human being.

[0753] As used herein, “diabetic retinopathy” refers to changes in the retina due to tire micro vascular changes seen in diabetes. The blood vessels that supply oxygen to the retina of the eye are damaged due to long-term high levels of blood sugar (hyperglycemia). The disease generally develops slowly over a period of months but over time, diabetic retinopathy can get worse and cause vision loss. Diabetic retinopathy usually affects both eyes. Diabetic retinopathy progresses from mild non-proliferative abnormalities, characterized by increased vascular permeability, to moderate and severe non-proliferative diabetic retinopathy (NPDR), characterized by vascular closure, to proliferative diabetic retinopathy (PDR), characterized by the growth of new blood vessels on the retina and posterior surface of the vitreous. Macular edema, characterized by retinal thickening from leaky blood vessels, can develop at all stages of retinopathy. Furthermore conditions such as pregnancy, puberty, blood glucose control, hypertension, and cataract surgery can accelerate these changes.

[0754] Non-proliferative diabetic retinopathy, proliferative diabetic retinopathy and diabetic maculopathy are the three main types of diabetic retinopathy.

[0755] Non-Proliferative Diabetic Retinopathy (NDPR) is considered as the early stage of retinopathy and is the most common seen in diabetics. Tire tiny blood vessels in the retina are only mildly affected, but may form bulges (micro aneurysms) and connections with each other (intraretinal micro vascular anomalies) and / or leak fluid (edema), protein deposits (exudates) and blood (hemorrhage). Another typical sign of non-proliferative diabetic retinopathy (NPDR) is the presence of puffy white patches on the retina (cotton wool spots). These changes can occur anywhere throughout the retina, including the macula.

[0756] There are three stages of non-proliferative diabetic retinopathy which are detailed below:1902004-0002-005-W01

[0757] (1) Mild Non-proliferative Diabetic Retinopathy: At this earliest stage, at least one micro aneurysm may occur. Micro aneurysms are small areas of balloon-like swelling in the retina's blood vessels.

[0758] (2) Moderate Non-proliferative Diabetic Retinopathy: As the disease progresses, some blood vessels that nourish the retina are blocked.

[0759] (3) Severe Non-proliferative Diabetic Retinopathy: Many more blood vessels are blocked, depriving several areas of the retina of blood supply. These areas of the retina send signals to the body to grow new blood vessels for nourishment.

[0760] Non-proliferative diabetic retinopathy should not cause any problems to the patient, as the vision remains normal as long as the macula is not affected. However, as the symptoms of diabetic retinopathy are generally not visible in this stage, it is recommended that regular retinal screening eye tests should be done to monitor the signs of progression to more serious stages of retinopathy.

[0761] Proliferative Diabetic Retinopathy (PDR): This stage comes after severe non¬ proliferative diabetic retinopathy and is characterized by the growth of abnormal new blood vessels in the eye. When the diabetes causes tire blood vessels to become blocked, parts of the eye and retina develop ischemia, as they become starved of oxygen and nutrients. The eye tries to respond to this condition, by growing a new blood supply to the oxygen starved areas. Unfortunately, fragile new blood vessels that bleed easily are formed instead. This process is called neo-vascularization. These abnormal new blood vessels grow in the wrong place on the surface of the retina and into the vitreous gel. Vitreous hemorrhage occurs when these new blood vessels bleed into the vitreous cavity. The blood blocks light that enters the eye from reaching the retina. The amount of sight loss can be mild to severe, and depends on how much blood is in the eye. Tire vision might slowly improve as the hemorrhage gradually clears over several months.

[0762] Abnormal new vessels also cause the formation of scar tissue which pulls on the retina and may result in fractional retinal detachment. The retinal detachment can affect any part of the retina. If it affects the macula, the patient might lose his / her central vision and it can be treated only with surgery.

[0763] Diabetic Maculopathy: Diabetic maculopathy is the most common cause of visual loss in diabetes. It occurs when the macula becomes affected by the retinopathy changes caused by diabetes. Tire macula is located at the center of the retina and is important for central vision and for seeing fine details clearly. Therefore, tlie central vision and ability to see detail will be1902004-0002-005-W01affected in the patients that develop diabetic maculopathy. For instance, the affected individuals might find it difficult to recognize faces in the distance or to read small prints. The amount of sight loss may be mild to severe. However, even in the worst cases, the peripheral (side) vision that allows the individual to get around at home and outside will remain unaffected.

[0764] Diabetic retinopathy (DR) is an ocular disorder characterized by excessive angiogenesis that develops in diabetes due to thickening of capillary basement membranes, and lack of contact between pericytes and endothelial cells of the capillaries. Loss of pericytes increases leakage of the capillaries and leads to breakdown of the blood-retina barrier. Diabetic retinopathy is the result of microvascular retinal changes. Hyperglycemia-induced pericyte death and thickening of the basement membrane lead to incompetence of the vascular walls. These damages change the formation of tire blood-retinal barrier and also make the retinal blood vessels become more permeable. Small blood vessels — such as those in the eye — are especially vulnerable to poor blood sugar (blood glucose) control. An over-accumulation of glucose and / or fructose damages the tiny blood vessels in the retina. Macular edema can also develop when tire damaged blood vessels leak fluid and lipids onto the macula. These fluids make the macula swell, which blurs vision. This damage also results in a lack of oxygen at the retina.

[0765] As the disease progresses, the lack of oxygen in the retina stimulates angiogenesis along the retina and in the clear, gel-like vitreous humor that fills the inside of the eye. Without timely treatment, these new blood vessels can bleed, cloud vision, and destroy the retina. Fibrovascular proliferation can also cause tractional retinal detachment. The new blood vessels can also grow into the angle of the anterior chamber of the eye and cause neovascular glaucoma.

[0766] Vision loss from diabetic maculopathy occurs in 2 ways.

[0767] Diabetic macular edema (DME) is the swelling and thickening of the macula. This is due to fluid leakage from the retinal blood vessels in the macula. The vision becomes blurry because the structure and function of the macular photoreceptor cells becomes disrupted. Vision loss from macular edema can be controlled with laser and injections into the eyeball.

[0768] Macular ischemia occurs when the tiny retinal blood vessels (capillaries) to the macula close up. The vision becomes blurry because the macula does not receive enough blood supply for it to work properly. Unfortunately, there are no effective treatments for macular ischemia.1902004-0002-005-W01Macular edema is due to leakage of fluid from the retinal blood vessels. Hard exudates are the yellowish deposits seen on the retina. They are caused by leakage of protein material.

[0769] Tire following medical conditions are some of the possible causes of diabetic retinopathy.

[0770] Diabetes: Prolonged hyperglycemia (high blood glucose levels) affects the anatomy and function of retinal capillaries. The excess glucose is converted into sorbitol when it is diverted to alternative metabolic pathways. Sorbitol leads to death or dysfunction of the pericytes of the retinal capillaries. This weakens the capillary walls allowing for the formation of micro aneurysms, which are the earliest signs of diabetic retinopathy. The weak capillary walls can also be responsible for increased permeability and the exudates. Due to the predisposition to increased platelet aggregation and adhesion (blood clot formation) as a result of diabetes, the capillary circulation becomes sluggish or even totally impaired by an occlusion. This can also contribute to the development of diabetic retinopathy.

[0771] Type 1 and Type 2 diabetes: Individuals diagnosed with type 1 diabetes, are considered insulin-dependent as they require injections or other medications to supply the insulin that the body is unable to produce on its own. Due to lack of insulin the blood sugar is unregulated and levels are too high. Individuals with type 2 diabetes are considered non-insulin-dependent or insulin-resistant. The individuals affected with this type of diabetes, produce enough insulin but the body is unable to make proper use of it. The body then compensates by producing even more insulin, which can cause an accompanying abnormal increase in blood sugar levels. All people with Type I diabetes (juvenile onset) and with Type II diabetes (adult onset) are at risk of developing diabetic retinopathy. However, people with Type 1 diabetes are more likely to cause retinopathy compared to type 2 diabetes.

[0772] Diabetes mellitus type 1 and Diabetes mellitus type 2: People with Diabetes mellitus type 1 and type 2 are at increased risk of developing diabetic retinopathy.

[0773] Excessive alcohol: Alcohol if used to extreme reduces Vitamin B12 and thiamine levels. However, alcohol consumption alone is not associated with diabetic retinopathy, the consumption of empty calories from alcohol makes adhering to a calorie-restricted diabetic diet very difficult and it is unclear that what effect moderate alcohol has on retinopathy.

[0774] Hypertension and other vascular risk factors such as obesity and dyslipidaemia can influence the onset and progression of retinopathy,

[0775] High cholesterol: Cholesterol can exacerbate retinopathy by hardening of large artery blood vessels and can cause damage to the small blood vessels of the eye.1902004-0002-005-W01

[0776] Renal disease, as evidenced by proteinuria and elevated urea / creatinine levels, is an excellent predictor of the presence of retinopathy.

[0777] Pregnancy: It can exacerbate existing retinopathy though probably not cause it directly. Women with diabetes have a slightly higher risk during pregnancy. It is recommended that all pregnant women with diabetes have dilated eye examinations each trimester to protect their vision.

[0778] Kidney impairment: Associated with diabetic retinopathy, though it appears that diabetic retinopathy leads to kidney impairment rather than vice versa.

[0779] Chromosome 15q deletion: A rare chromosomal disorder involving deletion of genetic material from the long arm of chromosome 15.

[0780] It is thought that intraocular surgery may possibly increase the risk of progression of diabetic retinopathy.

[0781] There are often no symptoms in the earliest stages of non-proliferative diabetic retinopathy. The signs and symptoms of diabetic retinopathy are commonly presented as the disease progresses toward advanced or proliferative diabetic retinopathy. The diagnostic signs of diabetic retinopathy include one more of the following: changes in the blood vessels; retinal swelling (macular edema); pale deposits on the retina; damaged nerve tissue; visual appearance of leaking blood vessels; loss of central or peripheral vision; temporary or permanent vision loss; development of a scotoma or shadow in the field of view; spotty, blurry, hazy or double vision; eye pain; near vision problems unrelated to presbyopia; spots or dark strings floating in the vision (floaters); impaired color vision; vision loss; a dark or blind spot in the central vision; poor or reduced night vision; venous dilation and intraretinal micro vascular abnormalities; in the advanced stage of retinopathy tiny blood vessels grow along the retina, in the clear, gel-like vitreous humor that fills the inside of the eye; nerve damage (neuropathy) affecting ocular muscles that control eye movements; involuntary eye movement (nystagmus); fluctuating and progressive deterioration of vision; macular edema; macular ischemia; traction retinal detachment; sudden, severe painless vision loss; increased vascular permeability, leading to edema; endothelial cell proliferation; flashes of light (photopsias) or defects in the field of vision; presence of abnormal blood vessels on the iris (rubeosis), cataract (associated with diabetes) and vitreous cells (blood in the vitreous or pigmented cells if there is a retinal detachment with hole formation); micro aneury sms — physical weakening of the capillary walls which predisposes them to leakages; hard exudates — precipitates of lipoproteins / other proteins leaking from retinal blood vessels; haemorrhages -----rupture of1902004-0002-005-W01weakened capillaries, appearing as small dots / larger blots or "flame’ hemorrhages that track along nerve-fiber bundles in superficial retinal layers (the haemorrhage arises from larger and more superficial arterioles); cotton wool spots — build-up of axonal debris due to poor axonal metabolism at the margins of ischaemic infarcts; and neo-vascularization -an attempt (by residual healthy retina) to revascularize hypoxic retinal tissue.

[0782] Described herein are soluble ALK6 fusion proteins which bind their BMP ligands and sequester the ligands preventing their binding to endogenous transmembrane receptors and thus inhibiting signal transduction for the treatment of retinopathy.

[0783] As a system, the mammalian retina is subject to diseases that affect the balanced interconnection of the neural retina and the vasculature that nourishes it; visual loss occurs when this balance is disturbed. Diseases such as photoreceptor degenerations that primarily affect the neural retina also affect the retinal vasculature. Diseases that are clinically characterized by abnormality' in the choroidal or retinal vasculature, such as ROP, also affect the retinal neurons. These conditions all involve hypoxic ischemic disorders of neural tissue. Photoreceptors are specialized cells that have the highest oxygen requirements of any cell in the body, which plays a role in all hypoxic ischemic diseases of the retina.

[0784] In normal development, as the rod photoreceptors differentiate and begin to produce rhodopsin (the molecule responsible for the capture of light); their extraordinarily high oxygen demands render the retina hypoxic, driving the growth of the retinal blood vessels. However, in ROP, supplemental oxygen administered for the acute cardiopulmonary care of the prematurely bom infant renders the retina hyperoxic, interrupting normal vascular growth and leaving the peripheral retina avascular. Upon cessation of the supplemental oxygen, the peripheral retina becomes hypoxic. Hypoxia instigates a molecular cascade that leads to the formation of the abnormal retinal blood vessels that are clinically used to diagnose ROP. Even though a premature infant is subjected to high ambient oxygen, immature lungs and other medical complications often lead to fluctuations in blood oxygen and, consequently, to episodes of both hypoxia and hyperoxia at the retina which affect the sensitive photoreceptors. The developing neural retina and its vasculature are under cooperative molecular control, and the vascular abnormalities of ROP are related to the function of the neural retina. Recent studies have found that the degree of dysfunction of the rods in ROP helps predict the degree of abnormality observed in the retinal vasculature, but the degree of abnormality observed in tire retinal vasculature may not help predict the degree of dysfunction of the rods in ROP. Thus, the rods cause ROP.1902004-0002-005-W01

[0785] As used herein, an “immature retina” refers to a retina of a preterm infant or a retina of similar morphology / function to that of a pre-term infant retina. An immature retina can be characterized by the presence of poorly developed or disorganized blood vessels with or without the presence of scar tissue, in general, a human preterm infant is one born at 37 weeks gestation, or earlier. Conversely, tire term “retinal maturity” refers to a retina of a full-term infant or a retina of similar morphology / function to that of a full-term infant.

[0786] As used herein, the phrases “reduces rod energy demand” or “suppresses rod energy demand” refer to a reduction in oxygen demand of a rod cell of at least 10%; preferably the reduction of oxygen demand of a rod cell is at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90% or more. In general, it is preferred that the oxygen demand of a rod cell is maintained below the level necessary to induce pathological angiogenesis (i.e., blood vessel growth) or vascular abnormalities.

[0787] As used herein, the term “vascular abnormalities” is used to refer to an abnormal or pathological level of vascular blood vessel growth (e.g., angiogenesis) or morphology (e.g., tortuosity) that does not permit proper development of the retina to “retinal maturity” as that term is used herein. One of skill in the art can titrate the amount of agent administered or the timing of administration to maintain the growth and morphology of blood vessels below that of pathological blood vessel growth as assessed by, for example, Laser Doppler Blood Flow analysis. In an alternative embodiment, the level of tortuosity’ of retinal blood vessels is used to assess the degree of pathological blood vessel morphology and / or growth. Methods for measuring tortuosity are further described herein.

[0788] As used herein, the term “supplemental oxygen” refers to a concentration of oxygen above that of ambient air (i.e., about 20-21%) that is necessary’ to maintain blood oxygen levels in a subject at a desired level. In general, supplemental oxygen is supplied in a clinical setting to maintain a blood oxygen level of 100% as assessed using, for example, transcutaneous oxygen monitoring. Monitoring blood oxygen levels and altering the level of “supplemental oxygen” to maintain, for example, a 100% blood oxygen level is a standard procedure in a clinical setting (e.g., a neonatal intensive care unit) and is well known to those of skill in the art of medicine.

[0789] Rod Cell Phy siology and Metabolism

[0790] The rods perform three linked, metabolically demanding processes: generation of the dark current, mainten...

Claims

1902004-0002-005-W01CLAIMSWe claim:

1. A method for treatment of retinopathy in a human subject in need thereof comprising:administering an effective amount of a pharmaceutical composition to the subject, wherein the composition comprises a soluble recombinant bone morphogenetic protein receptor type- IB fusion protein comprising an ALK6 ECD polypeptide and a heterologous sequence, wherein the ALK6 ECD polypeptide comprises an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to an ALK6 ECD sequence of SEQ ID NO: 3; SEQ ID NO: 5; SEQ ID NO: 79, SEQ ID NO: 81, SEQ ID NO: 82, SEQ ID NO: 83, SEQ ID NO: 108; SEQ ID NO: 109; SEQ ID NO: 130, SEQ ID NO: 157, SEQ ID NO: 190 and SEQ ID NO: 437.

2. A method for treatment of retinopathy in a human subject in need thereof, comprising:administering an effective amount of a pharmaceutical composition to the subject, wherein the composition comprises a soluble recombinant bone morphogenetic protein receptor type- IB fusion protein comprising an ALK6 ECD polypeptide, a linker and a heterologous sequence, wherein the ALK6 ECD polypeptide comprises an amino acid sequence having at least 76%. 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to an ALK6 ECD sequence selected from SEQ ID NO: 1, 4, 11-45, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 80, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 110, 113, 132-156, 158-189, 191-194, 202, 213, 218, 223, 228, 233, 242, 247, 252, 257, 262, 272, 277, 283, 286, 292, 298, 304, 310, 316, 322, 328, 334, 340, 346, 352, 358, 364, 370, 376, 382, 388, 394, 400, 406, 412, 418, 425, or 431.

3. A method for treatment of retinopathy in a human subject in need thereof, comprising:administering an effective amount of a pharmaceutical composition to the subject, wherein the composition comprises a soluble recombinant bone morphogenetic protein receptor type- IB fusion protein comprising an ALK6 ECD polypeptide, a linker and a heterologous sequence, wherein the ALK6 Fc fusion protein comprises an amino acid sequence having at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to an amino acid sequence selected from SEQ ID NO: 291, 297, 303, 309, 315, 321, 327,1902004-0002-005-W01333, 339, 345, 351, 357, 363, 369, 375, 381, 387, 393, 399, 405, 411, 417, 423, 424, 430, and 436.

4. The method of claim 3, wherein the fusion protein polypeptide comprises an amino acid sequence having at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to an ALK6 ECD fusion protein sequence selected from SEQ ID NO: 291.

5. The method of claim 1, 2 or 3, wherein the ALK6 ECD sequence comprises at least one point mutation as compared to SEQ ID NO: 1.

6. The method of any preceding claim, wherein the ALK6 ECD sequence comprises an amino acid sequence that is at least 70%, 75%, 80%, 85%. 86%, 87%, 88%. 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 86, SEQ ID NO: 88, SEQ ID NO: 90 or SEQ ID NO: 2867. The method of any preceding claim, wherein the ALK6 ECD comprises an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 69.

8. The method of any preceding claim, wherein the ALK6 ECD comprises an amino acid sequence that is at least 70%, 75%, 80?% 85%, 86%, 87%, 88%, 89%, 90%, 91?% 92%, 93%, 94?% 95%, 96%, 97?% 98%, 99%, or 100% identical to SEQ ID NO: 90.

9. The method of any preceding claim, wherein the ALK6 ECD comprises an amino acid sequence that is at least 70%, 75?% 80%, 85%, 86?% 87%, 88%, 89?% 90%, 91%, 92%, 93?% 94%, 95%, 96?% 97%, 98%, 99?% or 100% identical to SEQ ID NO: 286.

10. The method of any preceding claim, wherein the ALK6 ECD comprises an amino acid sequence that is at least 70?% 75%, 80?% 85?% 86%, 87%, 88?% 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 233 or SEQ ID NO:242.

11. The method of any preceding claim, wherein the point mutation is selected from one or more of V16I; K20Y, K20F, H22S, _22’A, H23G, V30I, I33T, I33S, S35I, S49Q and L51M.

12. Tire method of any preceding claim, wherein the polypeptide binds one or more of BMP6, BMP7 and / or BMP 10.1902004-0002-005-W0113. The method of claim 1, wherein the ALK6 ECD sequence is selected from SEQ ID NO: 190 and tire sequence comprises point mutations K20Y and H22S.

14. Tire method of claim 1, wherein the ALK6 ECD sequence is selected from SEQ ID NO: 190 and the sequence comprises point mutations K20Y, H22S and I33T.

15. The method of claim 1, wherein the ALK6 ECD sequence is selected from SEQ ID NO: 190 and the sequence comprises point mutations H22S and I33T.

16. The method of any preceding claim, wherein the heterologous region is an Fc region.

17. The method of any preceding claim, wherein the heterologous region is a hinge region.

18. Tire method of any preceding claim, wherein the heterologous sequence is an Fc sequence according to SEQ ID NO: 285.

19. The method of any preceding claim, wherein the retinopathy is selected from diabetic retinopathy, age-related macular degeneration (AMD), choroidal neovascularization (CNV), vision loss, night blindness, photopsia, proliferative retinopathy, non¬ proliferative retinopathy, retinitis pigmentosa and hypertensive retinopathy.

20. A method for treatment of age-related macular degeneration (AMD) in a human subject in need thereof comprising: administering an effective amount of a pharmaceutical composition to tire subject, wherein the composition comprises a soluble recombinant bone morphogenetic protein receptor type- IB fusion protein comprising an ALK6 ECD polypeptide and a heterologous sequence, wherein the ALK6 ECD polypeptide comprises an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99?% or 100 % identical to an ALK6 ECD sequence of SEQ ID NO: 3; SEQ ID NO: 5: SEQ ID NO: 79, SEQ ID NO: 81, SEQ ID NO: 82, SEQ ID NO: 83, SEQ ID NO: 108; SEQ ID NO: 109; SEQ ID NO: 130, SEQ ID NO: 157, SEQ ID NO: 190 and SEQ ID NO: 437.

21. A method for treatment of age-related macular degeneration (AMD) in a human subject in need thereof, comprising:administering an effective amount of a pharmaceutical composition to the subject, wherein the composition comprises a soluble recombinant bone morphogenetic protein receptor type- IB fusion protein comprising an ALK6 ECD polypeptide, a linker and a heterologous sequence, wherein the ALK6 ECD polypeptide comprises an amino acid sequence having at least 70%, 75%, 80?% 85%, 86%, 87?% 88%, 89%,1902004-0002-005-W0190%, 91%. 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to an ALK6 ECD sequence selected from SEQ ID NO: 1, 4, 11-45, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 80, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 110, 113, 132-156, 158-189, 191-194, 202, 213, 218, 223, 228, 233, 242, 247, 252, 257, 262, 272, 277, 283, 286, 292, 298, 304, 310, 316, 322, 328, 334, 340, 346, 352, 358, 364, 370, 376, 382, 388, 394, 400, 406, 412, 418, 425, or 431.

22. A method for treatment of age-related macular degeneration (AMD) in a human subject in need thereof, comprising:administering an effective amount of a pharmaceutical composition to the subject, wherein the composition comprises a soluble recombinant bone morphogenetic protein receptor type-lB fusion protein comprising an ALK6 ECD polypeptide, a linker and a heterologous sequence, wherein the ALK6 Fc fusion protein comprises an amino acid sequence having at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to an amino acid sequence selected from SEQ ID NO: 291, 297, 303, 309, 315, 321, 327, 333, 339, 345, 351, 357, 363, 369, 375, 381, 387, 393, 399, 405, 411, 417, 423, 424, 430, and 436.

23. The method of claim 3, -wherein the fusion protein polypeptide comprises an amino acid sequence having at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to an ALK6 fusion protein sequence selected from SEQ ID NO: 291.

24. The method of claim 20, 21 or 22, wherein the ALK6 ECD sequence comprises at least one point mutation as compared to SEQ ID NO: 1.

25. The method of any one of claims 20-24, wherein the soluble recombinant bone morphogenetic protein receptor type- IB fusion protein comprises an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to an amino acid sequence of SEQ ID NO: 86, SEQ ID NO: 88, SEQ ID NO: 90 or SEQ ID NO: 286.

26. The method of any one of claims 20-25, wherein the ALK6 ECD comprises an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 69.1902004-0002-005-W0127. The method of any one of claims 20-25, wherein the ALK6 ECD comprises an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 90.

28. The method of any one of claims 20-25, wherein the ALK6 ECD comprises an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 286.

29. Use of a soluble recombinant bone morphogenetic protein receptor type-lB fusion protein for treatment of retinopathy in a human subject in need thereof, comprising administering an effective amount of the fusion protein, comprising:(i) an ALK6 extra cellular domain (ECD);(ii) a linker sequence; and,(iii) an Fc domain sequence;wherein the ALK6 ECD sequence comprises or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to an ALK6 ECD sequence of SEQ ID NO: 286, wherein the position corresponding to position 60 of SEQ ID NO:69 is a glycine (G) residue, and wherein the ALK6 fusion protein demonstrates retained BMP10 binding.

30. Use of a soluble recombinant bone morphogenetic protein receptor type-lB fusion protein for treatment of retinopathy in a human subject in need thereof, comprising administering an effective amount of the fusion protein, comprising:(iv)an ALK6 extra cellular domain (ECD);(v) a linker sequence; and,(vi) an Fc domain sequence;wherein the ALK6 Fc fusion protein sequence comprises or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to an ALK6 Fc fusion sequence of SEQ ID NO: 291, wherein the position corresponding to position 60 of SEQ ID NO: 69 is a glycine (G) residue, and wherein the ALK6 fusion protein demonstrates retained BMP 10 binding.1902004-0002-005-W0131. Use of a soluble recombinant bone morphogenetic protein receptor type- IB fusion protein for treatment of retinopathy in a human subject in need thereof, comprising administering an effective amount of the fusion protein, comprising:(vii) an ALK6 extra cellular domain (ECD);(viii) a linker sequence; and,(ix) an Fc domain sequence;wherein the ALK6 ECD sequence comprises or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to an ALK6 ECD sequence of SEQ ID NO: 437, wherein the position corresponding to position 60 of SEQ ID NO: 69 is a glycine (G) residue, and wherein the ALK6 fusion protein demonstrates complete BMP 10 binding.

32. The use of any one of claims 100-102, wherein the ALK6 fusion protein demonstrates BMP 10 binding comparable to SEQ ID NO: 49.

33. The use of any one of claims 100-103, wherein the ALK6 fusion protein demonstrates BMP 10 binding comparable to binding of an ALK6 w ildt pe (wt) Fc fusion protein.

34. Tire use of any one of claims 100-104, wherein the ALK6 fusion protein demonstrates an nM ICso value of about 7.2 for BMP 10 binding.

35. The use of any one of claims 100-104, wherein the ALK6 fusion protein demonstrates an nM ICso value of about 4.8 for BMP7 binding.

36. The use of any one of claims 100-105, wherein the retinopathy is age related macular degeneration (AMD).

37. A soluble recombinant bone morphogenetic protein receptor type- IB fusion protein comprising an ALK6 ECD polypeptide and a Fc sequence, wherein the ALK6 ECD polypeptide comprises an amino acid sequence selected from a sequence of SEQ ID NO: 130:Lysi - Lys2 - Glus - Aspr - Glys - Glue - Ser? - Thrs - Alas - Proio - Thru - Proi2 - Argis -Proi4 - Lysis - Xaaie -- Leui? - Argis - Cysis - Xaa?.o - Cys?.i - Xaa?.?.- Xaa’22- Xaa”22-Xaa23 - Xaa’23 - Xaa.'i - Cy - Pro26 - Xaa?.? - Aspss - Xaa29 - Xaaso- Asnsi - Asn32 - Xaass - Cys34 - Xaass - Thrse - Xaas? - Glyss - Xaass - Cysro - Pheri - Xaa42 - Xaa 43 - Ile44 - G1U4S - Glu46 - Asp47 - Asp4s - Xaa49 - Glyso - Xaasi - Xaas?. - Xaass - Xaas4 - Xaass - Serse - Glys? - Cysss - Xaass - Xaaeo - Xaaei - Glu62 - Gly ’63 - Sere4 - Aspes - Pheee - Glne? - Cyses - Xaaes- Asp?o - Xaa?i - Pro?2 - Xaa?3 - Xaa?4 - Xaa?s -1902004-0002-005-W01Xaa76 -- Arg77 - Arg-s - Xaa79-Ileso - Glusi - Cyss2 -• Cysss - Xaas4 - Xaass - Xaass -Xaas? - Xaass - Cy s«9 - Asnso - Xaasi - Xaa92 - Leu93 - Xa 94 - Pross - Thrss - Leu97 - Pro98 ~ Pross - Leuioo - Lysioi - Asmo2 - Argios - Aspioi - Pheios - Valios - Xaaio7 - Xaaios - Xaaio9 - Xaano - Xaam - Xaain - Xaam;whereinXaai6 is V or IXaa2o is V, F, K, Y, T, or A;Xaa?.?. is G, E, H or S;Xaa'22 is absent, G, S, or A;Xaa’!22 is absent or S;Xaa?,3 is S. II, G, or L;Xaa235is absent, L or H;Xaa 4 is H or S;Xa 2? is E or D;Xaa?_9 is S or A;Xaa30is V or I;Xaa 3 is I or T;Xaa35 is S or I;Xa 37 is D or N;Xaa39 is Y or H;Xa 42 is T or A;Xaa43is M or I;Xaa49 is S or Q;Xaa51is L or E;Xaa52is P or T;Xaass is V or T;Xaas4 is V or L;Xaass is T or A;Xaa59is L or M;Xaa60is G or K;Xaa61is L or Y;Xaass is R or K;Xaa?i is T or S;1902004-0002-005-W01Xaa73 is I or K;Xaa74 is P or A;Xaa75 is II or Q;Xaa76is Q or L;Xaa79is S or T;Xaa84is T or R;Xaass is absent, T or E;Xaass is R or X;Xaas7 is N or L;Xaass is absent, E or E;Xaas>i is K or Q;Xa 92 is D or L;Xaa94 is H or Q;Xaaior is absent;Xaa108is absent;Xaaiog is absent;Xaa110is absent;Xaai 11 is absent;Xaai 12 is absent; and,Xaa.113 is absent,38. The fusion protein of claim 37, wherein Xaa60 is a glycine (G) residue.

39. The fusion protein of claim 37, wherein the polypeptide binds BMP 10.

40. The fusion protein of claim 37, further comprising a linker sequence.

41. Tire fusion protein of claim 37, further comprising a linker sequence selected from SEQ ID NO: 6, SEQ ID NO: 7 or SEQ ID NO: 8.

42. The fusion protein of claim 37, wherein the Fc sequence comprises an amino acid sequence according to SEQ ID NO: 285.

43. A soluble recombinant bone morphogenetic protein receptor type- IB fusion protein comprising an ALK6 ECD polypeptide and a Fc sequence, wherein the ALK6 ECD polypeptide comprises an amino acid sequence selected from a sequence of SEQ ID NO: 157:Xaai — Xaa2 — aa3 — Xaa4 — Xaas — aa6 — Xaar — Xaas — X a9 — Xaaio — Xaan — Xaai 2 — Xaai3—Xaai4 - Xaa15—Xaai6—Eeui7—Argis—Cysi9 - Xaa20—Cys2i - aa22 - Xaa 221902004-0002-005-W01- Xaa'X? - Xaa23 - Xaa'23 - Xaa24 - Cys25 - Pro26 - Xaa27 - Asp28 - Xa 29 - Xaaso - Asii3i - Asii32 - Xaa33 - Cys34 - Xaa 35 - Tims - Xaa37 - Glyss - Xaa39 - Cys40 - Phe4i - Xaat2 - Xaa43 - He: s - Gluts - Glute - Asp47 - Asp s - Xaa49- Glyso - Xaasi - Xa s2 - Xaas - Xaasi - Xaass Serse - Glys? - Cysss - Xaas9 - Xaaeo - Xaasi -- Glue?, - Glyss - Sers4 - Aspes - Phess - Glns7 - Cysss - Xaass - Asp7o - Xa 7i - Pro72 - Xaa73 - Xaa- 1 - Xaa75 - Xa 76 - Arg?? - Arg?s - Xaa79 - Ileso - Glusi - Cyss2 - Cysss - Xaa«4 - Xaass -Xaass - Xaas? - Xaass - Cyss9 - Asngo - Xaa9i - Xaa92 - Leu93 - Xaa<?i - Pro95 - Thr-, -Leu97 - Pro9s -- Pro99 - Xaaioo - Xaaioi - Xaaio2 - Xaaios - Xaaio4 - Xaaios - Xaaios -Xaaio7 - Xaaios - Xaaio - Xaano - Xaam - Xaam - Xaamwherein: Xaai is K or absent;Xaa2 is K or absent;Xaas is E or absent;Xaa is D or absent;Xaas is G or absent,Xaas is E or absent;Xaa? is S or absent;Xaas is T or absent;Xaao is A or absent;Xaai 0 is P or absent;Xaa11 is T or absent;Xaa is P or absent;Xaai 3 is R or absent;Xaai4 is P or absent,Xaai s is K, P or absent;Xaai 6 is V or absence;Xaa20 is V, F, K, A, R, N, D, C, E, Q, G, H, I, L, M, P, S, T, W, or Y;1902004-0002-005-W01 Xaa22is G, H, V, F, K, A, R, N, D, C, E, Q, I, L, M, P, T, W, Y or S;Xaa’22 is absent, G, S, or A;Xaa”22 is absent or S;Xaa23 is S, H, V, F, K, A, R, N, D, C, E, Q, 1, L, M, P, T, W, Y or G;Xaa’23 is absent, L or FI;Xaa24 is V, F, K, A, R, N, D, C E, Q, G, H, I, L, M, P, S, T, W, or Y;Xa 27 is E or D;Xaa29 is S, G or A;Xaaao is V, A, G or I;Xa 33 is I, S or T;Xaa 5 is S, T, G, A or I;Xaaa? is D, A, G or N;Xa 39 is Y, A, G or H;Xaa42 is T or A;Xaa43 is M or I;Xa 49 is S, A, G or Q;Xaasi is L, A, G or E;Xaas2 is P or T:Xaa.53 is V, A, G or T;Xaasr is V, A, G or L;Xaass is T, G or A;Xaa59 is L, M, V, F, K, A, R, N, D, C, E, Q, G, H, I, P, S, T, W, or Y;Xaaso is G, K, V, F, A, R, N, D, C, E, Q, H, I, L, M, P, S, T, W, or Y;Xaasi is L, Y, V, F, K, A, R, N, D, C, E, Q, G, H, I, M, P, S, T, or W;1902004-0002-005-W01 Xaass is R or K;Xaa?i is T or S;Xaa?3 is I or K;Xaa74is P or A;Xaa75 is II or Q;Xaa76is Q or L;Xaa79 is S or T;Xaas4 is T, R or absent;Xaass is absent, T or E;Xaass is R, N or absent;Xa s7 is N, L or absent;Xaass is absent, E or L;Xaasi is K, Q or absent;Xa 92 is D, L, Y or absent;Xa 94 is H, Q or absent;Xaaioo is absent, V or L;Xaaioi is absent, V or K;Xaai 02 is absent, I or X;Xaaios is absent, G or R;Xaaio4 is absent, P, D or A;Xaai 05 is absent or F;Xaaios is absent, F, W, Y, N, Q, K, H, D, G, E or V;Xa io7 is absent, L, M, V, F, K, A, R, N, C, E, Q, G, H, I, P, S, T, W, or Y or D; Xaai os is absent, R, T, Q, L, K, W or G;1902004-0002-005-W01Xaaio9 is absent, S or P;Xaano is absent or I;Xaain is absent, R or H;Xaai is absent or H; andXaaiB is absent or R.

44. The fusion protein of claim 43, wherein Xaa60 is a glycine (G) residue.

45. The fusion protein of claim 43, wherein tire polypeptide binds BMP 10.

46. The fusion protein of claim 43, further comprising a linker sequence.

47. The fusion protein of claim 43, further comprising a linker sequence selected from SEQ ID NO: 6, SEQ ID NO: 7 or SEQ ID NO:

848. Tire fusion protein of claim 43, wherein the Fc sequence comprises an amino acid sequence according to SEQ ID NO: 285.

49. The fusion protein of claim 43, wherein the ALK6 ECD sequence an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a sequence selected from any one of SEQ ID NO: 132 to 155.

50. A soluble recombinant bone morphogenetic protein receptor type- IB fusion protein comprising an ALK6 ECD polypeptide and a Fc sequence, wherein the ALK6 ECD polypeptide comprises an amino acid sequence selected from a sequence of SEQ ID NO: 190:Lysi - Lys?. - Glus - Aspr - Glys - Glus - Ser? - Thrs - Alas - Proio -- Thn i - Proi 2 - Argi3 -Proi4 - Xaais - Xaais - Leun - Argis - Cysi9 - Xa 2o - Cy S21 - Xaan - Xaa’22 - Xaa”22 - Xaa23 - Xaa’23 - Xaa24 - Cys25 - Pro2s - Xaa27 - Asp28 - Xaa29 - Xaaso- Asnsi - Asns2 - Xaa33 - Cys34 - Xaass - Thns - Xaa?7 - Glyss - Xaas9 - Cys o - Pheri - Xaa42 - Xaais - Ile44 -- Glu45 -- Glu46 - Asp4? - Asp4s - Xaa49 - Glyso - Xaasi - Xaa-52 - Xaass - Xa 54 - Xaass - Serss - Glys? - Cysss - Xaas9 - Xaaso - Xaasi - Glu62 - G1 y63 - Sers4 - Aspss - Phess - Gins? - Cysss - Xaa 9- Asp?o - Xaari - Pro?2 - Xaa?3 - Xaa?4 - Xaa?s - Xaa?s - Arg?? - Arg?s - Xaa?9 - Ileso - GIusi - Cyss?. - Cyss3 - Xaas4 - Xaass - Xaass - Xaas? - Xaass- Cyss9 - Asn o - Xaa i - Xaa92 - Leu93 - Xa 94- Pro s - Ihr s- Leu9? - Progs - Pro99 - Leuioo - Lysioi - Asmo2 - Argios - Xaa104 - Pheios - Valios - Xaaio? - Xaaios - Xaaio9 - Xaano - Xaain - Xaai - Xaans;1902004-0002-005-W01 wherein Xaai 5 is K or P;Xaais is V or I;Xaa20 is V, F, K, A, R, N, D, C E, Q, Ci. H, I, L, M, P, S, T, W, or Y;Xaa22 is G, H, V, F, K, A, R, N, D, C, E, Q, I, L, M, P, T, W, Y or S;Xaa’22 is absent, G, S, or A;Xaa”22 is absent or S;Xaa23 is S, H, V, F, K, A, R, N, D, C, E, Q, 1, L, M, P, T, W, Y or G;Xaa’23 is absent, L or II;Xa24 is V, F, K, A, R, N, D, C, E, Q, G, H, I, L, M, P, S, T, W, or Y:Xa 27 is E or D;Xaa29 is S, G or A;Xaaso is V, A, G or I;Xa 33 is I, S or T;Xaa 5 is S, T, G, A or I;Xaaa? is D, A, G or N;Xa 39 is Y, A, G or H;Xaa42 is T or A;Xaa43 is M or I;Xa 49 is S, A, G or Q;Xaasi is L, A, G or E;Xaa52is P or T;Xaa.53 is V, A, G or T;Xaasr is V, A, G or L;Xaass is T, G or A;1902004-0002-005-W01Xaa59is L, M, V, F, K, A, R, N, D, C. E, Q, G, H, I, P, S, T, W, or Y;Xaaso is G, K, V, F, A, R, N, D, C, E, Q, II, I, L, M, P, S, T, W, or Y; Xaasi is L, Y, V, F, K, A, R, N, D, C, E, Q, G, H, I, M, P, S. T, or W;Xaaes is R or K;Xaa7i is T or S;Xaa?3 is I or K;Xaa74is P or A;Xaa75 is H or Q;Xaa76is Q or L;Xaa?9 is S or T;Xaas4 is absent, T or R;Xaa«5 is absent, T or E;Xaase is absent, R orN;Xaas7 is N or L;Xaass is absent, E or L;Xaa9i is absent, K or Q;Xa 92 is absent, D, Y or L;Xa 94 is absent, H or Q;Xaa104 is D or A;Xaaio7 is absent;Xaai os is absent;Xaa109 is absent;Xaai 10 is absent;Xaai 11 is absent;1902004-0002-005-W01Xaaii2 is absent; and,XaaiB is absent.

51. The fusion protein of claim 50, wherein Xaa60 is a glycine (G) residue.

52. The fusion protein of claim 50, wherein tire polypeptide binds BMP10.

53. The fusion protein of claim 50, further comprising a linker sequence.

54. The fusion protein of claim 50, further comprising a linker sequence selected from SEQ ID NO: 6, SEQ ID NO: 7 or SEQ ID NO:

855. Tire fusion protein of claim 50, wherein the Fc sequence comprises an amino acid sequence according to SEQ ID NO: 285.

56. The fusion protein of claim 50, wherein the ALK6 ECD sequence an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a sequence selected from any one of SEQ ID NO: 158 to 189.

57. A soluble recombinant bone morphogenetic protein receptor type- IB fusion protein comprising an ALK6 ECD polypeptide and a heterologous sequence, wherein the ALK6 ECD polypeptide comprises an amino acid sequence selected from a sequence of SEQ ID NO: 437:Lysi - Lys?. - Glus - Aspr - Glys - Glus - Ser? - Thrs - Alas - Proio -- Thn i - Proi 2 - Argi3 -Proi4 - Xaais - Xaais - Leun - Argis - Cysi9 - Xa 2o - Cy S21 - Xaa?2 - Xa 23 - His 'i - Cys25 - Pro26 - Xaa? - Asp28 - X a29 - Xaaso- Asnsi - Asn32 - Xaaas- Cys34 - Xaa35- Thrso - Xaa37- Glyss - Xaa39- Cysro - Phe4i - Xaai2 - Xaan - Ile44 - Gluts - Glu s - Asp47 -- Asp s - Xa 49 - Glyso - Xaasi - Xaas2 - Xaass - Xaas4 - Xaass - Sers6 - Glys? - Cysss - Xaas9 - Xaaeo - Xaaei - Glue? - GL..3 - Sere4 - Aspes - Pheee - Giner - Cys68 - airn - Aspro - Xaa?i - Pro?2 - Xaa?3 - Xaar4 - Xaars - Xaa?e - Arg?? - Argrs - Xaa?9 - Ileso - Glusi - C ss?. -- Cysss - Xaas - Xaass - Xaase - Xaas? - Xaass -- Xa s9 - Xaago - Xaa9i - Xaa92 -Xaa93 - Xaa94 - Xaags - Xaa96 - Xaa97 - Xaags - Xaa99 - Xaaioo - Xaaioi - Xaaio2 - Xaaios - Xaaio4 - Xaaios - Xaaioe - Xaaio? - X ios - Xaai 9 - Xaa110 - Xaam - Xaaii2 - Xaaii3wherein: Xaais is K or P;Xaaie is V or I;Xaa2o is V, F, K or Y;1902004-0002-005-W01 Xaa22 is G, H or S;Xaa’22 is absent, G, S or A;Xaa23 is S. H or G;Xa 27 is E or D;Xaa29 is S or A;Xaa30is V or I;Xaa33is I or T;Xaa35 is S or I;Xaa37 is D or N;Xa 39 is Y or H;Xaa42 is T or A;Xaa43 is M or I;Xaarg is S or Q;Xaa51is L or E;Xaa52is P or T;Xaa.53 is V or T;Xaas* is V or L;Xaass is T or A;Xaa59is L or M;Xaa60is G or K;Xaa61is L or Y;Xaa<59 is R or K;Xaa7i is T or S;Xaa73is I or K;1902004-0002-005-W01 Xaa74 is P or A;Xaa?5 is II or Q;Xaa76is Q or L;Xaa79 is S or T;Xaas4 is T or R;Xaass is absent, T or E;Xaass is R or X;Xaas7 is absent, N or L;Xaass is absent, E or L;Xaass is absent or C;Xaa9o is absent orN;Xaa9i is absent, K or Q;Xa 92 is absent, D or L;Xaa93 is absent or L;Xaa94 is absent, H or Q;Xaa95 is absent or P;Xaa s is absent or T;Xaa97 is absent or L;Xaaos is absent or P;Xa 99 is absent or P;Xaai oo is absent, V or L;Xaaioi is absent, V or K;Xaaio2 is absent, I or N;Xaai 03 is absent, G or R;1902004-0002-005-W01Xaaio4 is absent, P, D or A;Xaaios is absent or F;Xaaios is absent, F or V;Xaaio7 is absent or D;Xaaios is absent or G;Xaaios is absent, S or P;Xaano is absent or I;Xaain is absent, R or II;Xaam is absent or H; and,Xaam is absent or R.

58. The fusion protein of claim 57, wherein Xaa60 is a glycine (G) residue.

59. The fusion protein of claim 57, wherein the polypeptide binds one or more of BMP6, BMP7 and / or BMP10.

60. Tlie fusion protein of claim 57, further comprising a linker sequence.

61. The fusion protein of claim 57, further comprising a linker sequence selected from SEQ ID NO: 6, SEQ ID NO: 7 or SEQ ID NO: 8.

62. The fusion protein of claim 57, wherein the Fc sequence comprises an amino acid sequence according to SEQ ID NO: 285.

63. The fusion protein of claim 57, wherein the ALK6 ECD sequence an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%. 88%, 89%, 90%. 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a sequence selected from any one of SEQ ID NO: 90, 286, 292, 298, 304, 310, 316, 322, 328, 334, 340, 346, 352, 358, 364, 370, 376, 382, 388, 394, 400, 406, 412, 418, 425 and 431.

64. A soluble recombinant bone morphogenetic protein receptor type- IB fusion protein comprising an ALK6 extra cellular domain (ECD) polypeptide and a heterologous sequence, wherein the ALK6 ECD polypeptide comprises an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to an ALK6 ECD sequence1902004-0002-005-W01selected from SEQ ID NO: 132-156, 158-189, 191-194, 202, 213, 218, 223, 228, 233, 242, 247, 252, 257, 262, 272, 277 and 283.

65. A soluble recombinant bone morphogenetic protein receptor type- IB fusion protein comprising: an ALK6 extra cellular domain (ECD) and a heterologous sequence wherein the ALK6 ECD sequence comprises an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to an ALK6 ECD sequence selected from SEQ ID NO: 202, 213, 218, 223, 228, 233, 242, 247, 252, 257, 262, 272, 277 and 283.

66. A soluble recombinant bone morphogenetic protein receptor type-lB fusion protein comprising: an ALK6 extra cellular domain (ECD) and a heterologous sequence wherein the ALK6 ECD sequence comprises an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to an ALK6 ECD sequence selected from SEQ ID NO: 90, 286, 292, 298, 304, 310, 316, 322, 328, 334, 340, 346, 352, 358, 364, 370, 376, 382, 388, 394, 400, 406, 412, 418, 425 and 431.

67. A soluble recombinant bone morphogenetic protein receptor type-lB fusion protein comprising: an ALK6 extra cellular domain (ECO) and a heterologous sequence wherein the ALK6 ECD sequence comprises an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to an ALK6 ECD sequence according to SEQ ID NO: 286.

68. The fusion protein of any one of claims 64-67, wherein the polypeptide binds BMP6, BMP7 and / or BMP10.

69. Tire fusion protein of any one of claims 64-68, further comprising a linker sequence.

70. Tlie fusion protein of any one of claims 64-67, further comprising a linker sequence selected from SEQ ID NO: 6, SEQ ID NO: 7 or SEQ ID NO: 8.

71. The fusion protein of any one of claims 64-67, wherein the Fc sequence comprise an amino acid sequence according to SEQ ID NO: 285.

72. A soluble recombinant bone morphogenetic protein receptor type- IB fusion protein comprising: an ALK6 extra cellular domain (ECD), a linker sequence and a heterologous sequence wherein the fusion protein sequence comprises an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%,1902004-0002-005-W0192%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical SEQ ID NO: 291, 297, 303, 309, 315, 321, 327, 333, 339, 345, 351, 357, 363, 369, 375, 381, 387, 393, 399, 405, 411, 417, 423, 424, 430, and 436.

73. A soluble recombinant bone morphogenetic protein receptor type- IB fusion protein comprising: an ALK6 extra cellular domain (ECD), a linker sequence and a heterologous sequence wherein the fusion protein sequence comprises an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 291.

74. The fusion protein of claim 72 or 73, wherein the linker sequence is according to SEQ ID NO: 6.

75. Tlie fusion protein of claim 72, 73 or 74, wherein the heterologous sequence is an Fc sequence comprising an amino acid sequence according to SEQ ID NO: 285.

76. The fusion protein of any one of claims 37-75, wherein the ALK6 ECD polypeptide is present as a homodimer.

77. A soluble recombinant bone morphogenetic protein receptor type- IB fusion protein comprising:(i) an ALK6 extra cellular domain (ECD);(ii) a linker sequence; and,(iii)an Fc domain sequence;wherein the ALK6 ECD sequence comprises or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to an ALK6 ECD sequence of SEQ ID NO: 286, wherein the position corresponding to position 60 of SEQ ID NO: 69 is a glycine (G) residue, and wlierein the ALK6 fusion protein demonstrates retained binding to BMP 10.

78. Tlie fusion protein of claim 77, wherein the ALK6 fusion protein demonstrates BMP10 binding comparable to SEQ ID NO: 49.

79. The fusion protein of claim 77, w herein the ALK6 fusion protein demonstrates BMP 10 binding comparable to binding of an ALK6 w ildtype (wt) Fc fusion protein.

80. The fusion protein of claim 77, wherein the ALK6 fusion protein demonstrates an nM ICso value of about 7.2 for BMP10 binding,81. Tire fusion protein of claim 77, wherein the ALK6 fusion protein demonstrates an nM IC50 value of about 4.8 for BMP7 binding.1902004-0002-005-W0182. A soluble recombinant bone morphogenetic protein receptor type- IB fusion protein comprising:(i) an ALK6 extra cellular domain (ECD);(ii) a linker sequence; and,(iii)an Fc domain sequence;wherein the fusion protein sequence comprises or consists of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to an ALK6 fusion protein sequence of SEQ ID NO: 291, wherein the position corresponding to position 60 of SEQ ID NO: 69 is a glycine (G) residue, and wherein the ALK6 fusion protein demonstrates retained BMP 10 binding.

83. The fusion protein of claim 82, wherein the ALK6 fusion protein demonstrates BMP10 binding comparable to SEQ ID NO: 49.

84. The fusion protein of claim 82, wherein the ALK6 fusion protein demonstrates BMP 10 binding comparable to binding of an ALK6 wildtype (wt) Fc fusion protein.

85. The fusion protein of claim 82, wherein the ALK6 fusion protein demonstrates an nM ICso value of about 7.2 for BMP10 binding,86. Tire fusion protein of claim 82, wherein the ALK6 fusion protein demonstrates an nM ICso value of about 4.8 for BMP7 binding.

87. The fusion protein of any one of claims 37-86, wherein the position corresponding to position 60 of SEQ ID NO: 69 is a glycine (G) residue, and wherein the ALK6 fusion protein demonstrates retained BMP 10 binding.

88. The fusion protein of any one of claims 37-87, wherein the ALK6 fusion protein demonstrates BMP10 binding comparable to SEQ ID NO: 49.

89. Tire fusion protein of any one of claims 37-88, wherein the ALK6 fusion protein demonstrates BMP 10 binding comparable to binding of an ALK6 wildtype (wt) Fc fusion protein.

90. The fusion protein of any one of claims 37-89, wherein the ALK6 fusion protein demonstrates an nM IC50 value of about 7.2 for BMP10 binding.

91. The fusion protein of any one of claims 37-90, wherein the ALK6 fusion protein demonstrates an nM IC50 value of about 4,8 for BMP7 binding.1902004-0002-005-W0192. The fusion protein of any one of claims 37-91, wherein the linker sequence comprises an amino acid sequence selected from SEQ ID NO: 6, SEQ ID NO: 7 or SEQ ID NO: 8.

93. The fusion protein of any one of claims 37-92, wherein the Fc sequence comprises an amino acid sequence selected from SEQ ID NO: 10, SEQ ID NO: 106 or SEQ ID NO: 107,94. A pharmaceutical composition comprising a fusion protein according to any one of 37-93; and, at least one pharmaceutical acceptable carrier or buffer.

95. The pharmaceutical composition of claim 94, wherein the ALK6 ECD polypeptide is present as a homodimer.

Images